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Introduction
Late transplant dysfunction and transplant loss remains an important problem after kidney 
allograft transplantation.1 The prospects of a patient who falls back to dialysis treatment 
after kidney transplantation are bad; not only is the quality of life severely affected 
but also survival is poor.2 A gradual decline in kidney allograft function is observed in 
approximately 40 to 50% of the patients two or more years after transplantation.3-4 The 
loss of function is often accompanied by an increase in blood pressure and proteinuria. 
Various factors, alloantigen-dependent and alloantigen-independent, may contribute to 
this gradual loss of function, a syndrome which has been designated chronic transplant 
dysfunction (CTD) (Figure 1). When CTD is recognized, a biopsy is usually taken after 
prerenal (arterial obstruction) or postrenal (urine tract obstruction) causes of functional 
decline are excluded. The biopsy sample that has been taken may demonstrate a specifi c 
cause of dysfunction such as recurrent glomerular disease or a de novo glomerulopathy, 
however, in the majority of cases non-specifi c chronic changes are found that do not allow 
exact identifi cation of the cause(s) of graft decline.5-9 
Figure 1: Factors that may cause chronic transplant dysfunction.
a BKV, polyomavirus type BK en b PTLD, post-transplant lymphoproliferative disease.
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Since 1991 efforts have been made to standardize the interpretation of pathologic fi ndings 
of renal allograft biopsies in the Banff Working Classifi cation of Renal Allograft Pathology. 
This system uses the term chronic allograft nephropathy (CAN) (Table 1) to classify the 
chronic/sclerosing changes, which include chronic obliterative vascular alterations, tubular 
atrophy, glomerulosclerosis, and interstitial fi brosis.10-11 CAN is graded by the severity of 
interstitial fi brosis and tubular atrophy because they are most accurately assessed, develop 
regardless of the etiology of allograft decline, and correlate with the degree of functional 
impairment. 12 Interstitial fi brosis is considered to be present when the supporting connective 
tissue in the renal parenchyma exceeds 5% of the cortical area.10 Tubular atrophy refers 
to the presence of tubules with thick redundant basement membranes, or a reduction of 
greater than 50% in tubular diameter compared to surrounding non-atrophic tubules. 
The causes of CAN are multifactorial (Figure 2) and include both chronic rejection and 
chronic calcineurin inhibitor toxicity.11 A recently published large study of protocol 
biopsies of patients who received a kidney-pancreas transplant identifi ed two distinctive 
phases of tissue injury leading to CAN. An early phase with tubulointerstitial damage due 
to ischemia, severe rejection or subclinical rejection predicted a mild degree of CAN at 
1-year after transplantation. Beyond one year subclinical rejection became less common 
although still persisted in 12.3% of the biopsies at 10 years. Changes attributed to chronic 
calcineurin nephrotoxicity increased progressively with time.13 
Figure 2: Factors that may induce CAN. 
a BKV, polyomavirus type BK. 
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Table 1: Banff 1997. Chronic/sclerosing lesion scoring 
Chronic Allograft Nephropathy (CAN) 
Grade Histopathological Findings
Grade I (mild)
Mild interstitial fi brosis and tubular atrophy without (a) or with 
(b) specifi c vascular changes suggesting chronic rejection  
Grade II (moderate)
Moderate interstitial fi brosis and tubular atrophy without (a) or with 
(b) specifi c vascular changes suggesting chronic rejection  
Grade III (severe)
Severe interstitial fi brosis and tubular atrophy without (a) or with 
(b) specifi c vascular changes suggesting chronic rejection
Quantitative Criteria for Allograft Glomerulopathy (“cg”)  
cg0
No glomerulopathy, double contours in <10% of peripheral capillary loops in most 
severely affected glomerulus  
cg1
Double contours affecting up to 25% of peripheral capillary loops in the most 
affected of nonsclerotic glomeruli 
cg2
Double contours affecting 26 to 50% of peripheral capillary loops in the most 
affected of nonsclerotic glomeruli 
Quantitative Criteria for Interstitial Fibrosis (“ci”)  
ci0 Interstitial fi brosis tissue in up to 5% of cortical area 
ci1 Mild- Interstitial fi brosis tissue in 6 to 25% of cortical area 
ci2 Moderate- interstitial fi brosis of 26 to 50% of cortical area  
ci3 Severe interstitial fi brosis of >50% of cortical area
Quantitative Criteria for Tubular Atrophy (“ct”) 
ct0 No tubular atrophy 
ct1 Tubular atrophy in up to 25% of the area of cortical tubules 
ct2 Tubular atrophy involving 26 to 50% of the area of cortical tubules 
ct3 Tubular atrophy of >50% of cortical tubulus
Quantitative Criteria for Fibrous Intimal Thickening (“cv”) 
cv0 No chronic vascular changes 
cv1
Vascular narrowing of up to 25% lumenal area by fi brointimal thickening of 
arteries ± breach of internal elastic lamina or presence of foam cells or occasional 
mononuclear cells* 
cv2
Increased severity of changes described above with 26 to 50% narrowing of vascular 
lumenal area* 
cv3 Severe vascular changes with >50% narrowing of vascular lumenal area*
* in most severely affected vessel. Note if lesions characteristic of chronic rejection (elastica breaks, 
  infl ammatory cells in fi brosis, formation of neointima) are seen 
proefschrift bakker.indd   12 1-12-2004   9:01:13
Chapter 1
13
Quantitative Criteria for Mesangial Matrix Increase (“mm”)* 
mm0 No mesangial matrix increase 
mm1 Up to 25% of nonsclerotic glomeruli affected (at least moderate matrix increase) 
mm2 26-50% of nonsclerotic glomeruli affected (at least moderate matrix increase) 
mm3 >50% of nonsclerotic glomeruli affected (at least moderate matrix increase) 
* The threshold criterion for the moderately increased “mm” is the expanded mesangial interspace between 
  adjacent capillaries. If the width of the interspace exceeds two mesangial cells on the average in at least 
  two glomerular lobules the “mm” is moderately increased
Quantitative Criteria for Arteriolar Hyaline Thickening (“ah”) 
ah0 No PAS-positive hyaline thickening  
ah1 Mild-to-moderate PAS-positive hyaline thickening in at least one arteriole  
ah2 Moderate-to-severe PAS-positive hyaline thickening in more than one arteriole 
ah3 Severe PAS-positive hyaline thickening in many arterioles 
Indicate arteriolitis (signifi cance unknown) by an asterisk on ah 
A major challenge is to recognize the factors that are still operating in damaging the 
allografted kidney. The nature of the changes that are found in the biopsy in the vascular 
and glomerular compartments may sometimes be suggestive of the etiology of graft 
dysfunction. Chronic allograft glomerulopathy (CAG) indicates an alloantigen dependent 
insult at the level the glomeruli but is found in a minority (5-15%) of late biopsies with 
CAN.14-18 At light microscopy it is characterized by glomerular enlargement, swelling 
of endothelial and mesangial cells, mesangiolysis, infi ltration with mononuclear cells, 
mesangial matrix expansion and widening of the subendothelial zone with interposition 
of mesangial cells and matrix leading to characteristic basement membrane double 
contours.19 Immufl uorescence staining may show a non-specifi c pattern of IgM binding; 
in the vast majority staining for C4d (see below) is positive.20-21 At electronmicroscopy 
(EM) an electron-lucent zone of fi ne fl occular material in the glomerular subendothelial 
space is observed. Concentric intimal thickening of arteries and arterioles may result from 
chronic rejection (CR) but may also be donor-derived or result from cardiovascular risk 
factors present in the recipient.22-23 The presence of infl ammatory cells in a fi brotic intima, 
disruptions of the elastica, and myofi broblast proliferation resulting in the formation of a 
second neointima, are changes considered to be more specifi c for CR.10 The evaluation of 
larger arteries is sensitive to sampling error. Nodular hyaline insudation in the periphery of 
small arterioles either patchy or circumferential designated as peripheral nodular hyaline 
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degeneration (PNHD) is a specifi c but probably not very sensitive sign of chronic CsA 
nephrotoxicity.24-27 
During recent years, newer methods to defi ne the cause of graft deterioration including 
immunostaining for C4d, a covalently bound fragment of a split product of the complement 
factor C4, and the EM examination of the peritubular capillaries (PTCs) have been under 
evaluation. The demonstration of C4d indicates local complement activation. Antibodies that 
bind to antigen trigger the assembly of C1qrs complexes that in turn catalyze the cleavage 
of complement components C4 and C2. C4b, generated in this way, forms amide or ester 
bonds with nearby proteins or saccharides, then associates with C2a to form the classical C3 
convertase, C4b2a. Formation of C3 convertase on the surface of cells amplifi es activation 
of complement but is also subject to various control mechanisms. Factor I together with 
a membrane bound co-factor protein, cleaves C4b to yield C4d, a catalytically inactive 
fragment. Complement-mediated injury of cells may also be prevented by changes in 
cellular metabolism induced by sublytic amounts of the membrane attack complex, which 
render cells less sensitive to complement-mediated injury. 
It has recently been shown that the demonstration of the fragment C4d in the PTCs is a 
reliable tool for identifying a humoral component of acute rejection (AR).28-32 It has been 
estimated that approximately 20 to 30% of all AR episodes have a humoral component, 
which adversely affects graft survival unless an intensifi ed antirejection therapy with 
plasmapheresis (or immunoadsorption), mycophenolate mofetil, tacrolimus, or intravenous 
immunoglobulins is instituted. C4d staining has also been used to demonstrate a humoral 
contribution in chronic rejection. Positive C4d staining of the PTCs was found in 13, 34 
or 61% in three retrospective studies of patients with presumed chronic rejection.33-35 
An association between the presence of C4d deposits in PTCs and CAG was reported 
in one of the studies,35 which was not confi rmed in another study.36 Also an association 
with a high degree of multilayering of the basement membrane of PTCs has been reported 
(see below). At present, the signifi cance of peritubular staining for the C4d in late biopsy 
samples with CAN is not fully established. The study of sequential biopsies of allografted 
kidneys has revealed that C4d deposits in the PTCs may appear or disappear at any time 
post transplantation.36 The presence of capillary C4d in grafts biopsies taken late after 
transplantation had no prognostic signifi cance, in contrast to the presence of C4d in biopsies 
taken within six months after transplantation.37 Several authors have also emphasized that 
complement activation at the endothelial surface may not result in complement mediated 
damage.38 It has been shown that allografts may accommodate to the presence of anti-donor 
antibodies.39-43 C4d has been demonstrated in organ transplants with “accommodation”, 
i.e., organs that function perfectly well despite the presence of circulating anti-donor blood 
group antibodies. The presence of C4d and the absence of immunoglobulin deposits or 
proefschrift bakker.indd   14 1-12-2004   9:01:14
Chapter 1
15
other components of the complement system may also indicate that the metabolism of the 
endothelium has been modifi ed to enhance the clearance of immune complexes. Additional 
studies of protocol biopsies need to be performed to demonstrate the importance of the C4d 
staining for the diagnosis of chronic humoral rejection in biopsies with CAN. 
Recently it has been recognized that extensive reduplication of the peritubular capillary 
basement membranes (PTCR) is associated with CAG.35,44,45 However, only a portion of 
patients with CAG shows well-developed PTCR.46 In one study some biopsies with well 
developed PTCR did not display CAG,46 which could not be confi rmed in another study.45 
The signifi cance of well-developed PTCR and its predictive value for CR in the absence of 
CAG remains to be established. 
Polyomavirus type BK (BK virus) may reactivate from latency under immunosuppression 
and causes a chronic form of tubulointerstitial nephritis. BKV nephropathy occurs in a 
small percentage of patients, on average 6-18 months after transplantation and is related 
to intensifi ed immunosuppression and multiple courses of antirejection therapy.47 
Patchy tubulointerstitial infl ammation, characteristic intranuclear inclusion bodies, 
progressive tubular atrophy and interstitial fi brosis characterize the histology of BKN. 
Immunohistochemistry or EM can achieve diagnostic confi rmation of BK-viruses infection. 
The presence of decoy cells in the urine and measurement of BKV DNA in the plasma are 
useful tools for early detection. In the same kidney BKN may coincide with tubulitis due 
to AR. The detection of transplant endarteritis is diagnostic of AR (Banff type II rejection). 
Interstitial mononuclear infl ammatory cell infi ltrates and typical tubulitis in areas lacking 
cytopathic changes are also suggestive of AR (morphological changes suggestive of Banff 
type I rejection). Additional histochemical studies to detect the tubular expression of 
MHC-class II (HLA-DR), can be used to establish a diagnosis of concurrent AR.48 Tubules 
affected by AR show positive staining for HLA-DR antigens, whereas tubules affected 
by BKV do not. Currently, the prevalence of BKN in different transplant centers varies 
between less than 1 to 5.5%.47
Outline of the thesis
The studies as described in this thesis focussed on several issues: the contribution of chronic 
CsA nephrotoxicity to late allograft dysfunction and CAN; the pathogenesis of chronic CsA 
nephrotoxicity with special reference to direct tubulotoxicity; and possible differences in 
renal cortical interstitial matrix composition or cortical messenger RNA (mRNA) content 
of allografts that suffer from either chronic rejection or chronic CsA nephrotoxicity. The 
latter studies were done to explore if new tools could be developed in the differentiation of 
chronic rejection from chronic CsA nephrotoxicity.
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In chapter 2 an extensive and detailed literature review of chronic CsA nephrotoxicity 
after kidney allograft transplantation is presented. 
In chapter 3 the tubulotoxicity of CsA is studied in cultured human proximal tubular 
epithelial cells by assessment of cell death through either necrosis or apoptosis. 
In chapter 4 the impact of chronic CsA nephropathy on the incidence CAN and possible 
prevention by withdrawal of CsA after a critical time frame was studied. The chapter 
describes the results of the extended 15-year follow-up of an open-label, randomized trial 
that examined conversion to azathioprine as early as 3 months after transplantation.
Chapter 5 investigated whether the cortical ECM composition differs between allografts 
that lost function because of CR or chronic CsA nephrotoxicity. The cortical interstitial 
ECM composition of kidney allografts of three groups of patients was studied: those 
suffering from chronic CsA nephrotoxicity, those with chronic rejection and a third group 
of patients who were on cyclosporine medication but who were most likely to suffer from 
CR. The study investigated the proteins collagen I, III, and IV, collagen IVα3 and laminin 
β2 by immunohistochemistry with the use of a computerized morphometric method. 
In chapter 6 we investigated whether renal cortical mRNA levels of several proteins 
can serve as discriminating tools for chronic CsA nephrotoxicity or chronic allograft 
rejection. Total RNA was extracted from the cortex of renal biopsies, and mRNA levels 
of transforming growth factor β (TGF-β) and the extracellular matrix (ECM) molecules 
collagen Iα1, IIIα1, IVα3, decorin, fi bronectin, and laminin β2 were measured by real-
time PCR. 
Chapter 7 summarizes and discusses the studies described in this thesis. 
Chapter 8 gives a summary in Dutch.
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Abstract 
Although extensively studied, the pathophysiologic characteristics of chronic cyclosporine 
A (CsA) nephrotoxicity are still far from being completely understood. The recognition of 
chronic CsA nephrotoxicity in allografted kidneys is hampered by a lack of easily assessable 
sensitive and specifi c markers. Long-term results of CsA withdrawal trials and trials that 
evaluated CsA sparing or withdrawal after the diagnosis of chronic allograft nephropathy 
(CAN) have shown that chronic CsA nephrotoxicity has a more important role in the etiology 
of late transplant dysfunction than appreciated before. Various hypotheses have explained 
the renal structural changes of chronic CsA nephrotoxicity including ischemia, cellular 
toxicity, and the stimulation of renal fi brosis by growth factors or cytokines. Possible ways 
to prevent chronic CsA nephrotoxicity include improved therapeutic drug monitoring and 
CsA withdrawal or avoidance. Patients with aspecifi c CAN in late biopsy may benefi t from 
withdrawal of CsA or a reduction of its dose. Current knowledge is being discussed. It is 
concluded that in the near future more strategies are likely to be used to prevent loss of 
allograft function as a result of drug toxicity.
Introduction
Twenty-fi ve years after its introduction in organ transplantation, cyclosporine A (CsA) 
is still one of the most widely used immunosuppressive drugs. The use of CsA-based 
immunosuppressive therapy has allowed signifi cant improvement in the success rate of 
kidney transplantation, providing approximately 90% allograft survival at 1 year.1 A major 
drawback of the drug, however, is its renal toxicity. Acute functional CsA nephrotoxicity 
is characterized by renal vasoconstriction and is largely reversible on dose reduction.2 
An irreversible decline in kidney function associated with irreversible pathologic changes 
may also occur after long-term CsA therapy.3 In this review, we focus on the impact of 
chronic CsA nephrotoxicity on long-term allograft survival after kidney transplantation, 
its recognition and pathogenesis, and the current knowledge on strategies to avoid or 
ameliorate chronic CsA nephrotoxicity.
proefschrift bakker.indd   22 1-12-2004   9:01:17
Chapter 2
23
Impact of chronic CsA nephrotoxicity on long-term allograft 
survival 
Late graft loss remains a major problem after kidney transplantation. About 50-60% of 
allograft loss after the fi rst year of transplantation is explained by the death of the recipient, 
mainly resulting from a cardiovascular event. The second most common cause of late graft 
attrition is a transplantation-related condition designated as chronic transplant dysfunction 
(CTD), which accounts for 30 to 40% of late losses.4 The condition is clinically characterized 
by a relatively slow but variable rate of decline in glomerular tranplantation rate (GFR), 
increasing proteinuria, and aggravated or new-onset hypertension. The cause may be 
multifactorial, and both alloantigen-dependent and alloantigen-independent mechanisms 
may be involved, including chronic CsA nephrotoxicity. 
The specifi c understanding of the importance of chronic CsA nephrotoxicity in renal 
transplantation has long been hampered by the lack of specifi c and sensitive markers of this 
condition and the absence of studies with long-term follow-up. Chronic CsA nephrotoxicity 
may affect the allografted kidney rather slowly, and it may take many years before the real 
impact of chronic CsA nephrotoxicity is evident in clinical trials. However, several lines of 
new evidence suggest that chronic CsA nephrotoxicity may have a more prominent role in 
CTD than appreciated before. 
It is now understood that acute rejection (AR) may have a detrimental effect on long-
term kidney allograft survival, especially when it is multiple, is accompanied by vascular 
involvement, is late (after 3 months), or occurs in a kidney of a donor who is more than 50 years 
old.5-6 The introduction of CsA (Sandimmune; Sandoz, Basel, Switzerland) signifi cantly 
decreased AR rates, but long-term graft survival improved only modestly, suggesting an 
important nephrotoxic effect of the drug. After the subsequent use of the microemulsion 
formulation of CsA (Neoral; Novartis AG, Basel, Switzerland), drug delivery improved 
and an additional decrease in the number of AR episodes was observed. Large data base 
information found a better long-term graft survival since the introduction of Neoral.7 
However, a single-center conversion study that used antibody induction therapy found no 
difference in patient or graft survival, renal function or progression to chronic allograft 
nephropathy (CAN) at 5 years, probably because of an increase in nephrotoxicity.8 In our 
own Sandimmune-Neoral conversion study, 20% of stable renal transplant patients treated 
with once-a-day low-dose CsA experienced chronic CsA nephrotoxicity after conversion to 
a twice-a-day Neoral regimen given according to the manufacturers guidelines.9 
Data derived from studies on patients with various autoimmune diseases or solid organ 
transplants other than a kidney who were treated with CsA also indicate a relatively 
high incidence of chronic CsA nephrotoxicity.10-14 Chronic renal failure (GFR 
proefschrift bakker.indd   23 1-12-2004   9:01:17
Chronic cyclosporine nephrotoxicity in renal transplantation
24
<29 mL/min⋅1.73 m2) affected 7% to 21% within 5 years after transplantation of a nonrenal 
organ in the United States. In heart transplant patients, end-stage renal failure has been 
observed in 6-10%, the frequency of which apparently increases with a longer period of 
follow-up.15 Heart transplant patients receive relatively high doses of CsA because of 
fear of rejection. However, renal functional or structural changes have also been observed 
frequently in patients on a regimen of lower doses of CsA for autoimmune disease. Two 
studies examined patients with psoriasis and included pretreatment and posttreatment 
protocol biopsies.11,14 Biopsies taken at 1 year showed de novo interstitial fi brosis in more 
than 40% of patients in the study of Svarstad.11 Zachariae et al.14 reported a histologic 
follow-up of 25 patients. Seventeen patients had normal baseline histologic features, and at 
2 years all had histologic changes compatible with chronic CsA nephrotoxicity. At 4 years, 
all studied biopsies (n = 11) displayed moderate to severe fi brosis. It should borne in mind 
that patients allografted with a single kidney may be even more susceptible to chronic CsA 
nephrotoxicity simply because they have a much smaller renal mass. 
More direct evidence of the importance of chronic CsA nephrotoxicity as an etiologic factor 
of CTD has come from recently analyzed data in 2 azathioprine conversion studies with 
more than 10 years of follow-up that show a signifi cant higher incidence of CAN and graft 
loss in the patients who continued on a regimen of CsA (discussed later),16-17 and 2 studies 
that evaluated the conversion to mycophenolate mofetil (MMF) in patients with established 
aspecifi c CAN (also discussed later).18-19 A recently published large study of protocol 
biopsies of patients who received a kidney-pancreas transplant identifi ed 2 distinctive 
phases of tissue injury leading to CAN. An initial-phase early posttransplantation period 
with tubulointerstitial damage caused by ischemia, severe rejection, or subclinical rejection 
predicted a mild degree of CAN at 1 year after transplantation. Beyond one year, subclinical 
rejection became less common, although it still persisted in 12.3% of the biopsies at 
10 years. Changes attributed to chronic calcineurin nephrotoxicity increased progressively 
with time.20
Pathology and diagnosis of chronic CsA nephrotoxicity 
The structural lesions due CsA nephrotoxicity that are most frequently found in native kidneys 
are nonspecifi c and include tubular atrophy, interstitial fi brosis, slight mononuclear cell 
infi ltration, Bowman’s capsule basement membrane thickening, glomerular collapse, global 
sclerosis and nonspecifi c arteriolar hyalinosis as seen in hypertension or diabetes. Glomerular 
thrombosis or necrosis and signs of arteriolar thrombotic microangiopathy are rare with the 
use of lower doses of CsA.21 Also, tubular alterations including honeycomb vacuolization 
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of the proximal tubular epithelium, giant mitochondria, and microcalcifi cations or minor 
changes of endothelial or smooth muscle cells now occur infrequently.21 Reduplication 
and tangling of the arteriolar endothelial basal lamina on electron microscopy (EM) were 
reported in 1 study.22 The most specifi c marker of CsA nephrotoxicity is nodular hyaline 
insudation in the periphery of small arterioles, either patchy or circumferential, designated 
as peripheral nodular hyaline degeneration (PNHD).21 Arterioles in up to 2 layers of smooth 
muscle cells are involved and may become completely obstructed. EM has suggested that 
the deposits of PNHD occur at sites of myocyte necrosis.21 Immunofl uorescence staining 
is often positive for immunoglobulin M and C3,21 representing nonspecifi c binding of 
plasma proteins. PNHD must be differentiated from the arteriolar hyaline changes as 
seen in diabetes or long-standing hypertension, in which the hyaline insudation occurs on 
the inside of the smooth muscle cell (SMC) layer.21 The differentiation may be diffi cult 
on light microscopy, especially when the lesions are more pronounced, and EM may be 
needed. PNHD may regress or even completely vanish on reduction of dose or withdrawal 
of CsA.23
The hallmark of irreversible chronic CsA nephrotoxicity is the occurrence of tubulointerstitial 
and glomerular changes, including segmental and global glomerulosclerosis, interstitial 
fi brosis, and tubular atrophy.21 The tubulointerstitial changes may be found before renal 
function is impaired.10 In a rat model of chronic CsA nephrotoxicity, it was observed that 
these changes occur even before PNHD is noted.24 The severity of the tubulointerstitial 
changes correlates with the degree of glomerular sclerosis.22 Nonaffected glomeruli are 
hypertrophied25 and presumably preserve function by hyperfi ltration. 
In a series of 192 patients treated with CsA for various autoimmune diseases, 26% of the 
biopsies showed interstitial fi brosis; however, PNHD was only noted in 4%.26 Nonspecifi c 
arteriolar hyalinosis was observed more frequently. In another study with protocol biopsies 
of patients with uveitis, a high incidence of arteriolar hyaline changes was found that 
increased steadily with time.14 However, in this study, it was not clear whether the specifi c 
PNHD lesion was scored. In 1994, an international advisory board of nephropathologists 
with extensive experience in the evaluation of kidney biopsies of patients on a regimen of 
CsA found that the reproducibility and diagnostic reliability of the evaluation of arteriolar 
lesions including PNHD were poor;26 the interobserver variation on tubulointerstitial 
changes was low.
The diagnosis of chronic CsA nephrotoxicity in allografted kidneys is diffi cult because of the 
more frequently observed chronic rejection or nonspecifi c fi ndings. Various insults that are 
alloantigen-dependent or alloantigen-independent may be operative at the same time, and 
it may be diffi cult to estimate the specifi c contribution of each of these factors. The nature 
of changes in the vascular and glomerular compartments may sometimes be suggestive of 
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an etiologic factor in graft deterioration. Allograft glomerulopathy with reduplication of 
the glomerular basement membrane indicates an alloantigen-dependent insult at the level 
the glomeruli but is found in a minority of late biopsies.27 Concentric intimal thickening 
of arteries and arterioles may result from chronic rejection.28 When PNHD is found, CsA 
nephrotoxicity should be considered. Striped fi brosis in renal allografts is not a marker 
of CsA nephrotoxicity because it has also been shown in a high proportion of late kidney 
allograft biopsies from patients maintained on a regimen of azathioprine and prednisone.29 
Recently, we studied the composition of the interstitial matrix of allografted kidneys with 
chronic CsA nephrotoxicity and chronic rejection. During chronic CsA nephrotoxicity, 
tubulointerstitial collagens III and IV accumulated preferentially, and no increase in 
collagen I was noted. An early increase in deposition of collagen I along with collagens III 
and IV was more specifi c for chronic rejection.30 
Pathogenesis of chronic CsA nephrotoxicity 
Several hypotheses have been proposed to explain the pathogenesis of the chronic CsA 
nephrotoxicity. These hypotheses are not mutually exclusive. Many supporting data 
are derived from rat models in which CsA nephrotoxicity has been extensively studied. 
Although the lesions of chronic CsA nephrotoxicity in rats resemble the lesions as seen in 
man,31 there are important differences. Rats need much higher doses of CsA than humans, 
combined with salt depletion, or a special strain of spontaneously hypertensive rats has 
to be used. Therefore one should be cautious to extrapolate the data. Table 1 summarizes 
some of the work done in animals and humans.
The vascular hypothesis
This hypothesis assumes that chronic CsA nephrotoxicity is the result of ischemia. It 
is supported by morphologic and functional studies that report renal vasoconstriction, 
increased vascular resistance, decreased renal plasma fl ow, and pathologic alterations of 
renal arterioles. The fact that affected glomeruli appear shrunken, and that the fi brosis as 
studied in rats is initially patchy and occurs perpendicular from the corticomedullary junction 
may indicate a primary vascular etiology.25 Additional evidence is derived from animal 
studies that show modulation of CsA-induced renal fi brosis by drug-induced modulation 
of intrarenal nitric oxide (NO) production (Table 1). Inhibition of NO production increased 
vasoconstriction and augmented fi brosis, whereas stimulation of NO production improved 
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Table 1: Experimental work on pathogenesis of CsA nephrotoxicity 
Mediator, Enzyme, 
System*
Experimental setting Effect induced by CsA *
RAAS
Rat kidney
JGA hyperplasia; increase renin content; increased 
AT1 receptor reversed by antagonist; controversial 
amelioration of vasoconstrictor response by AT1 
antagonist or ACE inhibitor; less fi brosis with ACE 
inhibitor or AT1 antagonist independent of blood 
pressure reduction; TGF-β1 expression decreased 
by AT1 antagonist 
Rat plasma Renin increased
Human kidney
JGA hyperplasia, decreased renin after CsA 
withdrawal; AT1 receptor antagonist; ACE 
inhibitor- no effect on vasoconstrictor response
Human plasma Renin increase controversial
Human renal cortex fi broblasts culture ACE inhibitor- reversed collagen synthesis
Human PTEC culture
ACE inhibitor- reversed stimulated 
TGF-β secretion
TGF-β
Cultured cells, human and animal Increased secretion
In vivo expression, rodents and humans Increased expression
Gene polymorphism, humans Affected degree of fi brosis
Blocking antibody in rats Fibrosis not reduced
Osteopontin
Rat model, CsA nephrotoxicity
Increase paralleling macrophage infi ltration and 
fi brosis
Human biopsy No correlation with macrophage infi ltration
MCP-1 Human allograft biopsy Increased tubular expression
IGF-1
Cultured human renal fi broblasts Production stimulated
Receptor antibody, cultured fi broblasts Collagen synthesis abrogated
IGF-1BP2 or 3 Cultured human renal fi broblasts Secretion inhibited
PDGF Cultured human tubular cells Increased secretion
TIMP-1
Cultured human skin fi broblasts mRNA up-regulated
Biopsy rat model, CsA nephrotoxicity Increased expression
PAI-1 Biopsy rat model, CsA nephrotoxicity Increased expression in area of tubular atrophy
MMP-2 or 9 Cultured human renal fi broblasts Reduced secretion
P-glycoprotein Rat model, CsA nephrotoxicity
CsA induced P-glycoprotein expression; inverse 
correlation with severity of fi brosis and angiotensin 
II expression
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Experimental setting Effect induced by CsA *
NO
Endothelium-dependent vasodilatation 
in vivo, in vitro, ex vivo in humans and 
animals 
Impaired but not in all studies
Tissue, plasma, urinary metabolite levels 
in humans or animal models
Contradictory results
Tissue NOS isoforms expression
iNOS decrease, eNOS increase in vitro, not in an 
animal model 
NO modulation, rat model, CsA 
nephrotoxicity
NO inhibition- more fi brosis, tubular apoptosis; NO 
enhancement- less fi brosis and tubular apoptosis, 
TGF-β1 and PAI-1 downregulated
L-arginine or L-NAME administration, 
animals 
Improvement or worsening of renal hemodynamics
L-arginine administration, human organ
transplantation
No improvement of renal function or hemo-
dynamics in 3 studies; 1 study showed improvement
Endothelin-1
Cultured renal cells Increased secretion
Human renal biopsy Increased expression
Urinary and plasma levels, rat and human Elevated
Receptors, rat kidney Increased
Endothelin 1 antibody treatment, rat Partial relief of vasoconstriction
Receptor blockade, rat
Partial relief of vasoconstrictor response, 
not all studies
Receptor blockade, human
Modest increase in renal blood fl ow; 
no increase in GFR
Blockade receptors in rat model No effect on fi brosis
VGEF Rat model, CsA nephrotoxicity
Increased expression in biopsy; VGEF 
administration ameliorated CsA-induced 
pathologic changes 
ROS Vit E administration in rat model Reduced fi brosis and mRNA of TGFβ and 
osteopontin
Uric acid Rat model, CsA nephrotoxicity
Pharmacologically induced hyperuricemia 
augmented fi brosis and arteriolar hyalinosis, 
increased renin, and decreased NOS-1 and 3 in rat 
kidney
Thromboxane A2
Blockade receptor in rat model, CsA 
nephrotoxicity
Less fi brosis
Table reference: See also reference 15 for addiotional references.
*  Abbreviations: RAAS renin-angiotensin-aldosterone system,TGF-β transforming growth factor beta, 
 MCP-1 monocyte chemoattractant protein 1, IGF-1 insulin growth factor 1, IGF-1BP insulin growth factor 
 binding protein, TIMP-1 tissue inhibitor of matrix metaloproteinase 1, PAI-1 plasminogen activator inhibitor 
 1, MMP matrix metaloproteinase, P-GP P-glycoprotein, NO nitric oxide, VEGF vascular  endothelial growth 
 factor, ROS reactive oxygen species, JGA juxta glomerular apparatus,  iNOS inducible nitric oxide synthetase, 
 eNOS  endothelial nitric oxide synthetase, NOS nitric oxide synthetase
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renal blood fl ow and decreased fi brosis.32 In our own Sandimmune-Neoral conversion 
study, it was found that the use of calcium channel and beta blockers reduced the risk of 
nephrotoxicity, independent from their effect on blood pressure. Both class of drugs may 
counteract CsA-induced vasoconstriction, which may be partly mediated by nervus truncus 
sympathicus activation.9,3 
Direct cytotoxicity
CsA may directly damage renal cells and induce cell death and subsequent fi brosis. 
CsA is a highly lipophilic substance, which binds extensively to the cell membrane and 
its organelles and is concentrated in renal tissue 5- to -10-fold.34 It may infl uence the 
physical properties of cellular membranes, but it does not seem to disrupt its integrity.35 
Ultrastructural morphologic studies of native kidneys have shown CsA-induced pathologic 
changes in endothelial cells, proximal tubular cells and smooth muscle cells. To study 
the direct cytotoxic effects, the drug has been added to cell culture systems. Usually, a 
broad concentration range was tested because of uncertainty of the concentration in vitro 
that corresponds to tissue concentrations in vivo. In the reported studies, differences in 
experimental conditions varied and sometimes major differences were evident, which 
could have been of relevance.
Endothelial cells 
Several cell culture studies did not fi nd a direct cytotoxic effect of CsA on human umbilical 
vascular endothelial cells at CsA concentrations up to 10 µg/mL.36-37 In human umbilical 
vascular endothelial cells treated with a higher CsA concentration (12 µg/mL), an up-
regulation of adhesion molecules (intercellular adhesion molecule 1 [ICAM-1], vascular 
cell adhesion molecule 1 [VCAM-1], and E-selectin) was observed together with increased 
adherence of leukocytes.38 In a study of cultured rat endothelial cells, no toxicity was 
observed during a 6-day exposure period at maximum CsA concentrations of 1 µg/
mL.39 However, other studies did report cytotoxicity in bovine aorta endothelial cells at 
1.2 µg/mL,40 or 12 µg/mL.41 Cell death of bovine glomerular endothelial cells was also 
reported, occurring at 1.2 µg/mL and within 3 hours42 and suggested that endothelial cells 
derived from glomeruli are more sensitive. Further evidence for endothelial cytotoxicity 
is derived from studies that show an increase of various plasma markers of endothelial 
dysfunction that tend to normalize after CsA withdrawal.43 Another study reported an 
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elevated number of circulating endothelial cells compared with levels in allografted patients 
not receiving calcineurin inhibitor therapy or in normal control subjects.44 Although 
these data are somewhat contradictory, it can still be suspected that CsA is cytotoxic for 
endothelial cells, especially at high concentrations. 
Tubular cells 
Morphologic alterations of proximal tubular epithelial cells (PTEC) and a higher rate 
of tubular apoptosis in biopsies with CsA nephrotoxicity45-46 have suggested that CsA 
could be directly involved in tubulotoxicity. The lack of tubular atrophy in the absence 
of signifi cant glomerular sclerosis in human studies, however, argues against a direct 
tubulotoxic effect.22
Contradictory results have been reported in cell culture studies that used PTEC from 
various nonhuman and human sources. Two human studies reported loss of viability at 
a CsA concentration of 0.05 or 1 µg/mL,47-48 whereas another study found no toxicity, 
despite the fact that higher concentrations (up to 10 µg/mL) were used.49 The variance may 
be explained by differences in experimental protocols. In the positive studies, PTEC were 
deprived of essential culture supplements before incubation with CsA47 or were of fetal 
origin.48 Recently, necrosis or apoptosis was studied in cultured adult human PTEC.50 No 
direct toxic effect of CsA was shown at concentrations up to 10 µg/mL, whereas higher 
concentrations proved to be toxic because of the vehicle Cremophore EL. 
Smooth muscle cells 
CsA stimulates the contraction and proliferation of cultured rat smooth muscle cells 
through an endothelin 1-dependent pathway and likewise the proliferation of human 
pulmonary artery smooth muscle cells, without signifi cant toxicity at concentrations up 
to 0.12 µg/mL.51-53 Two studies reported cytotoxicity at slightly higher concentrations up 
to1 µg/mL.51-54 In 1 of these studies, no proliferative effect of CsA on smooth muscle cell 
growth was found. 54 Another study reported visceral smooth muscle cell dedifferentiation 
depending on calcineurin inhibition.55 The overall data on smooth muscle cells are limited 
and lack a proof of cytotoxicity. 
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Growth Factors and Cytokines 
Cyclosporine A may induce tissue remodeling by growth factor or cytokine release (Table 
1). Results from in vivo and in vitro studies have suggested that CsA may stimulate 
matrix deposition independently of morphologic or functional vascular changes. In rats, 
CsA stimulates early interstitial matrix deposition, which precedes PNHD development 
and occurs independently of the hemodynamic changes.24,56,57 It has been shown that 
angiotensin II plays a prominent role in chronic CsA nephrotoxicity in rodent models of 
chronic CsA nephrotoxicity.57-60 Coadministration of angiotensin-converting enzyme 
(ACE) inhibitors or angiotensin II type 1 receptor antagonists minimize tubulointerstitial 
fi brosis independently of renal hemodynamic changes.58-60 In vitro experiments with 
renal resident cells derived from rodents, primates, and humans have demonstrated that 
CsA stimulates the production of collagen.47,61 Also, evidence for an impairment of 
matrix degradation has been found in cell culture studies47,62 and in a rat model of CsA 
nephrotoxicity.63 Various growth factors have been implicated in this scarring process. CsA 
stimulates the expression of transforming growth factor β1 (TGF-β1) by renal resident cells 
and macrophages.24,64,65 This increase in TGF-β1 expression may be driven by angiotensin 
II,66 or by endothelin. 
There is abundant evidence that CsA stimulates endothelin production.67 Blockade of 
endothelin receptors in a rat model of CsA nefrotoxicity, however, did not result in a 
decrease in fi brosis, which draws into question the importance of this endothelin-TGF-β1 
interaction.57,68 Losartan or enalapril decreased TGF-β1 messenger RNA (mRNA) and 
decreased extracellular matrix deposition in a rat model,59 emphasizing a central role of 
angiotensin II in rodents. Pirfenidone, a novel antifi brotic compound, decreased TGF-β1 
mRNA and protein expression and ameliorated fi brosis in CsA-treated rats.69 However, 
the use of TGF-β1 antibodies did not change the extent of tubulointerstitial fi brosis 
despite a decrease in PNHD and preservation of function.64 In cultured human PTEC, 
enalapril prevented the CsA-induced TGF-β 1 secretion.70 Likewise, TGF-β 1 plasma 
levels decreased in renal allograft recipients with losartan treatment.71 Angiotensin II also 
stimulates (CTGF) gene expression. However, this pathway is shown to be calcineurin-
dependent and directly inhibited by CsA itself, which makes it a less likely candidate to be 
involved in chronic CsA nephrotoxicity. 
CsA treatment of cultured human renal cortical fi broblasts stimulated insulin-like growth 
factor 1 (IGF-1) secretion and inhibits secretion of IGF-1 binding proteins 2 and 3.47 CsA 
signifi cantly stimulated collagen synthesis in the same model and inhibited the expressions 
of enzymes involved in matrix degradation. CsA did not affect TGF-β1 protein secretion in 
the same study. An anti-IGF-I receptor antibody abrogated increased collagen synthesis. In 
human PTEC, CsA also stimulated the secretion of the fi brogenic cytokine platelet-derived 
growth factor.47
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Signifi cant infi ltration with mononuclear cells occurs before the development of interstitial 
fi brosis in rats with chronic CsA nephrotoxicity.72 The macrophage chemoattractant 
osteopontin was found to be upregulated in PTEC and correlated with the degree of 
macrophage infi ltration and fi brosis development in rats.58 However, in humans no 
correlation was found between tubular osteopontin expression and monocyte-macrophage 
infi ltration.73 In biopsies of human kidney transplant recipients who were believed to have 
chronic CsA toxicity, intense tubular staining for endothelin 1, RANTES (regulated upon 
activation, normal T-cell expressed and secreted), and monocyte chemoattractant protein 
1 mRNA was found in areas of tubular atrophy and fi brosis. So far, it is not clear what 
triggered the upregulation of these molecules.74 
Prevention of Chronic CsA Nephrotoxicity
Currently, calcineurin inhibition is still a cornerstone in immunosuppressive therapy after 
kidney transplantation. Possible ways to prevent chronic CsA nephrotoxicity include a better 
control of CsA exposure, withdrawal of CsA after a critical time frame, or the complete 
avoidance of CsA. Also, the use of tacrolimus instead of CsA may be considered. 
Improved therapeutic drug monitoring
Almost 25 years of CsA therapy has been monitored in trough blood levels (C0). C0 
levels were kept within the “therapeutic range”, with differences in target levels in various 
transplantation centers (in the United States, often 150-250 µg/L; in Europe, 100-200 
µg/L), but a signifi cant number of patients experienced a lack of effi cacy or renal toxicity. 
Data from the Collaborative Transplant Study have indicated that the 1-year CsA dose is 
signifi cantly associated with long-term graft survival with evidence of a worse prognosis 
at doses less than 3 mg/kg per day or higher than 6 mg/kg per day.75 Recently, it has been 
shown that C0 levels correlate poorly with systemic CsA exposure as measured by the area 
under the 12-hour concentration versus time curve [(AUC(0-12)] because of extensive 
interpatient and intrapatient variability in CsA absorption and metabolism.76 A number 
of patients are overexposed or underexposed to the drug when C0 monitoring is used. 
These data suggest that there could be a therapeutic window for individual dosing that 
combines maximum effi cacy with minimal toxicity. Neoral, the microemulsion preparation 
of CsA, displays a predictable absorption profi le with the absorption phase of the drug 
having the greatest interpatient and intrapatient variability. The 4-hour AUC [AUC(0-4)] 
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as estimated by limited sampling models (LSMs) has been shown to correlate closely 
with systemic exposure.77 Inadequate CsA exposure is a major risk factor for (subclinical) 
AR, which predisposes to late allograft failure.78 Neoral dosing based on AUC(0-4) 
measurement conveys a higher effi cacy and lower risk of toxicity of the drug early after 
transplantation than dosing on C0 levels.79 The concentration 2 hours after ingestion (C2 
level) is a good predictor of the absorption phase measured by the AUC(0-4), and C2-
guided dose adjustments resulted in much lower AR rates early post-transplantation.80-81 
Newer studies show that achieving AUC(0-4) values of 4400 to 5500 µg⋅h/L or C2 levels 
of 1500 to 2000 µg/L during the fi rst 3 days after transplantation minimizes the risk of 
rejection and improves graft function.80,82,83 However, in comparison with C0 levels, 
the single-point C2 level does not correlate better with total systemic exposure to CsA 
as measured by AUC(0-12).84 C2 monitoring thus prevents underexposure and provides 
higher effi cacy but does not give better protection than C0 monitoring against overexposure 
of the drug with the risk of long-term nephrotoxicity. As compared with C0 monitoring, 
the use of LSMs has improved the estimation of systemic exposure, but equations are 
rigid and not reliable in patients with an abnormal absorption profi le. A compartmental 
population pharmacokinetic model for CsA in renal transplant recipients combined with the 
maximum a posteriori Bayesian fi tting method seems more practical because it offers the 
important advantage of fl exibility in sampling times after drug administration and provides 
the opportunity for long-term AUC-guided dosing.84 The performance of this model is 
comparable to that of LSMs in kidney transplant patients and superior in SPK recipients. 
Measuring CsA concentrations at the time points 0, 2 and 3 postdose hours provides an 
excellent estimation of the AUC(0-12). However, it remains to be shown that therapeutic 
drug monitoring of CsA based on AUC estimation will provide protection against long-
term CsA nephrotoxicity. 
Withdrawal studies
An alternative approach is to reduce the exposure to CsA after the period of the highest 
chance of AR. A number of clinical trials have examined the safety of CsA withdrawal from 
dual therapy with steroids and replacement by azathioprine. Improvements in renal function, 
lipid profi le, hypertension, and the incidence of gout were reported.85 A 10% increase in 
the AR rates was also observed. However, a higher rate of subsequent graft loss was not 
reported.85 Recently analyzed 15-year data from a single-center, open-label, prospective 
randomized study that compared CsA continuation with conversion to azathioprine 3 
months after transplantation showed a higher risk of CAN in the group that continued 
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CsA (relative risk, 4.3; 95% confi dence interval, 1.4-12.9).16 In the study, predominantly 
white recipients were included who were generally well matched for human leukocyte 
antigens. A better death-censored graft survival was observed in the azathioprine group 
after 2 post-transplantation years. The 15-year death-censored graft survival was 81.9% vs 
69.2% (P = 0.012). The study showed that long-term allograft function is better preserved 
after conversion to a calcineurin inhibitor-free immunosuppressive regimen. These results 
are in line with data from a not yet published multicenter Australian conversion study with 
an identical follow-up. In this study, a highly signifi cant difference in mean graft survival 
was found favoring CsA usage shorter than 6 months (13.3 vs. 11.8 years, P <0.01).17 
CsA withdrawal from a triple regimen has also been studied and resulted in a similar increase 
in AR rates.86 It was found that MMF continuation instead of a switch to azathioprine 
provided better protection against AR.87 Another drug that has been used after the 
withdrawal of CsA is sirolimus. The use of sirolimus in a triple-drug regimen together with 
CsA and steroids directly after transplantation results in a lower incidence of AR than when 
azathioprine is used.88 However, a mild adverse effect on renal function has been noted, 
which is in line with earlier animal studies that showed increased CsA nephrotoxicity.89 This 
adverse effect may be explained by a pharmacokinetic interaction of sirolimus with CsA 
that increases systemic CsA exposure and CsA at the tissue level. Both drugs are substrates 
for P-glycoproteins and for cytochrome P-450 3A4 and are mutually competitive, mostly 
at the gut level, increasing each other’s oral bioavailability.90 The administration of either 
drug at 4-hour intervals may minimize the interaction in the absorption phase, but at the 
tissue level a second interaction occurs. Sirolimus increases renal tissue concentrations 
of CsA, whereas CsA decreases the sirolimus concentration.91 The specifi c interaction of 
sirolimus with CsA at the tissue level impairs precise pharmacodynamic titration of CsA by 
whole-blood levels. Results for CsA withdrawal at 3 months from a sirolimus-containing 
triple regimen have been reported.92 A non-signifi cant 6% increase of AR was noted, but at 
1 year a better GFR (difference, 6 mL/min) was seen in the group that was withdrawn from 
CsA. The 3-year results showed a 6% higher graft survival (P = 0.052) and a signifi cantly 
higher GFR of 12 mL/min.93 CsA therapy in this study was monitored on C0 measurements, 
and the study did not include highly sensitized patients or patients with severe rejection 4 
weeks previously; also, there were few black recipients, no HLA-identical patients, and no 
patients with poor allograft function. 
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Tacrolimus-Based Vs CsA-based Immunosuppression
Several studies reported a lower incidence and lesser severity of AR early after 
transplantation with a tacrolimus-based immunosuppressive regimen as compared with 
CsA-based treatment irrespective of the type of CsA formulation used.94 A higher GFR 
and a reduced requirement for antihypertensive and lipid-controlling medication were 
also recorded. A better graft survival at 1 year after transplantation was found in pediatric 
patients receiving tacrolimus compared with those receiving the CsA microemulsion 
formulation.95 The 3-year kidney allograft survival in adult patients receiving tacrolimus 
was higher only in the patients who experienced delayed graft function.96 Another study 
reported equivalent graft survival at 5 years, but a higher incidence of treatment failure 
was observed during CsA therapy, which led to higher crossover to tacrolimus.97 Yet 
another study found no difference in graft survival at 5 years in pairs of kidneys allocated 
to either initial tacrolimus or initial CsA treatment; however, treatment failures were not 
examined.98 In protocol biopsies, a higher degree of allograft fi brosis was reported at 1 year 
after transplantation in patients on a regimen of CsA compared with those on a regimen of 
tacrolimus,99 whereas in a different study of 2-year biopsies, no difference in CAN score 
or subclinical rejection was observed.100 These data are still inconclusive on the long-term 
benefi t of tacrolimus-based therapy over CsA-based therapy. Early posttransplantation 
tacrolimus seems to provide a higher level of protection against rejection; however, newer 
ways of therapeutic drug monitoring were not used in any of the mentioned studies. 
An important trade-off of tacrolimus-based therapy is the higher incidence of posttransplant 
diabetes mellitus, which may have an adverse effect on graft and patient survival.101 
Tacrolimus may also induce chronic calcineurin inhibitor nephrotoxicity with pathologic 
characteristics similar to those of chronic CsA nephrotoxicity.
Avoidance of Calcineurin Inhibitors
Long-term CsA nephrotoxicity could be prevented by complete avoidance of the drug. 
A prerequisite is the use of an alternative equipotent immunosuppressive drug with an 
acceptable safety profi le. A recent study on sirolimus-based therapy suggested that the 
drug has antirejection effi cacy similar to that of CsA and at 6 and 12 months the GFR was 
higher in the patients receiving sirolimus.102 Long-term results of studies on calcineurin-
free immunosuppressive therapy are still lacking. 
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CsA sparing in patients with established CAN
CsA sparing in patients with established CAN has been studied with MMF as the sparing 
agent.18 The slope in GFR decline before and after intervention was compared. Fifty to 
sixty percent of the patients treated with either a reduced dose of CsA (n = 67) or tacrolimus 
(n = 33) showed an improvement in the rate of decline; more than 90% of the patients who 
stopped calcineurin inhibitor medication (n = 18) showed a slowing of the loss of function. 
A small risk of AR was noted. Another ongoing multicenter study examined the withdrawal 
of CsA in patients with chronic gradually declining allograft function. After 6 months, 
stabilization or improvement was seen more often (58% vs 32%) in the patients who were 
converted to MMF (n = 73) as compared with the ones that continued on CsA (n = 70). No 
signifi cant differences in AR, graft loss, or death were observed.19 These studies show that 
it may be advantageous to withdraw patients from CsA when allograft function is declining 
and renal biopsy indicates aspecifi c signs of CAN.
Conclusions
CsA-based immunosuppressive therapy is associated with signifi cant long-term 
nephrotoxicity. The recognition of chronic CsA nephrotoxicity in allografted kidneys is 
still imperfect and needs to be improved. New strategies to prevent toxicity such as CsA 
withdrawal after a critical period, improved therapeutic drug monitoring, and the use of a 
calcineurin inhibitor-free immunosuppressive regimen are likely to be implemented more 
often in the near future. Patients with aspecifi c CAN in late biopsy samples may benefi t from 
withdrawal of CsA or a reduction of its dose in conjunction with MMF administration.
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Abstract
Background: The pathogenesis of chronic cyclosporine A (CsA) nephrotoxicity is largely 
unknown. In this study we examined whether CsA produces cell death through necrosis or 
apoptosis of either cultured human proximal tubular epithelial cells (PTEC) or the porcine 
tubular cell line LLC-PK1.
Methods: Primary isolates of human PTEC and LLC-PK1-cells were treated for various 
time periods with CsA at concentrations of 0.01-100 µg/ml. Apoptosis was studied by the 
assessment of annexin binding and propidium iodide uptake, the measurement of cellular 
DNA content and cell cycle analysis, and by the evaluation of nuclear morphology. Cell 
death was studied by the trypan blue exclusion method. Hypoxic conditions were simulated 
through chemical ATP depletion. 
Results: In human PTEC, cell death was observed at CsA concentrations higher than 
10 µg/ml; at these concentrations PTEC died as a result of necrosis and toxicity of its 
vehicle Cremophore EL, and not as a result of CsA inducing apoptosis. The addition of 
cycloheximide to relief a possible block in the apoptotic process had no effect on human 
PTEC, but did result in apoptosis of LLC-PK1. In human PTEC, CsA did not augment cell 
death induced by chemical ATP depletion. 
Conclusions: The results of this in vitro study do not support the hypothesis that CsA 
directly induces cell death of proximal tubular epithelial cells. 
Introduction
Cyclosporine A (CsA) is one of the most widely used drugs in organ transplant patients.1 
CsA-based immunosuppressive regimens are associated with 1-year success rates for 
kidney transplants of ~ 90%,2 but a major drawback is CsA renal toxicity. Acute CsA 
nephrotoxicity is characterized by renal vasoconstriction and is largely reversible upon 
dose reduction.3 An irreversible decline in kidney function may also be observed after 
long-term CsA use and is associated with structural changes such as interstitial fi brosis, 
tubular atrophy, arteriolar hyalinosis and glomerulosclerosis.4 
The exact pathogenesis of chronic CsA nephrotoxicity remains unknown.1 Morphological 
studies reported proximal tubular epithelial cell vacuolization and inclusion bodies early 
after transplantation during CsA treatment, and animal and human studies have found 
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an increase in the urinary excretion of the proximal brush border enzyme N-acetyl-β-D-
glucosaminidase.5 Moreover, the urinary excretion of β2-microglobulin is enhanced during 
CsA therapy, suggesting proximal tubular cell damage.6 It has recently been hypothesized 
that a high concentration of CsA directly induces tubular cell necrosis and that a lower 
therapeutic concentration of the drug promotes apoptosis.7 In both human and animal 
studies, a higher rate of tubular cell apoptosis has been described during CsA exposure;8-9 
however, it is still not clear whether this increased apoptotic activity is the result of a direct 
toxic effect of CsA or the result of an indirect mechanism such as ischemia. The aim of the 
present study was to examine whether CsA directly induces cell death of cultured proximal 
tubular epithelial cells by either necrosis or apoptosis.
Materials and methods
Materials
CsA was obtained as Sandimmune®, containing Cremophore EL and alcohol as vehicle 
(2:1) (Novartis Pharma B.V. Arnhem, The Netherlands), and as a powder (Sigma, St Louis, 
MO, USA) which was dissolved in ethanol. The mouse monoclonal antibody anti-Fas15 
was a gift from Prof. L.A. Aarden (Central Laboratory of The Netherlands Red Cross 
Blood Transfusion Service, Amsterdam, The Netherlands). Antimycin A (AA), 2-deoxy-D-
glucose (DOG) and cycloheximide (CHX) were obtained from Sigma.
Cell cultures
All cell cultures were performed in an incubator using a humidifi ed 5% CO2/95% air 
mixture at 37°C. Human primary proximal tubular epithelial cells (PTEC) were obtained 
from pre-transplant renal biopsies as described previously.10 In brief, small fragments of 
pre-transplant biopsies were placed in 25 cm2 fl asks (Costar, Cambridge, MA, USA) coated 
with a matrix of type I bovine collagen (Sigma) and decomplemented fetal calf serum (FCS; 
Gibco BRL, Breda, The Netherlands) in Dulbecco’s modifi ed Eagle’s medium (DMEM/
HAM-F12 at a ratio of 1:1 (Seromed, Biochrom KG, Berlin, Germany) supplemented with 
insulin (5 µg/ml), transferrin (5 µl/ml), selenium (5 ng/ml), hydrocortisone (36 ng/ml), 
tri-iodothyronine (4 pg/ml) and epidermal growth factor (10 ng/ml) (all from Sigma). 
Medium was replaced every 3 days. The cells grown from the biopsied tissue showed 
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the characteristic morphology of tubular cells and immunofl uorescence staining confi rmed 
their proximal descent (Figure 1A and 1B). Subculturing of these cells was performed in 
the same type of medium using 25 and 75 cm2 fl asks (Costar) coated with FCS only. PTEC 
between passage 2 and 7 were used for the experiments. The porcine cell line LLC-PK1 was 
kindly provided by Dr Michael P. Ryan (Department of Pharmacology, University College 
Dublin, Ireland). The cell line was originally obtained from the ATCC (Manassas, VA, 
USA), and cells have the characteristics of renal PTEC.11 LLC-PK1 cells were subcultured 
in 75 cm2 fl asks (Costar) using DMEM culture medium (Seromed) supplemented with 10% 
(v/v) decomplemented FCS. LLC-PK1 cells were used between passage 210 and 230. 
100 101 102 103 104 100 101 102 103 104
Figure 1: (A) Morphological appearance of primary cultures of human PTEC. The characteristic 
“dome” is the cell layer that has been lifted from the solid surface as a result of active ionic transport 
processes. (B) FACS analysis using a monoclonal antibody against alanine aminopeptidase (CD13), 
a cell surface marker that distinguishes proximal from distal TEC but not from fi broblasts, and an 
antibody against Thy-1/CD90 that is present on fi broblasts but not on TEC. The grey area under the 
curve represents cells that were incubated with the specifi c monoclonal antibody, while the white area 
represents cells that were incubated with the secondary antibody only (see Material and methods). 
The strong staining for CD13 and the absence of staining for CD90 confi rms the proximal descent 
of the cultured TEC.
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Fluorescence-activated cell sorter (FACS) analysis
For FACS analysis, cells were harvested by brief trypsinization to prevent proteolysis of 
surface receptors. After the cells were washed twice with FACS buffer (1% BSA, 1% 
decomplemented normal human serum, 0.02% sodium azide in PBS), 105 cells were 
incubated with specifi c monoclonal antibodies against either alanine aminopeptidase 
(CD13) or Thy-1/CD90 (AS02, Dianova-Hamburg, Germany). After incubation for 45 min 
at 4°C, cells were washed twice with FACS buffer and subsequently incubated with goat 
anti-mouse Ig-PE (DAKO) for 30 min at 4°C. Finally, the cells were washed, fi xed with 1% 
paraformaldehyde, and assessed for fl uorescence using a FACScan and LYSIS-II software 
(Becton Dickinson, Mountain View, CA, USA).
Cell treatments
For viability and apoptosis assays, cells were washed with PBS, trypsinized and seeded 
at a concentrations of 1.5 x 105 (human PTEC) or 0.5 x 105 (LLC-PK1 cells) in 24-well 
plates (Greiner, Frickenhausen, Germany) coated with FCS, and grown for 24 h to assure 
culture subconfl uence. They were then washed with PBS and treated for 24 h with CsA 
dissolved in culture medium, in a humidifi ed incubator supplying a 5% CO2/95% air 
mixture at 37°C. CsA-containing solutions were prepared by direct dilution of the clinical 
formulation Sandimmune® (CsA 50 mg/ml in Cremophore EL and ethanol 2:1)) in culture 
medium or by dissolution of CsA powder (Sigma) in absolute ethanol (5 mg/ml), with 
further dilutions made in culture medium. The fi nal concentrations achieved were checked 
by a radioimmunoassay and the biological activity was measured in an OKT3 T-cell 
proliferation assay. Inhibition of T cell proliferation was found with CsA dilutions up to 
0.01 µg/ml. 
To induce a state resembling tissue hypoxia in vivo, cultured cells were ATP depleted 
with the use of glucose-free culture medium and the addition of 2 µM Antimycine A, an 
inhibitor of the mitochondrial respiratory chain, and 5 mM 5-deoxy-D-glucose, an inhibitor 
of glycolysis. 
Evaluation of cell viability
Cell viability was evaluated using the trypan blue exclusion assay. In brief, spontaneously 
detached cells and cells obtained after trypsinization were pooled and tested visually for 
their ability to exclude the dye. Cells that stained with trypan blue were considered dead.
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Detection of apoptosis
After the culture supernatant was harvested, cells were washed in PBS and trypsinized to 
single cell suspensions. Trypsin was subsequently inactivated by the addition of culture 
medium supplemented with 10% FCS. PBS and the cell suspension were pooled with the 
supernatant and pelleted by centrifugation for 5 min at 230 g. 
For morphological assessment, cells were fi xed with 1% paraformaldehyde and kept on 
ice for at least 10 min. Cytospin specimens were prepared, stained for 3 min with Hoechst 
33258 and evaluated by fl uorescent microscopy. 
For the assessment of phosphatidylserine externalization, cells were washed in 1 ml annexin 
buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM CaCl2, pH 7.4 adjusted at 4°C), resuspended 
in 50 µl FITC-annexin V (Nexins Research, Kattendijke, The Netherlands) (1/250 in 
binding buffer) and incubated for 15 minutes in the dark on ice. Prior to measurement, 
100 µl of propidium iodide (PI; Molecular Probes, Leiden, The Netherlands) diluted in 
annexin buffer (fi nal concentration 1 µg/ml) was added. Labeled cells were analyzed on a 
FACScan using the Lysis II software. The percentage of cells binding FITC-annexin V and/
or PI was calculated using the WinMDI2.7 software. Cells that were negative or positive 
for both dyes were considered live or dead, respectively, while apoptotic cells were only 
positive for FITC-annexin V.12 
To evaluate cellular DNA content, cells were washed and resuspended in 100 µl of 1 mM 
EDTA/PBS at 4°C, fi xed by adding 700 µl 100% ethanol at –20°C and incubated for 30 min 
at –20 °C. Subsequently, cells were washed twice in 1 mM EDTA/PBS and resuspended in 
300 µl PBS to which the following was added: EDTA (1 mM), PI (10 µg/ml) and RNAse A 
(50 µg/ml; Sigma). After a 45 minutes incubation at room temperature, cells were analyzed 
on a FACScan. The fraction of cells in each phase of the cell cycle was calculated according 
to cell DNA content using the WinMDI2.7 software. 
Results
The effect of CsA on the viability and mode of cell death of primary isolates of human 
PTEC 
Primary cultures of human PTEC were obtained from biopsies taken at kidney 
transplantation.10 The proximal tubular descent of the cells growing out the tissue was 
confi rmed by their characteristic epitheloid cell shape, their ability to form domes (Figure 
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1A) and their immunofl uorescence staining for alanine aminopeptidase (CD13), a cell-
specifi c marker for PTEC. Isolates were cultured for 24 h in the presence of increasing 
concentrations of the clinical formulation Sandimmune®, and tested for their ability to 
bind annexin V and to take up PI. As an apoptosis control we used the mouse monoclonal 
antibody anti-Fas15 (1 µg/ml) combined with cycloheximide (10 µg/ml) dissolved in 
culture medium, as described previously.12
At CsA concentrations of 10 µg/ml or lower, no signifi cant increase in either annexin V 
binding or PI uptake was observed (Figure 2). Similar results were obtained when the 
number of cells seeded in the wells was reduced to 25%, the incubation period with CsA 
was extended to 72 h, or 20% (v/v) serum added to the media during CsA exposure (results 
not shown). A signifi cant increase in the number of annexin V, PI positive cells (71% vs 
medium control 6.8%) was noted when a CsA concentration of 100 µg/ml was used. In the 
apoptosis control, signifi cantly more cells stained for annexin V alone or for both dyes. 
Subsequently, the DNA content of the cells was examined after 24 hours of incubation with 
CsA and the stage of the cell cycle was analyzed (Figure 3). A signifi cant increase in the 
number of cells with a reduced DNA content (sub-G0/G1 fraction) was observed only at the 
highest CsA concentration (100 µg/ml). Next, we incubated PTEC for 24 h with increasing 
concentrations of CsA, and tested for dead cells by the use of the trypan blue exclusion 
method or for apoptosis by the evaluation of nuclear morphology (Figure 4). As expected, a 
concentration-dependent increase in cell death was observed at concentrations >10 µg/ml. 
However, no increase in the number of apoptotic cells was found (Figures 4 and 5).
The effect of CsA vs its vehicle on the viability of primary isolates of human PTEC
Next we compared the cytotoxicity of CsA or its vehicle Cremophore EL on human PTEC. 
PTEC were incubated for 24 h with high concentrations of Sandimmune, starting at 
10 µg/ml, or its vehicle at comparable dilutions. Cell death was determined by the trypan 
blue exclusion assay (Figure 6). The vehicle itself exerted a profound cytotoxic effect, 
which was at least equal to the effect of Sandimmune at comparable dilutions. To examine 
the toxicity of CsA alone, CsA powder was dissolved in alcohol and diluted further in 
culture medium. PTEC were incubated with increasing concentrations of CsA for 24 h. 
Concentrations up to 10 µg/ml did not result in an increased rate of cell death, as assessed 
by the trypan blue method or in an increase of cells that displayed morphological signs 
of apoptosis (data not shown). A higher concentration could not be tested because of the 
inability to dissolve CsA. These results suggest that in primary isolates of human PTEC, 
the acute cellular toxicity of CsA at concentrations >10 µg/ml is mainly the result of vehicle 
toxicity and is not caused by the drug. 
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Figure 2: The effect of Sandimmune® on apoptosis or cell death of PTEC, as assessed by fl ow 
cytometric analysis of FITC-annexin V binding and PI staining. Cells were treated for 24 h with 
medium, the anti-Fas15 monoclonal antibody combined with cycloheximide 10 µg/ml (A) or increasing 
concentrations Sandimmune (B) Bottom-right quadrants: cells with externalized phosphatidylserine 
but still with an intact cell membrane, indicative of cells in early apoptosis. Top-right quadrants: cells 
positive for both dyes, i.e. late apoptotic or necrotic cells. 
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Figure 3: The effect of Sandimmune® on the cell cycle of human PTEC. Human PTEC were 
incubated for 24 h with the anti-Fas15 monoclonal antibody combined with cycloheximide (A) 
medium (B) or increasing concentrations of CsA (C-F) and the DNA contents of the cells was 
analyzed on a Facscan. An increase in the number of cells with reduced DNA content was observed 
at a Sandimmune concentration of 100 µg/ml and in the apoptosis control.
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Figure 4: The effect of Sandimmune® on cellular viability and nuclear morphology of human 
PTEC. Cells were exposed to increasing concentrations of Sandimmune for 24 h. Cell death was 
measured by the trypan blue exclusion assay, and apoptosis by analysis of nuclear morphology 
using fl uorescence microscopy after staining with Hoechst 33258. Results are expressed as the mean 
± SEM of a representative experiment, performed in triplicate wells (n = 3).
Figure 5: Nuclear morphology of Sandimmune®-treated human PTEC. PTEC were treated for 24 h with 
medium (A) CsA 0.1 µg/ml (B) CsA 100 µg/ml (C) or the antiFas15 monoclonal antibody combined 
with cycloheximide (D) Cytospin preparations were stained with Hoechst 33258 (magnifi cation: 
×400) and examined by fl uorescent microscopy. No change in nuclear morphology was seen after 
incubation with CsA 0.1 µg/ml. The apoptosis control (D) showed nuclei with characteristic signs of 
apoptosis, i.e. condensation and fragmentation (arrows). No such change was found after incubation 
with CsA 100 µg/ml, although nuclear morphology appeared different with some nuclei larger in size 
and some smaller.
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Figure 6: Comparison of the cytotoxic effect of Sandimmune® and the vehicle Cremophore EL 
on human PTEC. Cells were exposed to Sandimmune or vehicle at comparable dilutions for 24 h. 
Numbers on the x axis indicate the corresponding CsA concentration of the Sandimmune dilutions. 
Results are expressed as the mean ± SD of experiments performed in duplicate wells (n = 3). *P < 0.05 
and **P < 0.01 compared with the medium control.
The effect of combined CsA and cycloheximide on apoptosis in primary isolates of human 
PTEC and LLC-PK1 cells
The addition of cycloheximide may relief the resistance to a pro-apoptotic stimulus in 
PTEC,12 therefore we examined the effect of CsA plus cycloheximide on both human 
PTEC and the porcine proximal tubular cell line LLC-PK1, for which a pro-apoptotic 
infl uence of CsA has been described.7 Human PTEC or LLC-PK1 were incubated with 
1 µg/ml of the clinical formulation Sandimmune combined with cycloheximide (10 µg/ml) 
or cycloheximide alone for 24 h, and apoptosis was evaluated by nuclear morphology 
(Figure 7A). In human PTEC, the addition of cycloheximide did not increase the number 
of cells with apoptotic nuclear morphology, whereas the combination produced apoptosis 
in 27.5 ± 3.5% of LLC-PK1 cells. Cycloheximide alone, however, induced a comparable 
degree of apoptosis, disclosing a difference in the regulation of apoptosis between primary 
isolates of human PTEC and LLC-PK1 cells. Similar results were obtained for PTEC 
when CsA concentrations of  >10 µg/ml were used. A dose-response curve of CsA, with 
or without 10 µg/ml cycloheximide added to the medium, did not reveal pro-apoptotic 
features of CsA in LLC-PK1 cells (Figure 7B). Depriving LLC-PK1 cells of serum for 24 
h did not change the results, and neither did treatment with CsA dissolved in alcohol. The 
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addition of 20% (v/v) serum to medium of human PTEC did not prime these cells to enter 
apoptosis during simultaneous exposure to CsA and cycloheximide (data not shown). 
A
B
Figure 7: The effect of Sandimmune® combined with cycloheximide on apoptosis of human PTEC 
and LLC-PK1 cells (A) Human PTEC and LLC-PK1 cells were treated for 24 h with cycloheximide 
(10 µg/ml) with or without Sandimmune® 1 µg/ml, and apoptosis was evaluated by examining 
nuclear morphology. (B) Dose-response curve of 24-h Sandimmune® treatment of LLC-PK1 in the 
presence of cycloheximide. In human PTEC, the addition of cycloheximide to Sandimmune® did 
not result in an increase in the number of cells entering apoptosis. In LLC-PK1 cells, cycloheximide 
treatment produced a signifi cant increase in apoptosis. However, no effect of CsA either alone or in 
combination with cycloheximide was noted. Results are expressed as the mean ± SD of experiments 
performed in triplicate wells (n = 3) (A), or the mean ± SEM of experiments performed in duplicate 
(n = 3) (B). *P < 0.05; **P < 0.01.
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The effect of CsA on cell viability during chemical ATP depletion
Due to the renal vasoconstrictor potential of CsA in vivo and the demonstrated direct 
inhibitory effect of the drug on the ATP production of isolated mitochondria,3,13 we decided 
to examine cell death of human PTEC that were cultured under simulated hypoxic conditions 
and co-exposed to CsA. PTEC were therefore subjected to chemical ATP depletion using 
glucose-free culture medium, to which 2 µM Antimycine A and 5 mM 2-deoxy-D-glucose 
were added. The viability of cells was assessed by the trypan blue exclusion assay and 
apoptosis was evaluated by examining nuclear morphology. After 3, 6 and 24 h of ATP 
depletion a signifi cant increase in the number of dead cells was observed. The amount 
of cell death, however, was not infl uenced by the addition of CsA 1 µg/ml (Figure 8). No 
increase in apoptosis was noted at any time point or condition (data not shown). The use of 
a CsA concentration of 10 µg/ml did not change the results.
Discussion
In this study we examined the infl uence of CsA on the viability of cultured proximal 
tubular epithelial cells by measuring cell death through either necrosis or apoptosis. 
Human cells derived from primary isolates and an immortalized porcine cell line were 
used. Because CsA may be concentrated in renal tissue in vivo,14 and the corresponding 
levels in vitro have not been determined conclusively, we also examined concentrations 
that appear supraphysiological (up to 100 µg/ml). The results show that when CsA is used 
at concentrations as seen in vivo there is no effect on cell viability. Also, preconditioning 
for apoptosis by either ATP depletion or co-treatment with cycloheximide did not reveal 
any pro-apoptotic activity of CsA. At very high concentrations of CsA (>10 µg/ml), as 
used in the clinical formulation of Sandimmune, cultured human PTEC die as a result of 
necrosis due to vehicle toxicity. 
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Figure 8: The effect of chemical ATP depletion and Sandimmune® treatment on the viability of 
human PTEC. Cells were exposed for 3, 6 and 24 h to Antimycine A (2 µM) and 2-deoxy-D-glucose 
5 mM with or without Sandimmune® 1 µg/ml dissolved in glucose free culture medium. Cell death 
was measured by the trypan blue exclusion assay. Results are expressed as the mean ± SEM of 
experiments performed in triplicate wells (n = 5).
The exact pathogenesis of chronic CsA nephrotoxicity has remained elusive.1 
Histopathological studies have suggested a toxic effect of the drug on afferent arterioles and 
tubular epithelial cells, as exemplifi ed by hyaline changes in these vessels, morphological 
alterations in proximal tubular epithelial cells and a higher rate of tubular apoptosis assessed 
by the TUNEL assay.4,8 Evidence has also been presented to show that CsA may directly 
stimulate various cells in the kidney to locally produce profi brogenic growth factors.15 
Whether human PTEC are a direct target for CsA toxicity remains controversial. In the past, 
seemingly contradictory results have been obtained using cultured tubular epithelial cells 
and CsA concentrations achieved in vivo. Two studies reported loss of viability of cultured 
human PTEC after CsA exposure at CsA concentrations of 0.05 or 1 µg/ml,16-17 whereas 
another study did not, despite the fact that higher drug concentrations (up to 10 µg/ml) were 
used.18 This variance might be explained by differences in the experimental protocols. In 
the fi rst study,16 PTEC were deprived of essential culture supplements before incubation 
with CsA, whereas in the second study17 human PTEC were of fetal origin. 
The results of our in vitro study do not support the hypothesis that CsA induces apoptosis 
of human PTEC directly, as no increase in apoptosis was found over the full range of CsA 
concentrations tested (0.01-100 µg/ml). These fi ndings are at variance with three reports 
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that examined apoptosis induced by low concentrations of CsA in unspecifi ed human 
tubular epithelial cells,19 pig proximal tubular epithelial cells20 or LLC-PK1 cells.
7 The 
reason(s) for these discrepant results are not yet clear. Two of these previous studies19 
examined primary isolates of tubular cells, but used serum in their culture media.20 In 
contrast, we did not add serum during the isolation or subculture period of human PTEC 
in order to prevent undesired outgrowth of non-tubular cells.10 Differences in the primary 
cells studied may also be responsible for the variance. In another set of experiments we 
incubated human PTEC with tacrolimus, for which a similar histopathological pattern of 
nephrotoxicity has been described as for CsA. Likewise, no loss of cellular viability could 
be found, with 5 µg/ml the highest concentration tested (data not shown). 
To relief resistance to pro-apoptotic stimuli, cycloheximide has been used successfully in 
cell culture systems in the past.12 For PTEC, Fas ligation alone is not suffi cient to induce 
apoptosis, but in combination with cycloheximide, apoptosis is readily detectable.12 In our 
study, co-treatment of CsA and cycloheximide did not unmask a putative pro-apoptotic 
infl uence of CsA. Interestingly, we found a difference in regulation of apoptosis between 
primary isolates of human PTEC and the LLC-PK1 cell line. In LLC-PK1 cells, treatment 
with cycloheximide alone resulted in an increase in the number of cells entering apoptosis. 
This indicates that LLC-PK1 cells are a less suitable model for human PTEC when 
apoptosis is studied. 
In the present study we also decided to analyze the effect of CsA on PTEC that were 
chemically depleted of ATP, because CsA induces renal vasoconstriction in vivo and has 
an inhibitory effect on the ATP production of isolated mitochondria.13 We demonstrate 
that CsA does not affect cell death of ATP-depleted cultured human PTEC. However, 
this does not exclude the possibility that in vivo tissue hypoxia due to vasoconstriction or 
obstruction of afferent renal arterioles is still responsible for tubular cell apoptosis during 
CsA treatment, as has been suggested by the results of a study in salt-depleted rats.9 In this 
study, CsA treatment produced an increase in apoptosis in tubular cells, which was partially 
reversed by co-treatment with losartan, an angiotensin II type 1 receptor antagonist, or with 
L-arginine, a substrate for nitric oxide synthetase. 
We conclude that the cellular viability of cultured adult human PTEC is not infl uenced by 
short-term exposure to CsA at physiological concentrations during normo-oxic or simulated 
hypoxic experimental conditions. At very high drug concentrations, cultured human PTEC 
die as a result of cell necrosis, an effect that might solely be based on vehicle toxicity. 
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Abstract
Background: Conversion from cyclosporine to azathioprine after renal transplantation 
has been shown to be benefi cial in terms of allograft function, cardiovascular risk factor 
profi le and the incidence of gout. A higher incidence of acute rejection, however, has also 
been reported and uncertainty still exists about the long-term outcome after conversion. 
We report on the extended follow-up of an open-label, randomized trial that examined 
conversion to azathioprine as early as 3 months after transplantation. 
Methods: One hundred twenty-eight patients were enrolled in this single-center study. 
Three months after transplantation they were randomly assigned to continue cyclosporine 
treatment (N = 68), or they were converted to azathioprine (N = 60). The steroid dose was 
temporarily increased in the patients who were converted. 
Results: Patient survival was not different in the two groups. Graft survival tended to be 
lower (64.7 % vs. 76.5 % at 15 years) in the cyclosporine continuation group (P = 0.14), 
when data were analyzed on an intention to treat basis. The graft survival of the patients that 
stayed on their assigned treatment was signifi cantly higher in the azathioprine arm, starting 
at two years’ post-transplantation. The glomerular fi ltration rate was signifi cantly higher in 
the patients who were converted to azathioprine. More allograft biopsies were taken from 
patients remaining on cyclosporine for suspicion of cyclosporine-related nephrotoxicity 
and prompted a high rate of late conversions (19%). The relative risk of chronic allograft 
nephropathy was signifi cantly higher in the group that continued cyclosporine [relative 
risk 4.3, (95% CI, 1.4 to 12.9); P = 0.009]. Conversion to azathioprine reduced the need of 
blood pressure and lipid lowering drugs. 
Conclusion: Conversion to a calcineurin inhibitor-free immunosuppressive regimen 
three months after renal transplantation improved allograft function, reduced the need of 
cardiovascular risk factor-controlling medication, and reduced the incidence of chronic 
allograft nephropathy.
Introduction
The introduction of cyclosporine A in clinical renal transplantation has improved the 
effi cacy of immunosuppressive treatment, leading to a decline in the incidence of acute 
rejection episodes and allograft loss in the fi rst year after transplantation. However, the 
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drug has many toxic side effects: it raises the blood pressure and serum cholesterol level 
and could cause nephrotoxicity, both of which contribute to mortality and graft loss in the 
late post-transplantation period.1 Reducing the exposure to the drug after the period with 
the highest risk of acute rejection could, therefore, be advantageous. It was hypothesized 
that the withdrawal of cyclosporine and the replacement by azathioprine, or more recently, 
mycophenolate, after a certain post-transplantation time frame would preserve the better 
short-term results of cyclosporine therapy, while avoiding the consequences of long-term 
exposure to the drug. As a result, a number of clinical trials have examined the safety 
of cyclosporine withdrawal after renal transplantation. Improvements in renal function, 
lipid profi le, hypertension, and the incidence of gout were reported in these conversion 
trials. Although a meta-analysis of the azathioprine conversion trials reported an 11% [95% 
confi dence interval (CI), 7 to 15] higher incidence of acute rejection after conversion, these 
episodes were not associated with a higher rate of subsequent graft loss.2
Conversion or discontinuation of cyclosporine is still not common practice in most 
transplant centers, mainly because of uncertainty about long-term outcome. The reported 
follow-up of patients in the published studies has thus far been relatively short. Only two 
studies reported data on patient and graft survival beyond six years’ post-transplantation 
with a maximum follow-up of 10 years.3-4 In both studies, graft survival curves tended 
to deviate after fi ve years in favor of azathioprine, but the number of patients at risk was 
rather limited. Therefore, it was hypothesized that after a longer period of follow-up a 
signifi cant difference would occur.
An open-label prospective randomized trial was initialized at our center in 1983 that 
compared cyclosporine continuation with conversion to azathioprine three months after 
transplantation.3 In 1995, data on 8 years’ follow-up were published; in the present report 
we extend the analysis of outcome to a 15-year follow-up period and provide additional 
data on histological abnormalities seen in allograft biopsies taken during the observation 
period.
Methods
Patients and trial design 
The design of this open-label randomized study has been previously reported.3 In summary, 
a total of 128 patients were enrolled in the study. Immediately after transplantation each 
patient received cyclosporine and prednisone according to a standard schedule.3 No 
prophylactic therapy with poly- or monoclonal T-cell antibodies was given. At 3 months’ 
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post-transplantation, patients were randomly assigned to continue cyclosporine treatment 
(N  =  68), or were converted to azathioprine (N = 60). For patients who continued 
cyclosporine treatment, the dose after randomization was 5 mg/kg daily with further dose 
adjustments made according to whole blood trough-level monitoring.3 Patients who were 
converted to azathioprine treatment received azathioprine in a dose that was gradually 
increased to 2 to 2.5 mg/kg daily, depending on leukocyte count. Concomitant with the 
conversion, the dose of prednisone was temporarily increased and subsequently tapered 
slowly over a period of 10 months to a steady dose of 10 mg/day.3 First and third acute 
rejection episodes were treated with high-dose corticosteroids. Second rejection episodes or 
steroid-resistant acute rejection episodes were treated with rabbit antithymocyte globulin. 
In the analysis of the study reported in 1995, acute rejection was scored as the institution 
of anti-rejection treatment.3 A higher, but not statistically signifi cant, incidence of acute 
rejection episodes after conversion to azathioprine was found [difference, 10.8% (95% CI, 
−0.2 to 22)].
For the present extended follow-up, blood pressure values, number of antihypertensive 
drugs, serum cholesterol levels, lipid-lowering therapy, and glomerular fi ltration rate (GFR) 
as estimated by Nankivell’s formula,5 were recorded at 3 months, 1, 5, 10, and 15 years after 
transplantation. The cyclosporine dosing was recorded at 1 year post-transplantation. 
In addition, cardiovascular events (cardiac, cerebral or peripheral), the occurrence (and 
type) of cancer, and the cause of death were documented. We also evaluated the number 
of out-of-protocol conversions to a non-calcineurin inhibitor-based immunosuppression 
and the number of patients who returned to cyclosporine therapy, as well as the reasons for 
these changes.
Finally, the number and indication of every allograft biopsy was assessed. The following 
clinical guidelines were used to perform a percutaneous allograft biopsy: suspicion 
of acute rejection, suspicion of recurrent/de novo glomerulopathy as suggested by 
urinalysis; persistent isolated proteinuria >1 g/24 hr; or a gradual loss of graft function 
(>20% over baseline) within the observation period without an obvious explanation (e.g., 
transplant artery stenosis or graft hydronephrosis). All pathology reports of allograft 
biopsies taken during the observation period were reviewed. Biopsy samples classifi ed 
as chronic allograft nephropathy (CAN) were re-examined by a pathologist blinded for 
the instituted immunosuppressive regiment and scored according to the Banff 97 working 
classifi cation of renal allograft pathology.6 In this study, CAN was defi ned by functional 
and histologic criteria. A gradual loss of graft function (>20% over baseline) without an 
obvious explanation was required in combination with biopsy fi ndings of nonspecifi c 
pathology, such as glomerulosclerosis, tubular atrophy and interstitial fi brosis with or 
without peripheral nodular arteriolar hyaline changes, arterial intimal fi brosis, or signs of 
allograft glomerulopathy. 




The analysis was performed on an intention-to-treat basis. Patient survival, graft survival 
and the incidence of CAN were also analyzed separately in the patients who were not 
converted from their initial study assignment. Differences between therapy groups 
regarding continuous numerical variables were analyzed using the independent samples 
t test. Differences between ordered categorical variables were compared by the Mann-
Whitney U test. Survival and occurrence rates were estimated by the Kaplan-Meier product 
limit method and factor levels compared by the Wilcoxon-Gehan test. Cox proportional 
hazard regression was used for estimation of relative risks. In order to allow relative risk 
between therapy groups to change over follow-up time, extended Cox regression was used, 
with therapy groups defi ned as time-dependent variables. Statistical analysis of the data 
was performed using SPSS version 10.07 (SPSS, Inc., Chicago Il, USA).
Results
Patient characteristics
The characteristics of the study populations are summarized in Table 1. No signifi cant 
differences were observed.3 The mean follow-up time of the 68 patients who were 
randomized to continue cyclosporine treatment was 15.2 years (range, 13.0 to 17.6), and of 
the 60 patients who were converted to azathioprine, mean follow-up time was 15.4 years 
(range, 12.8 to 18.0). 
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Table 1. Baseline characteristics of patients and determinants of graft function and survival
Cyclosporine group (N = 68) Azathioprine group (N = 60)
Male/female 44/24 35/25
Age years 43.1 (11.9) 46.1 (10.9)
First/second transplantation 59/9 54/6
Mismatches  
HLA-A: zero/one/two 33/34/1 24/34/2
HLA-B: zero/one/two 19/45/4 17/39/4
HLA-DR: zero/one/two 38/26/4 37/22/1
Highest panel reactive antibodies (%)a 28.1 (30.7) 30.7 (33.1)
Donor age in years a 34.6 (15.1) 35.9 (14.6)
Cold ischemia time hoursa 29.2 (7.6) 29 (6.4)
Warm ischemia time minutes a 24.5 (5.4) 25.2 (7.5)
Number of rejection episodes 
Before randomization: 0/1/2/3 43/15/9/1 33/18/7/2
Smokers before transplantation (%) 29 (41%) 32 (53%)
HLA, human lymphocyte antigen. – a Mean (SD)
Adherence to treatment protocol 
During follow-up, immunosuppressive therapy was changed in 15 cyclosporine-treated 
patients (22%) and in 16 patients who were converted to azathioprine (27%). In the 
cyclosporine group, the main reason for out-of-protocol switch was cyclosporine 
nephrotoxicity (N = 13, 87%), based on biopsy fi ndings in 11 patients (84%); therapy was 
changed because of the suspected cyclosporine-related nephrotoxicity at a mean ± SEM 
of 8.6 ± 1.4 years’ post-transplantation. Conversion to azathioprine was performed in 
7 patients, conversion to mycophenolate in 5, and in 1 patient a lower cyclosporine trough 
level was pursued. Non-renal toxic side effects (gout and hypertension) were a reason 
to convert to azathioprine in 1 patient and to accept lower cyclosporine trough levels in 
another. 
The main reason to change therapy in the azathioprine group was non-renal toxicity 
(N = 11, 69%). Severe side effects on liver and bone marrow were documented in 
9 patients (82%). Nine patients were reconverted to cyclosporine therapy and 2 were 
switched to mycophenolate. One patient returned to cyclosporine treatment because of 
chronic rejection. In 1 patient immunosuppressive therapy was stopped because of post-
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transplant lymphoproliferative disease. In 2 patients prednisone was withdrawn because 
of steroid- related side effects and cyclosporine was reintroduced to maintain adequate 
immunosuppression. The remaining patient was reconverted to cyclosporine to control a 
nephrotic syndrome due to recurrent glomerular disease. The reintroduction of cyclosporine 
therapy in 13 patients (22% of total) took place at a mean ± SEM of 4.6 ± 1.0 years’ post-
transplantation.
Patient survival, vascular events, cancer and causes of death
Patient survival was not signifi cantly different in the two groups of patients. Ten and 15 years 
after transplantation, patient survival was 72.1% and 57.4% in the cyclosporine group 
versus 73.3% and 54.8% in the azathioprine group, respectively (P = 0.93) (Figure 1). The 
outcome did not differ if the analysis was restricted to patients that stayed on their initial 
immunosuppressive medication. Cardiovascular mortality 15 years after transplantation 
was also not signifi cantly different among the two study groups (cyclosporine continuation, 
21.2%; azathioprine conversion, 23.3%). Twenty patients (42.2%) in the cyclosporine 
group and 17 (36.2%) in the azathioprine group experienced at least one vascular event 
(cardiac, peripheral or cerebral) (P = 0.57). No difference was found in the cumulative 
incidence of skin cancer after 15 years (cyclosporine group, 15.2%; azathioprine group, 
16%; P = 0.5) or cancer of other organs (9.7% vs. 17.7%, respectively; P = 0.55).
Figure 1. Patient survival. 
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Before transplantation, diastolic blood pressure was 4 mm Hg (95% CI, 0.3 to 7.7) 
higher in the azathioprine group (Table 2); at randomization, no signifi cant differences 
in systolic or diastolic blood pressure were found between the two groups. Nine months 
after randomization diastolic blood pressure was 3.5 mm Hg lower in azathioprine 
group (95% CI, 0.3 to 6.7). No difference in blood pressure was observed at other post-
transplantation intervals. At one year, however, 20% more cyclosporine-treated patients 
needed antihypertensive medication (95% CI, 4 to 36), and this proportion increased to 
29% during follow-up (Table 2). No signifi cant differences were found in serum cholesterol 
levels over time, but more patients in the cyclosporine group needed lipid-lowering therapy, 
which was only signifi cant at 10 years (Table 2).
Graft survival
Graft survival censored for death with a functioning graft at 10 and 15 years was 75.3% 
and 64.7%, respectively, in the cyclosporine group versus 85.4% and 76.5%, respectively, 
in the azathioprine group (P = 0.14) (Figure 2). Although the study was not designed to 
detect differences in late graft loss, the graft survival curves tended to deviate with time. 
Therefore, we divided the follow-up time in different periods: <2 years’, 2 to 5 years’, 
and >5 years’ post-transplantation. The relative risk (RR) of graft loss in the cyclosporine 
group compared to the azathioprine group increased with time – RR in the fi rst 2 years of 
follow-up, 0.88 (95% CI, 0.22 to 3.50), P = 0.85; RR between 2 and 5 years follow-up, 
1.54 (95% CI, 0.37 to 6.46), P = 0.55; and RR beyond 5 years of follow-up, 2.90 (95% 
CI, 0.92 to 9.07), P = 0.070. When we analyzed the outcomes restricted to those who were 
not converted from their initial assignment we found a signifi cantly better graft survival in 
the azathioprine group starting at two years’ post-transplantation; graft survival censored 
for death with a functioning graft at 2, 5, 10 and 15 years was 94.7 vs. 93.7%, 92.7 vs. 
85.2%, 90.0 vs. 74.1%, and 81.9 vs. 69.2%, respectively (P = 0.012) (Figure 3). The RR 
of graft loss after two years’ post-transplantation in the cyclosporine group compared to 
the azathioprine group was 3.23 (95% CI, 1.05 to 9.94; P = 0.013); the RR of graft loss in 
the fi rst two years did not differ between the groups and was 1.16 (95% CI, 0.26 to 5.18; 
P = 0.90).
In both treatment arms the major cause of graft loss was death with a functioning graft: 22 
patients (32%) in the cyclosporine group versus 23 (38%) in the azathioprine group. 
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Figure 2: Graft survival censored for death with a functioning graft.
Figure 3: Graft survival censored for death with a functioning graft of the patients that stayed 
on the drug to which they were initially assigned. Vertical dashed lines indicate the start of the 
study 3 months’ post-transplantation (left lines), and the start of the period of survival benefi t in the 
azathioprine arm of the study 2 years’ post-transplantation (right lines).
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A gradual loss of function resulting in graft failure was seen in 18 patients (26%) who 
continued cyclosporine. In 16 of these patients a biopsy was performed that showed chronic 
allograft nephropathy (CAN) in 12 (75%), and recurrent renal disease in 4 patients (25%). 
In contrast, only 8 patients (13%) in the azathioprine group developed graft failure due to 
a gradual decline in function. Six patients were biopsied, showing CAN in 4 (67%) and 
recurrent renal disease in 2 patients (33%). Acute rejection resulted in graft loss in 2 patients 
that continued cyclosporine (3%) versus in 3 (5%) that switched to azathioprine treatment. 
In one patient in the azathioprine group, graft artery thrombosis, and in another patient, the 
cessation of immunosuppressive treatment because of post-transplant lymphoproliferative 
disease, resulted in loss of the graft. 
Graft function and proteinuria
Glomerular fi ltration rate as estimated by Nankivell’s formula, was signifi cantly better in 
the patients who were converted to azathioprine (Table 3). Three months after conversion 
the difference measured 10.4 ml/min (95% CI, 5 to 15.9 ml/min), increased to 17.1 ml/min 
(95% CI, 11.6 to 22.7) at 9 months after conversion, and persisted throughout the follow-up. 
No signifi cant difference between the groups in the proportions of patients with proteinuria 
over 1 g/24 hr was found at any point in time.
Cyclosporine dosing 
The mean dose of cyclosporine taken at one year post-transplantation in the cyclosporine 
arm of the study measured 5.1 ± 1.4 mg/kg. The cyclosporine dosage did not differ between 
the patients that developed CAN or lost their graft function compared to those who did not 
(CsA mg/kg groups: CAN yes/no, graft loss yes/no, CAN, or graft loss yes/no, mean ± SD, 
5.6 ± 1.4 vs. 5.0 ± 1.3; 4.8 ± 1.7 vs. 5.2 ± 1.2; 5.3 ± 1.6 vs. 5.0 ± 1.2 mg/kg; P = 0.15, P = 0.28, 
P = 0.61). The mean cyclosporine trough levels at one year post-transplantation were not 
signifi cantly different between the patients of the cyclosporine group who developed CAN 
and those who did not. The results were similar when the analysis was limited to those who 
stayed on cyclosporine treatment.
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Analysis of allograft biopsies
In order to evaluate the adherence to the biopsy guidelines we reassessed the indications 
for the biopsies that were taken in the follow-up period (Table 4). No signifi cant differences 
were found between the two groups with respect to the performance of a biopsy for a 
specifi c indication. We analyzed the histopathological fi ndings in biopsies that were 
obtained more than 6 months after randomization. A total number of 53 biopsies were 
identifi ed, 33 in the cyclosporine group, and 20 in the azathioprine group. Forty-seven 
biopsies (89%) yielded adequate material according to the Banff criteria. Of these, 30 
biopsies (64%) were taken in the group that continued cyclosporine and 17 (36%) in the 
group that switched to azathioprine (Table 5). Acute rejection was found in 2 patients of 
the cyclosporine group (3%) and in 3 patients of the azathioprine group (5%). Recurrent 
or de novo glomerulopathy was found in 8 patients in cyclosporine group (11.8%) and in 
7 patients of the azathioprine group (11.7%). CAN was diagnosed in 16 patients of the 
cyclosporine group (23.5%), but in only 4 patients of the azathioprine group (6.4%). In the 
cyclosporine group 15 patients received the drug until the diagnosis of CAN. None of the 
patients in the azathioprine group received cyclosporine prior to the diagnosis. 
The relative risks of biopsy-proven late acute rejection or recurrent/de novo glomerulopathy 
did not differ between the two groups. The relative risk of biopsy proven CAN during the 
follow-up period was signifi cantly higher in the group that continued cyclosporine [RR 4.3 
(95% CI, 1.4 to 12.9); P = 0.009] (Figure 4). Similar results were obtained when the analysis 
was restricted to patients who stayed on their initial immunosuppressive medication.
The Banff score of the biopsy samples that were diagnosed as CAN are depicted in Table 6. 
Eight biopsy samples in the cyclosporine group (50%) showed signs suggestive of chronic 
rejection (transplant glomerulopathy and/or pronounced arterial intimal fi brosis); in 5 
of these peripheral nodular arteriolar hyaline changes were also found, reminiscent of 
cyclosporine nephrotoxicity. In another 8 biopsy specimens of the cyclosporine group, 
peripheral nodular arteriolar hyaline changes were seen without signs suggestive of chronic 
rejection. A higher score was found for peripheral nodular arteriolar hyaline change in the 
cyclosporine group and a higher score for the degree of intimal fi brosis in the azathioprine 
group (Table 6). These histological data suggested that continued cyclosporine treatment 
3 months’ post-transplantation did not give better protection against chronic rejection 
than when a switch to azathioprine was performed. The higher incidence of CAN during 
continued cyclosporine treatment is most likely explained by additional cyclosporine-
related renal structural changes. 
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Table 4: Clinical indications and number of biopsies








Suspicion of acute rejection 12 (25%) 11 (92%) 11 (32%) 11 (100%) 1.000
Persistent proteinuria 4 (8%) 4 (100%) 7 (21%) 6 (85%) 1.000
Recurrent or de novo glomerulopathy 5 (10%) 5 (100%) 3 (9%) 3 (100%) 1.000
Chronic transplant dysfunction 27 (56%) 24 (88%) 13 (38%) 10 (77%) 0.370
Total 48 (100%) 44 (92%) 34 (100%) 30 (88%) 0.713
a For the difference in biopsy performance between the cyclosporine and the azathioprine group.
Table 5: Biopsy results in samples taken more than six months post-randomization
Biopsy diagnosis Cyclosporine group Azathioprine group
No. biopsies % No. patients % No. biopsies % No. patients %
Acute rejection 3 (10%) 2 (3%) 3 (18%) 3 (5%)
Glomerulopathy (recurrent/de novo) 11 (37%) 8 (11.8%) 9 (53%) 7 (11.7%)
Chronic allograft nephropathy 16 (53%) 16 (23.5%) 5 (29%) 4 (6.4%)
Total 30 26 17 14







Interstitial fi brosis a 1.50 ± 0.16b 1.5 ± 0.29 0.914
Tubular atrophy a 1.37 ± 0.27 1.5 ± 0.29 0.768
Arterial intimal thickening a 1.25 ± 0.27 2.5 ± 0.29 0.039
Allograft glomerulopathy a 0.19 ± 0.10 0 0.360
Peripheral arteriolar hyaline change a 1.25 ± 0.93 0 0.017
Percentage global glomerulosclerosis 38 ± 7.2 19 ± 11.1 0.283
a Scored according to the Banff 97 classifi cation on a scale of 0 to 3
b Mean ± SEM
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Figure 4: Cumulative incidence of chronic allograft nephropathy (CAN).
Discussion
The present paper is the fi rst to report the results of more than 10 years’ follow-up of a 
single-center, open, randomized trial comparing cyclosporine withdrawal and conversion 
to azathioprine with continued cyclosporine treatment. The conversion to azathioprine 
took place as early as 3 months’ post-transplantation. The results show that the earlier 
reported benefi cial effects of conversion on cardiovascular risk-factor control extend 
beyond 5 years’ post-transplantation. Furthermore, allograft function is better preserved 
after conversion and a lower incidence of CAN is found. 
In the intention-to-treat analysis of our study a better graft survival was observed in the 
azathioprine group beyond 5 years of follow-up, albeit not signifi cant, and the relative risk 
of graft loss in the cyclosporine-treated patients increased with time. It has been shown 
that a reduction in dose or withdrawal of calcineurin inhibitors slows the rate of decline in 
renal function of patients with CAN.7 The observed graft survival benefi t after conversion 
to azathioprine in our study may have been signifi cantly weakened by the high rate of late 
cyclosporine withdrawals in the cyclosporine continuation group due to cyclosporine-related 
proefschrift bakker.indd   77 1-12-2004   9:01:39
CsA withdrawal reduces chronic allograft nephropathy
78
nephrotoxicity (19%). When we analyzed the outcomes restricted to those who were not 
converted from their initial assignment, we found a signifi cantly better graft survival in the 
azathioprine group starting at two years’ post-transplantation and the cumulative incidence 
of CAN was still signifi cantly lower in the patients who used azathioprine. The lag time 
seen in the present study before the nephrotoxic effect of cyclosporine started to infl uence 
the graft survival curve confi rms previous observations after conversion to azathioprine,4 
and compares well with data on cyclosporine-induced irreversible nephrotoxicity observed 
in cardiac allograft recipients.8 
The estimated GFR values improved after conversion to azathioprine: three months after 
conversion the mean GFR was 10.4 ml/min higher. This increase can be explained by 
the disappearance of cyclosporine-induced renal vasoconstriction.9 However, since the 
difference in GFR tended to increase further at a longer period of follow-up, these data 
also suggest reversibility of renal structural changes after cyclosporine withdrawal.
The pathologic changes that are found in chronic deteriorating kidney allografts are often 
not specifi c.10 The descriptive term chronic allograft nephropathy (CAN) that has been 
adopted to classify these changes encompasses chronic obliterative vascular alterations, 
tubular atrophy, glomerulosclerosis, and interstitial fi brosis.6 CAN includes both changes 
due to chronic rejection and chronic calcineurin inhibitor nephrotoxicity. Herein, we report 
for the fi rst time a benefi cial effect of cyclosporine withdrawal on the incidence of CAN 
post-transplantation. The fact that the pathology data in our study were derived from 
kidney biopsies performed for cause prompted us to reassess the indication and the actual 
performance of a biopsy. We found no difference in biopsy performance for a specifi c 
indication in the two study arms. 
In our study cyclosporine trough levels were monitored routinely in the patients who 
continued cyclosporine, and dosing was adjusted accordingly. In spite of this, cyclosporine 
use had a marked infl uence on the incidence of CAN. The mean dose of cyclosporine taken 
at one year post-transplantation in the patients who continued on cyclosporine was 5.1 ± 
1.4 mg/kg, which compares well with the optimal dose defi ned by data obtained from the 
Collaborative Transplant Study registry. A cyclosporine dose between 3-6 mg/kg at one 
year was associated with better long-term allograft survival.11 In our study, no difference 
was found in cyclosporine dosage at 1 year post-transplantation between the patients of 
the cyclosporine group who did or did not develop CAN or who lost their transplant. 
Also, the mean cyclosporine trough levels at one year were not signifi cantly different. 
Recently, new and better ways to monitor cyclosporine exposure of individual patients 
have been investigated to optimize its effi cacy and to decrease toxic side effects. It has 
been shown that cyclosporine exposure measured by the area under the concentration over 
time curve (AUC) is highly variable among patients who have equal cyclosporine trough 
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levels.12 Formally, we cannot exclude that a proportion of our patients in the cyclosporine 
continuation group was overexposed to the drug and that better monitoring of cyclosporine 
therapy will reduce the incidence of cyclosporine nephrotoxicity and the occurrence of 
CAN post-transplantation. 
The fi nding that conversion to non-calcineurin immunosuppressive treatment reduces the 
long-term incidence of CAN is of special importance in an era of donor shortage, with 
an increasing use of kidneys from marginal donors.13-15 The recipients of these kidneys 
are likely to be more prone to graft failure as a result of cyclosporine nephrotoxicity than 
the recipients of a regular allograft merely because they cannot tolerate some loss of 
function.16
The single most important cause of graft loss in both treatment arms of our study was death 
with a functioning graft, which was usually related to a cardiovascular event.17-21 Renal 
transplant patients, after the fi rst post-transplant year, experience a fi ve-fold increase in 
cardiovascular mortality compared with age-matched controls.19 This stresses the need to 
reduce cardiovascular risk factors both before and after transplantation. The withdrawal 
of cyclosporine and replacement by azathioprine 3 months after transplantation reduced 
the need of cardiovascular risk-controlling medication over the entire 15-year period of 
follow-up.
The question can be raised whether every patient should be converted to a non-calcineurin-
based immunosuppressive regimen after a certain period of time. It is important to note 
that our study was performed in a cohort of predominantly Caucasian recipients, well 
matched for human lymphocyte antigen (HLA), and therefore the results cannot directly be 
extrapolated to other populations.16,22-24 Furthermore, the conversion to azathioprine was 
not completely harmless, as substantial toxicity of azathioprine therapy was encountered. In 
fact, the results of this study should encourage the use of mycophenolate as the “conversion 
agent” of choice rather than azathioprine. Mycophenolate therapy has a better safety profi le 
than azathioprine, has been associated with less acute rejection after conversion compared 
to azathioprine, and may by itself, according to U.S. renal transplant scientifi c registry 
data, further decrease the incidence of CAN.25-29 
Conclusion
Cyclosporine withdrawal 3 months after transplantation can be done safely, reduces the 
need of cardiovascular risk factor-controlling medication, improves allograft function, and 
reduces the incidence of CAN. 
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Abstract
Little is known regarding the composition of the interstitial extracellular matrix of kidney 
allografts with deteriorating function. Collagen I, III, and IV, the collagen IV α3 chain, 
and the laminin β2 chain were investigated in biopsies of allografted kidneys with chronic 
cyclosporine A nephrotoxicity (CsAT) (N = 17), chronic rejection (CR) (N = 12), or 
chronic allograft nephropathy (CAN) (N = 19). α-Smooth muscle actin expression was also 
examined. Normal native kidneys were used as control samples (N = 11). Biopsy samples 
were studied with routine light microscopy and immunostaining. The mean interstitial 
fi brosis scores were signifi cantly higher for the CR and CAN groups, compared with the 
chronic CsAT group. The cortical tubulointerstitial areas of the CR and CAN groups, but 
not the chronic CsAT group, contained more collagen I than did normal control samples. 
Differences were noted even in biopsies with mild fi brosis. Accumulation of collagen III, 
IV and IV α3 was increased in all patient groups. Collagen III accumulation was greater in 
the CR and CAN groups than in the chronic CsAT group. Receiver-operating characteristic 
curve analysis demonstrated that collagen I staining had the best discriminatory value in 
differentiating CR from chronic CsAT with a sensitivity of 63% and a specifi city of 94% at 
a cutoff value of 19%. Laminin β2 staining did not differentiate CR from CsAT. Increased 
α-smooth muscle actin staining did not differ among the three groups. It was concluded 
that, during chronic CsAT, collagen III and IV were preferentially accumulated in the 
tubulointerstitium. Early increases in the deposition of collagen I, with collagen III and IV, 
were more specifi c for CR. CR seems to elicit a more pronounced fi brotic response than 
does chronic CsAT. 
Introduction
Late loss of allograft function remains a major problem in renal transplantation.1 Kidney 
allograft failure is usually preceded by a process of chronic transplant dysfunction, which 
is characterized by a relatively slow but variable rate of decline in GFR, increasing 
proteinuria, and increases in BP. The pathologic changes in deteriorating grafts are often 
less specifi c. The term chronic allograft nephropathy (CAN) has been adopted to classify 
these changes, which include chronic obliterative vascular alterations, tubular atrophy, 
glomerulosclerosis, and interstitial fi brosis.2 
CAN includes both chronic rejection (CR) and chronic calcineurin inhibitor toxicity.2 
The nature of vascular, glomerular, and interstitial changes in CAN biopsy specimens 
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can sometimes help to defi ne more specifi cally the cause of graft dysfunction. Concentric 
intimal thickening of arteries and arterioles, often accompanied by a moderate degree of 
mononuclear cell infi ltration of the vessel walls, and duplication of the glomerular basement 
membrane are thought to indicate chronic rejection. Smooth muscle cell necrosis and 
peripheral nodular medial hyalinosis of arterioles are considered hallmarks of cyclosporine 
A (CsA) nephrotoxicity (CsAT).3-4 
Extracellular matrix (ECM) accumulates in the cortical interstitium regardless of 
the cause of chronic graft dysfunction, as observed in native kidneys with chronic 
diseases.4-5 Surprisingly, the ECM composition of deteriorating allografted kidneys has 
rarely been studied. Determination of the ECM molecules that accumulate could enhance 
our understanding of the pathogenesis of graft dysfunction and could potentially help 
defi ne the cause, if disease-specifi c changes are observed. In this study, we investigated 
whether the ECM composition differs between allografts that lose function because of CR 
and allografts with chronic CsAT. We studied the cortical interstitial ECM composition of 
kidney allografts of three groups of patients, i.e., patients with chronic CsAT, patients with 




All kidney allograft biopsies that were performed in our center for clinical reasons >1 yr 
after transplantation, in the period between March 1, 1976, and March 1, 2001, were 
reviewed. Cases that had available frozen-tissue and that met the criteria defi ned below 
were included. Patients with graft artery stenosis or diabetes mellitus were excluded. In 
addition, biopsy samples with histologic signs of de novo or recurrent glomerulonephritis 
or acute rejection were excluded. The group designated the chronic CsAT group (N = 17) 
consisted of patients who exhibited progressive declines in allograft function only after 
a switch was made from a CsA formulation with a lower bioavailability (Sandimmune; 
Sandoz, Basel, Switzerland) to one with a higher bioavailability (Neoral; Novartis, Basel, 
Switzerland).6 A brief period of acute rejection in the early posttransplantation period was 
allowed and occurred in eight cases. Before the switch, the patients used Sandimmune 
once daily, aiming at a 24-h trough level of 100 µg/liter, and demonstrated stable graft 
function for a mean of 5.1 ± 3.4 yr. After conversion to twice-daily Neoral therapy, a 
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higher target 12-h trough level of 150 µg/liter was adopted. To reach this level, the mean 
CsA dose was increased from 3.2 to 3.5 mg/kg.6 Nephrotoxicity was not observed in the 
fi rst months after conversion but became evident after 12 mo.6 Biopsies were obtained a 
mean of 2.4 ± 1.2 yr after switching. None of the studied biopsies in this group exhibited 
signs of chronic allograft glomerulopathy. No positive staining for C4d in the peritubular 
capillaries (see below) was observed. 
The patient group designated the CR group (N = 12) consisted of patients who exhibited 
progressive declines in renal allograft function with a calcineurin inhibitor-free 
immunosuppressive regimen. Immunosuppressive therapy consisted of prednisone and 
azathioprine. All of these patients initially demonstrated good allograft function (Table1). 
Thirty-three percent exhibited C4d positivity in their peritubular capillaries.
Table 1: Clinical characteristics of the patients studieda
Clinical Characteristic
Patient group
CsA Toxicity (N = 17) CAN (N = 19) CR (N = 12)
Time after transplantation (yr) 7.1 ± 3.3 5.5 ± 4.1 5.1 ± 4.3
Allograft age (yr) 51 ± 9 42 ± 15 34 ± 12b
BP, systolic (mmHg) 148 ± 19 154 ± 19 157 ± 22
BP, diastolic (mmHg) 86 ± 5 88 ± 9.7 90 ± 12
No. of antihypertensive medications 1.8 ± 1.1 2 ± 1.2 1.9 ± 1.1
Creatinine clearance (ml/min) 38 ± 12 34 ± 15 32 ± 7
Loss of clearance (ml/min) 26 ± 10 39 ± 19 49 ± 23b
Proteinuria (g/24 h) 1.3 ± 1.5 1.9 ± 1.9 4.0 ± 3.3
CsA trough level (µg/ml) 114 ± 30 113 ± 31
a Values are mean ± SEM. CsA, cyclosporine A; CAN, chronic allograft 
 nephropathy; CR, chronic rejection.
b P < 0.05, compared with chronic CsA toxicity and CAN groups.
A third group of patients received CsA but their allograft biopsy suggested CR as the 
cause of declines in allograft function. This group, designated the CAN group, consisted of 
patients with progressive declines in renal allograft function and biopsy fi ndings suggesting 
CR, including arterial intimal fi brosis (N = 15) and/or chronic allograft glomerulopathy 
with glomerular basement membrane duplication (N = 4). No temporal relationship existed 
between the loss of function and a switch to Neoral for any of these patients. In this group, 
21% of the biopsies were positive for C4d deposits in the peritubular capillaries. The 
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control group (N = 11) consisted of specimens from normal kidneys obtained in autopsies 
and from normal kidneys that had not been used for transplantation for anatomic reasons.
Clinical and laboratory data were obtained in chart reviews. The collected data included 
posttransplantation time, allograft age (donor age plus time after transplantation), systolic 
and diastolic BP, number of antihypertensive medications used, creatinine clearance (as 
estimated with the Cockroft-Gault formula), loss of allograft function, proteinuria, and 
CsA trough levels at the time of biopsy. The loss of allograft function was defi ned as the 
difference in the creatinine clearance measured before the worsening of allograft function, 
as assessed by the breakpoint in the regression lines of 1/serum creatinine, and the creatinine 
clearance measured at the time of the index biopsy.7
Light Microscopy
After routine staining, the biopsy specimens were coded and re-evaluated with light 
microscopy. An experienced pathologist who was blinded with respect to the instituted 
immunosuppressive regimen scored the histopathologic changes. The Banff 97 classifi cation 
system for histopathologic scoring of allografted kidneys was used.8 
Immunostaining
The ECM components that were studied were detected with an indirect immunoperoxidase 
technique. Staining for each molecule was performed in one session. The primary antibodies 
used were polyclonal mouse anti-human collagen I, anti-human collagen III, and anti-human 
collagen IV (Harlan Sera-Lab, Sussex, UK) and monoclonal mouse antibodies against the 
collagen IV α3 (Wieslab, Lund, Sweden) and laminin β2 (C4) (Developmental Studies 
Hybridoma Bank, Iowa City, IA) chains. The secondary antibody consisted of peroxidase-
coupled rabbit anti-mouse IgG (Dako, Glostrup, Denmark). Cryostat sections (4 µm) were 
mounted on glass slides, dried for 1 h, and stored at -20°C until used. The tissue was fi xed 
with 4% formalin for 10 minutes. After blocking of endogenous peroxidase by incubation 
for 30 min with 0.1% H2O2 in phosphate-buffered saline, the sections were incubated for 
30 min with 5% normal rabbit serum. The sections were then incubated with the primary 
antibody for 1 h, followed by incubation with the secondary antibody for 30 min. The 
sections were incubated for 10 min in a fi ltered solution of 0.5 mg/ml diaminobenzidine 
and 0.02% H2O2 and were then incubated for 5 min with 0.05% Cu2SO4 in saline solution. 
Counterstaining with hematoxylin was performed for 15 sec. Between all steps, the slides 
were rinsed with phosphate-buffered saline.
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Immunofl uorescence staining for C4d was performed on untreated slides, as described 
previously.9 Mouse anti-C4d (Quidel, San Diego, CA) was used as the primary antibody.9 
The secondary antibody was FITC-conjugated goat anti-mouse Ig (Sigma Chemical Co., 
St. Louis, MO). Staining was independently evaluated by two authors (Drs. Koop and 
Eikmans), who were blinded with respect to the diagnoses. A previously described scoring 
method was used.10 
Image Analysis 
After immunostaining, the slides were coded and analyzed in a blinded manner. Digital 
image analysis was performed with a Zeiss microscope equipped with a full-color 3CCD 
camera (DXD 950p; Sony Corp., Tokyo, Japan) and KS-400 image analysis software, 
version 3.0 (Zeiss-Kontron, Eching, Germany). This method of digital image analysis has 
been validated and demonstrated to be highly reproducible.11-12 Images of the renal cortex 
of each biopsy specimen were obtained and analyzed with the aid of automated script 
protocols (macros) developed in our department. Recording and analysis of images were 
performed with fi xed settings. The software allowed censoring of regions of noninterest. 
Larger vessels and glomeruli were omitted from the analyses. The deposition of each ECM 
component was determined in each biopsy sample by calculation of the percentage of 
surface area stained by the indicator dye, relative to the total surface area. The degree of 
deposition was assessed by evaluation of the entire renal cortex, with a minimum of fi ve 
microscopic fi elds per biopsy sample (at ×200 magnifi cation).
The biopsy specimens that were stained for the laminin β2 and collagen IV α3 chains were 
also directly evaluated for interstitial or tubular expression of those molecules, by two 
investigators (Drs. Bakker and Koop) who were blinded with respect to the diagnosis. In 
the few cases of discordant scoring, decisions were reached by consensus.
Statistical analysis
Statistical analysis was performed using SPSS for Windows software (SPSS, Inc., Chicago, 
IL). One-way ANOVA was used for comparisons of continuous variables with normal 
distributions. Either a Bonferroni or Games-Howel post-hoc procedure was used when 
appropriate. The Mann-Whitney U test was used to compare continuous variables that 
were not distributed normally. The data are expressed as mean ± SD or mean ± SEM, as 
indicated. In a general linear model, values were adjusted for differences in the loss of 
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allograft function and creatinine clearance at the time of biopsy. Correlations between 
the degree of deposition of individual ECM components and the clinical characteristics 
of the patients were evaluated with the Pearson correlation test. P < 0.05 was considered 
statistically signifi cant. Using a receiver-operating characteristic curve, we determined the 
cutoff point of the percentage of staining for the various ECM molecules that predicted the 
presence of CR with the best combination of sensitivity and specifi city. 
Results
Patient data
The clinical characteristics of the patients are presented in Table 1. The mean age of the 
allografted kidney was lower for the patients with CR, compared with the patients with 
chronic CsAT or CAN. The loss of creatinine clearance was greater for the patients with 
CR. The time after transplantation, BP values, number of antihypertensive drugs prescribed, 
and creatinine clearance at the time of biopsy were similar among the groups. No difference 
in CsA trough levels was observed between the groups receiving CsA.
Light-microscopic fi ndings
The chronic histopathologic changes that were observed in the biopsy samples in routine 
light-microscopic analyses are summarized in Table 2. The mean interstitial fi brosis scores 
for the CR and CAN groups were signifi cantly higher than that for the chronic CsAT group 
(CR group versus chronic CsAT group, P = 0.011; CAN group versus chronic CsAT group, 
P = 0.001). The tubular atrophy scores were higher for the CR and CAN groups, but the 
differences did not reach statistical signifi cance (CR group versus chronic CsAT, P = 0.422; 
CAN group versus chronic CsAT, P = 0.159). The percentages of global glomerulosclerosis 
did not differ among the groups. The mean peripheral arteriolar hyaline thickening score 
for the chronic CsAT group was higher than those for the CR and CAN groups, as expected 
from the case defi nitions. 
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Table 2: Light-microscopic features of the allograft biopsies studieda
Patient group
Histological Feature CSA Toxicity (N = 17) CAN (N = 19) CR (N = 12)
Interstitial fi brosis scoreb 0.58 ± 0.21 1.76 ± 0.19 c 1.65 ± 0.25 d
Tubular atrophy scoreb 0.69 ± 0.24 1.36 ± 0.22 1.29 ± 0.29
Arterial intimal thickening scoreb 0.77 ± 0.21 1.48 ± 0.19 1.40 ± 0.25
Allograft glomerulopathy scoreb 0.02 ± 0.17 0.25 ± 0.15 0.33 ± 0.19
Peripheral arteriolar hyalinosis scoreb 1.92 ± 0.12 e 0 ± 0.11 0 ± 0.15
Global glomerulosclerosis (%) 28.0 ± 7.1 32.5 ± 6.4 24.4 ± 8.4
a Values are mean ± SEM.
b Scored according to the Banff 97 classifi cation system.
c P < 0.01, compared with chronic CsA toxicity group.
d P < 0.05, compared with chronic CsA toxicity group.
e P < 0.01, compared with CAN or CR group.
ECM components
First we studied the typical interstitial collagens, i.e., collagens I and III. The mean areas 
stained for these collagens are presented in Figure 1. The collagen I-stained areas were 
signifi cantly increased in the CAN and CR groups, compared with the control group, but 
were not increased in the chronic CsAT group (mean area ± SEM for the CAN, CR, chronic 
CsAT, and control groups, 18.0 ± 2.5, 23.2 ± 4.4, 6.5 ± 1.5 and 3.3 ± 0.6%, respectively). 
No signifi cant difference was observed between the CAN and CR groups.
The areas stained for collagen III were increased in all patient groups (mean area ± SEM 
for the CAN, CR, chronic CsAT, and control groups, 26.8 ± 2.4, 28.9 ± 2.7, 16.7 ± 2.1, 
and 6.9 ± 2.2%, respectively). However, the areas of staining were signifi cantly greater for 
the CAN and CR groups, compared with the chronic CsAT group. The staining areas did 
not differ signifi cantly between the CAN and CR groups. Figure 2 presents representative 
images of immunostaining for collagen I and III in an allografted kidney with CR.
Next we studied whether typical basement membrane collagen type IV expression was 
increased to the extent observed in native kidney disease.5 The mean areas of staining for 
collagen IV were signifi cantly increased in all patient groups, compared with the control 
group, to the same degree (mean area ± SEM for CAN, CR, chronic CsAT, and control 
groups, 10.3 ± 5.1, 13.3 ± 5.6, 12.2 ± 1.4, 5.9 ± 1.5%, respectively) (Figure 3A). We also 
compared the staining areas for the three types of collagen in the three groups of patients. 
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Figure 1: Staining areas (mean ± SEM) for collagen (Col) I (A) and collagen III (B). CsAT, 
cyclosporine A nephrotoxicity; CAN, chronic allograft nephropathy; CR, chronic rejection. 
* P < 0.05, and ** P < 0.01.
Figure 2: Immunoperoxidase staining for cortical collagen (Col) I and III. Representative images of 
a normal control sample (left) and a kidney allograft with CR (right) are shown.
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In the CAN and CR groups, the areas staining for collagen III were greater than those for 
collagen IV (CAN group, P < 0.001; CR group, P < 0.01) but did not differ signifi cantly 
from those staining for collagen I. In the CsAT group, the area staining for collagen III 
was greater than that staining for collagen I (P < 0.001), but no signifi cant difference was 
observed in comparison with the area staining for collagen IV (P = 0.07).
When we studied biopsies with mild interstitial fi brosis (<25% interstitial expansion), we 
observed a difference in collagen I staining between the CsAT group and the CR and CAN 
groups combined (CsAT group, 6.5 ± 6%; CAN/CR group, 15.5 ± 8.7%, P < 0.05). In this 
subgroup with mild fi brosis, there was no difference between the time that had elapsed 
since transplantation (CAN/CR group) compared to the time that had elapsed since the 
Neoral switch (CsAT group). Collagen III and IV staining areas did not differ between the 
CsAT group and the CAN/CR subgroup. A meaningful comparison of biopsies with greater 
degrees of interstitial expansion was not possible because of the small numbers.
Figure 3: Staining areas (mean ± SEM) for collagen (Col) IV (A) and the collagen IV α3 chain (B). 
* P < 0.05, ** P < 0.01.
Because an earlier report suggested that immunostaining for the α3 chain of collagen IV 
and the β2 chain of laminin could differentiate CR from chronic CsAT,13 we also evaluated 
these molecules. The areas stained for the collagen IV α3 chain were increased in all 
patient groups, compared with the control group, to the same extent (mean area ± SEM 
for the CAN, CR, chronic CsAT, and control groups, 6.7 ± 1.1, 5.3 ± 1.2, 7.8 ± 0.8, 
and 1.1 ± 0.3%, respectively) (Figure 3B). The collagen IV α3 chain was expressed in 
a normal pattern, namely, at the distal tubular basement membrane (TBM), in all three 
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patient groups. No interstitial staining or new expression at the proximal TBM was noted. 
In none of the groups did the areas staining for the laminin β2 chain change signifi cantly, 
compared with the control group (Figure 4). However, we occasionally observed some 
new abnormal tubular expression in each of the groups (CsAT group, nine biopsy samples, 
53%; CAN group, eight samples, 42%; CR group, six samples, 50%). The new expression 
was mostly confi ned to atrophic tubules or tubules surrounded by infi ltrate, the proximal 
or distal morphologic features of which were diffi cult to assess. Less than 1% of tubules 
were affected in these samples, except for one sample in the CsAT group, three samples in 
the CAN group, and two samples in the CR group, in which 1 to 10% of tubules exhibited 
staining. No interstitial staining for the laminin β2 chain was observed, except for faint 
staining in some areas of periglomerular fi brosis.
Figure 4: Box and whisker plots of the median staining areas for the laminin β2 chain. The boxes 
contain 50% of the values. The upper and lower borders indicate the 25th and the 75th percentiles, 
respectively. The upper and lower whiskers indicate the highest and lowest values, respectively. The 
white lines in the boxes indicate the medians. No signifi cant differences were observed among the 
groups. (P values from the Mann-Whitney test: CsAT group versus CAN, CR, and control groups, 
0.847, 0.925, and 0.056, respectively; CAN group versus CR and control groups, 0.868 and 0.172, 
respectively; CR group versus control group, 0.463). 
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We investigated whether the observed qualitative and quantitative differences in the 
interstitial ECM composition in kidneys with CR or chronic CsAT were correlated with the 
numbers of interstitial myofi broblasts present, as assessed with immunohistologic staining 
for α-smooth muscle actin (SMA). Increases in SMA staining were observed for all patient 
groups, compared with the control group, but no differences were observed among the 
patient groups (Figure 5).
Figure 5: Box and whisker plots of the median staining areas for α-smooth muscle actin (SMA). 
* P < 0.05, ** P < 0.01, compared with control group.
Correlations and receiver-operating characteristic curve 
analysis 
Among the three groups of patients, we observed no correlation between the area of staining 
for the various molecules and the clinical variables of loss of allograft function, time after 
transplantation, allograft age, creatinine clearance, and proteinuria at the time of biopsy. A 
positive correlation (r2 = 0.379, P = 0.008) was observed between the interstitial fi brosis 
scores of all biopsy samples combined and the loss of creatinine clearance at the time of 
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biopsy. The interstitial fi brosis scores of all biopsy samples combined were also correlated 
with the areas of staining for collagen I and III (r2 = 0.499, P = 0.001, and r2 = 0.499, 
P = 0.002, respectively). A general linear model was used to adjust for differences in loss 
of function and creatinine clearance at the time of biopsy among the groups.
Receiver-operating characteristic curve analysis demonstrated that collagen I staining had 
the best discriminatory value in differentiating CR from chronic CsAT, with a sensitivity 
of 75% and a specifi city of 88% at a cutoff value of 13% cortical interstitial staining and 
with values of 63% and 94%, respectively, at a cutoff value of 19% staining. The fraction 
of the area under the curve was 0.92 of the total area (P = 0.001). None of the ratios of the 
mean staining areas for the studied molecules proved to be useful for discrimination of CR 
from chronic CsAT.
Discussion
The aim of this study was to examine the composition of the cortical interstitial ECM of 
kidney allografts with either CR or chronic CsAT. We wondered whether quantitative and/or 
qualitative differences in ECM accumulation occur. Therefore, we quantitatively compared 
the deposition of several ECM molecules. We chose to study the molecules collagen I, III, 
and IV, because these are known to accumulate in the renal cortical interstitium during 
native kidney disease.5,14 The laminin β2 and collagen IV α3 chains were investigated 
because an earlier report suggested that de novo expression of these molecules at the 
proximal TBM could differentiate CR from chronic CsAT.13 
In this study, we observed quantitative and qualitative differences in the ECM composition 
of kidney allografts with CR or chronic CsAT. Our results demonstrated that collagen I, 
III, and IV accumulated in the renal cortical interstitium during CR. The most prominent 
increases were observed for collagen I and III. A similar pattern of ECM deposition was 
observed in the kidneys of patients who likely had CR but were receiving CsA. In the 
kidneys of patients with chronic CsAT, however, only collagens III and IV accumulated 
signifi cantly. 
Regulation of renal interstitial ECM composition in vivo is complex and encompasses 
changes in ECM biosynthesis and degradation. In normal kidneys, collagen I and III are 
observed in the blood vessels and the interstitium (albeit in small amounts) (Figure 2).15 
Collagen IV is a natural component of the glomerular basement membrane and TBM, 
and its α3 chain is normally observed in the basement membranes of glomeruli and distal 
tubules.15 Laminin is observed in vessel walls and all basement membranes. The β2 chain, 
however, is observed only in glomeruli and vessel walls.16 
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Quantitative data on the ECM composition of the cortical interstitium of human allografts 
with chronic CsAT or CR were lacking. A few studies reported increases in collagen III in 
grafts with chronic dysfunction but did not compare changes induced by CR and chronic 
CsAT.17-18 A number of in vitro studies have addressed the effects of CsA on the production 
of ECM molecules by renal cells. One study reported that CsA stimulated the production 
of pro-collagen I and IV in cultures of murine proximal tubular epithelial cells and the 
production of pro-collagen I in cultures of murine renal fi broblasts.19 Increases in the 
cortical expression of collagen I and IV were observed in vivo in a rat model of CsAT.20 The 
deposition of collagen III was not assessed in that model, however. Other data on collagen 
production were derived from a study on cultured human cells, which demonstrated an 
increase in collagen III production by renal fi broblasts when they were treated with CsA.21 
Studies performed with a monkey renal fi broblast cell line (CV1) demonstrated that CsA 
stimulated the synthesis of type III collagen by a pathway leading to activation of the 
COL3A1 promoter and up-regulation of COL3A1 mRNA.22 We observed the increased 
deposition of collagen III and IV in the interstitium of the cortex of human renal allografts 
as a result of chronic CsAT. In contrast to the results of the study performed in rats, we 
observed no signifi cant increase in collagen I deposition. Although we did not observe a 
correlation between the time elapsed since the Neoral switch and the degree of collagen 
I deposition, we cannot exclude the possibility that, with time, collagen I would also 
accumulate during long-term chronic CsAT. The difference in collagen I staining between 
the CsAT and CAN/CR subgroups with mild fi brosis suggests that CR may stimulate 
collagen I accumulation earlier than does CsAT.
In our study, we observed greater expansion of the interstitial space in the CR group, 
compared with the chronic CsAT group, as well as more deposition of collagen type III. 
The difference in interstitial fi brosis could not be explained on the basis of differences in 
clinical variables, because no correlations with those variables were observed. 
We wondered whether the differences in ECM deposition between CR and chronic CsAT 
could be explained on the basis of a difference in the numbers of myofi broblasts present. 
SMA is a marker of activated myofi broblasts, which are thought to play a major role in 
the deposition of scar tissue.23 Two earlier reports described increases in interstitial SMA 
staining in deteriorating human kidney allografts.17-18 In CR, SMA-positive cell numbers 
were reported to increase with increases in the interstitial area fraction and collagen III 
deposition.18 In our study, we did not observe differences in SMA staining among the 
CR, CAN, and chronic CsAT groups; all samples contained more SMA-positive cells than 
normal. To explain the greater degree of interstitial ECM deposition during CR, compared 
with chronic CsAT, a higher rate of collagen production by myofi broblasts or a lower rate 
of ECM degradation by tissue metalloproteinases could be hypothesized. Data derived 
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from a primate model of chronic cardiac rejection support the latter hypothesis, because it 
was demonstrated that the progression of myocardial fi brosis was associated with increased 
expression of tissue inhibitor of metalloproteinases 1 and 2.24
We also examined the α3 chain of collagen ΙV and the β2 chain of laminin. Our results 
are at variance with a report by Abrass et al.,13 which suggested that a pattern of new 
expression of those molecules at the proximal TBM was specifi c for CR. In that study, 
CsAT resulted in the interstitial deposition of collagen I and III. Our study differs in the 
defi nitions of cases, the antibodies used, and the mode of analysis. The study by Abrass et 
al.13 examined patterns of distribution and provided no quantitative data on the investigated 
molecules. According to Abrass et al.,13 collagen I and III are not normally observed in the 
cortical interstitial area and the collagen IV α3 or laminin β2 chains are not expressed at 
the TBM. However, we and others observed that collagen I and III are normally present in 
the renal interstitium, albeit in small amounts.5,15,25-27 We also observed that the collagen 
IV α3 chain is normally expressed at the distal TBM, as noted earlier.16,28 This discrepancy 
may be related to the different antibodies used. In the study by Abrass et al.,13 allografted 
kidneys with rejection exhibited acute rejection; although the authors stated that their 
results also applied to allografts with CR, they did not systematically examine that idea and 
no data were presented. The new expression of the collagen IV α3 and laminin β2 chains at 
the proximal TBM observed by Abrass et al.13 might thus very well be related to tubulitis 
during acute rejection. In our study, we observed sporadic new expression of laminin β2 
at the TBM in a portion of the biopsy samples in each study group, especially in areas of 
tubular damage. Staining for this molecule did not differentiate CR from chronic CsAT. We 
observed increased expression of the collagen IV α3 chain in the CR, CAN, and chronic 
CsAT groups but no abnormal distribution pattern. We observed a small nonsignifi cant 
increase in collagen I staining for the chronic CsAT group, compared with normal control 
values. It is possible that a small increase in collagen I expression by the patients with 
chronic CsAT, which was below our detection limit, could have resulted in the expression 
pattern observed in the study by Abrass et al.13 
In conclusion, we observed a more pronounced fi brotic response in the tubulointerstitium, 
involving collagen I and III, in allografts with CR, compared with those with chronic 
CsAT. Early increases in cortical interstitial deposition of collagen I were more specifi c 
for CR. Staining for the molecules collagen IV α3 and laminin β2 was not useful for the 
differentiation of CR from chronic CsAT.
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Abstract
Background: In kidney transplantation, chronic allograft nephropathy (CAN) is the major 
cause of graft loss. Causes of CAN include chronic rejection and chronic cyclosporine A 
(CsA) nephrotoxicity. It is necessary to differentiate between these two entities in order to 
apply the appropriate therapeutic regimen for the individual patient, but this is hampered 
by the lack of discriminating functional and morphologic parameters. We investigated 
whether renal cortical mRNA levels for several matrix proteins can serve as discriminating 
parameters.
Methods: Patients with chronic rejection (N = 19) and chronic CsA toxicity (N = 17) 
were selected by clinical and histologic criteria. Protocol biopsies without histologic 
abnormalities, taken at 6 months after transplantation from patients receiving CsA, were 
used as controls (N = 6). Total RNA was extracted from the renal biopsy tissue, and 
mRNA levels of transforming growth factor-β (TGF-β) and the extracellular matrix (ECM) 
molecules collagen Iα1, IIIα1, IVα3, decorin, fi bronectin, and laminin β2 were measured 
by real-time polymerase chain reaction (PCR).
Results: In both patient groups, the mean collagen IVα3 and fi bronectin mRNA levels were 
signifi cantly elevated compared to those in controls, whereas only in CsA toxicity were 
the laminin β2 and TGF-β mRNA levels signifi cantly increased. The increase of laminin 
β2 and TGF-β mRNA levels was signifi cantly higher in the CsA toxicity group than in 
the chronic rejection group (P < 0.001 and P = 0.004, respectively). Receiver-operating 
characteristic (ROC) curve analysis showed that with a 15.6-fold increase in laminin β2 
mRNA expression as cut-off point, the presence of CsA toxicity could be predicted with an 
87% sensitivity and an 88% specifi city.
Conclusion: Renal laminin β2 and TGF-β mRNA levels can be used to differentiate between 
chronic rejection and chronic CsA toxicity in renal transplants. The method of mRNA 
quantifi cation might be applicable as an additional diagnostic tool in clinical practice.




Over the past decade, renal transplantation has become a very successful treatment modality 
for end-stage renal disease (ESRD). Due to improvement of immunosuppressive therapy, 
acute rejection episodes can be treated effectively, and the prevalence of early graft loss has 
diminished signifi cantly.1 Long-term graft loss, however, currently forms a major problem 
in renal transplantation.1-3
The term chronic allograft nephropathy (CAN) refers to the pathologic changes, including 
interstitial fi brosis, tubular atrophy, and fi brous intimal thickening, which are found in 
chronically dysfunctioning kidney transplants.2 Several risk factors for CAN have been 
recognized, such as the number and the severity of acute rejection episodes,4 ongoing 
chronic rejection, and excessive exposure to calcineurin inhibitors such as cyclosporine A 
(CsA).2,5 Therefore, the lesions that occur in biopsies of patients with CAN may result from 
either one or a combination of these factors. Paradoxically, changes induced by chronic 
rejection are clinically and histopathologically hard to distinguish from those caused by 
the nephrotoxic effects of chronic exposure to CsA, meant to prevent chronic rejection. 
This makes it diffi cult to determine the optimal dose of the immunosuppressive regimen, 
in which the benefi cial and nephrotoxic effects of CsA are balanced.6
Some changes observed in routine light microscopy may help reveal the cause of chronic 
renal allograft dysfunction. These include peripheral nodular arteriolar hyalinosis, 
suggestive of chronic CsA toxicity, and transplant vasculopathy (intimal fi brosis, disruption 
of the lamina elastica in the presence of infl ammation), suggestive of chronic rejection.7-8 
However, these lesions are not decisively present in all patients with either of the diagnoses. 
Furthermore, due to the fact that peripheral nodular arteriolar hyalinosis and transplant 
vasculopathy appear focally in the tissue, sampling errors may obscure their presence.
In this study, we describe how differentiation between chronic rejection and chronic CsA 
toxicity may be improved with the aid of molecular techniques, based on the results of 
a quantitative analysis of the renal cortical mRNA levels of several extracellular matrix 
(ECM) components and the ECM-regulating molecule transforming growth factor-β 
(TGF-β) in two groups of patients suffering from either disease entity.
We focused on several molecules that make up the interstitial compartment of the kidney 
and are known to accumulate in renal fi brosis, including collagens I and III, and fi bronectin, 
together with the ECM-regulating molecule TGF-β and its potential inhibitor decorin. In 
recent publications, attention has been drawn to expression of collagen IVα3 and laminin 
β2 in the discrimination between chronic rejection and CsA toxicity.9 These molecules are 
also the subject of the current study.
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We reviewed all kidney transplant biopsies performed in our center over the past 20 years, 
taken because of renal function loss beyond 1 year after transplantation. We selected two 
groups of patients: the chronic rejection group and the chronic CsA toxicity group.
The chronic rejection group (N = 19), consisted of patients who received either prednisone 
and azathioprine (N = 6), or prednisone and CsA (N = 13). Of the 13 patients using CsA, 
seven received the Sandimmune formulation and six received the Neoral formulation. These 
patients, with an initially well-functioning kidney transplant, developed a progressive 
decline in renal function. A biopsy was taken 4.8 ± 3.8 years after transplantation, in 
which transplant vasculopathy (intimal fi brosis, intimal infl ammation, and disruption 
of the lamina elastica), transplant glomerulopathy [characterized by double contours of 
the glomerular basement membrane (GBM)] or both were present as a histopathologic 
indication of chronic rejection, as defi ned by the Banff 97 classifi cation.7 Biopsies with 
peripheral nodular arteriolar hyalinosis, a lesion suggestive of CsA toxicity, and biopsies 
with signs of de novo or recurrent native disease were excluded. Patients suffering from 
diabetes and patients with graft arterial stenosis were excluded.
The chronic CsA toxicity group (N = 17), consisted of patients with an initially well-
functioning kidney transplant, who developed a progressive decline in renal function only 
after a switch was made from Sandimmune to Neoral; CsA formulations with a relatively low 
and a relatively high bioavailability, respectively. Before the switch, immunosuppression 
was aimed at CsA 24-hour trough levels of 100 μg/L by administration of Sandimmune 
once daily. After the switch, Neoral was administered twice daily, aiming at a 12-hour 
trough level of 150 μg/L. Thereby, the mean daily CsA dose was increased from 3.2 mg/kg 
to 3.5 mg/kg.10 Patients who developed a signifi cant and progressive decrease in renal 
function after this switch, in the absence of other features that might explain the decline in 
renal function, were included. Renal biopsies, taken 7.1 ± 3.4 years after transplantation 
and 2.5 ± 1.2 years after the switch from Sandimmune to Neoral, showed peripheral nodular 
arteriolar hyalinosis in 16 of the 17 patients, histopathologically supporting the functional 
selection. Biopsies with histologic features suggestive of chronic rejection or de novo or 
recurrent glomerulonephritis were excluded. Patients suffering from diabetes and patients 
with graft arterial stenosis were excluded.
C4d staining was performed on all biopsy samples. None of the patients in the CsA toxicity 
group showed C4d depositions in their peritubular capillaries, while 26% of the patients in 
the chronic rejection showed diffuse C4d depositions in the peritubular capillaries.




As controls (N = 6), we used protocol transplant biopsies taken from patients at 6 months 
after transplantation with stable graft function at the time of biopsy. Apart from some cases 
showing signs of minor nonspecifi c age-related alterations, none of the biopsies showed 
any signs of rejection or drug toxicity. The glomeruli (at least ten present in the sections 
for evaluation) did not show any abnormalities. Patients in this control group all used CsA 
as immunosuppressive medication.
Clinical data 
Clinical data included gender, patient age at time of biopsy, donor age, transplant-origin 
(cadaveric or living donor), number of acute rejection episodes, delayed graft function, 
time between transplantation and biopsy, time between switch and biopsy, mean arterial 
pressure (MAP), number of antihypertensive drugs used, use of angiotensin-converting 
enzyme (ACE) inhibitors, lowest serum creatinine, serum creatinine at biopsy, proteinuria 
at time of biopsy, and CsA trough levels. We estimated the best endogenous creatinine 
clearance and creatinine clearance at biopsy using the Cockcroft-Gault equation.11 The 
loss of renal function was defi ned as the best Cockcroft clearance minus the Cockcroft 
clearance at the time of biopsy.
mRNA isolation and cDNA synthesis 
Four micrometer cryostat sections of each biopsy were cut, air dried, and stored at 20°C 
until use for immunohistochemistry. One section was evaluated to localize the cortex, 
which was thereafter excised from the biopsy. RNA was subsequently extracted, as 
described previously.12 In brief, the tissue was lysed by rigorous mixing after suspension 
in 500 μL TRIzol® (Invitrogen Life Technologies, Carlsbad, CA, USA). After adding 
100 μL chloroform, the solution was centrifuged at 15,000g for 15 minutes. The RNA 
was precipitated by addition of 5 μg of glycogen and 250 μL isopropanol. cDNA synthesis 
was performed using an reverse transcription (RT) kit (Omniscript Reverse Transcriptase) 
(Qiagen GmbH, Westburg B.V., The Netherlands).
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Real-time polymerase chain reaction (PCR) 
For several ECM molecules and TGF-β1, forward and reverse primers (Life Technologies 
BRL and Biosource International, Nivelles, Belgium) and TaqMan probes (Biosource 
International) were designed, using Primer Express® 1.5 software (PE Applied Biosystems, 
Foster City, CA, USA). To prevent amplifi cation of genomic DNA, primers or probes were 
chosen spanning an exon-intron junction. Primers were located near the 3’ end of the mRNA. 
The 5’ ends of the Taqman probes were 6-carboxy-4,7,2’,7’-tetrachloro-fl uorescein (TET)-
labeled, except those for glyceraldehyde-3-phosphate dehydrogenase (GAPDH), collagen 
IVα3, and decorin, which were 6-carboxy fl uorescein (FAM)-labeled. The quencher dye at 
the 3’ side of the probe was 6-carboxy-tetramethyl-rhodamine (TAMRA). The sequences 
of the primers and of the TaqMan probes are shown in Table 1.
Real-time PCR was performed using the ABI Prism™ 7700 sequence detector and software 
(PE Applied Biosystems).13 Amplifi cation cycles were 95°C for 10 minutes, followed by 
40 cycles at 95°C for 30 seconds and at 60°C for 60 seconds. Kinetics of the reactions 
were determined using a standard curve. We used the ratio of the levels of the investigated 
molecule and GAPDH, a constitutively expressed gene, to correct for the amount of tissue 
used for RNA extraction and the effi ciency of cDNA synthesis. To confi rm the suitability of 
GAPDH as a housekeeping gene, we tested the correlation between the expression of two 
additional housekeeping genes [i.e., hypoxanthine phosphoribosyl transferase 1 (HPRT1) 
and β2-microglobulin (β2m)], and that of GAPDH in all samples.
Immunofl uorescence for C4d 
Immunofl uorescence staining for C4d was performed on untreated slides using standard 
procedures as described before.14-15 As the primary antibody, mouse anti-C4d antibody 
(Quidel, San Diego, CA, USA), diluted to 2 ng/mL in phosphate-buffered saline (PBS) and 
supplemented with 1% bovine serum albumin (BSA), was used. The secondary antibody 
was fl uorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG (Sigma Chemical 
Co., St. Louis, MO, USA), diluted 1:200 in BSA/PBS. The staining was evaluated 
independently by two of the authors (K.K. and M.E.), blinded for the diagnosis of the 
samples. C4d staining was observed in the peritubular capillaries (PTC) in a circumferential 
pattern. Sporadically, mesangial and GBM areas of the glomerulus stained positive. In 
accordance with scoring methods described in the literature on C4d deposition in renal 
allografts,16-17 biopsies were scored C4d-positive when more than 25% of the PTC showed 
an intense and circumferential staining as depicted in Figure 1. In most cases of diffuse 
positive samples all PTC were affected. In the few cases of discordant scoring, decision 
was reached by consensus.
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Figure 1: Immunofl uorescence staining for C4d. In some chronic rejection samples diffuse 
circumferential staining of peritubular capillaries for C4d was observed (original magnifi cation 
x 400). 
Immunohistochemistry 
For evaluation of protein expression in the tissue, immunohistochemistry was performed 
for laminin β2 and TGF-β. Four micrometer frozen sections were thawed, air dried, and 
incubated for 1 hour with mouse monoclonal anti-laminin ß2 antibodies (Developmental 
Studies Hybridoma Bank, Iowa City, IA, USA) diluted 1:16 in BSA/PBS, or rabbit 
polyclonal anti-TGF-β (Dako, Glostrup, Denmark), diluted 1:400 in BSA/PBS. The anti-
TGF-β antibodies stain both the active and latent form of TGF-β. The slides were washed 
in PBS, and subsequently incubated with horseradish peroxidase (HRP)-conjugated 
antimouse Envision and HRP-conjugated antirabbit Envision, respectively (Dako). After 45 
minutes of incubation, the slides were washed in PBS and the staining was developed with 
diaminobenzidine (DAB). The color was enhanced by incubating the slides in 0.5% CuSO4 
solution for 5 minutes. After counterstaining with hematoxylin, the slides were dehydrated 
and mounted. For each staining, all biopsy samples were stained in one session.
 
Digital image analysis 
To quantify the amount of staining for TGF-β and laminin β2, images of the cortical part 
of the biopsies were taken at a 200 magnifi cation using a Zeiss microscope equipped with 
a Sony DXC-950P 3 CCD color camera (Sony Corporation, Tokyo, Japan) and further 
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analyzed using KS-400 image analysis software (version 3.0 for Windows) (Carl Zeiss 
Vision GmbH, Oberkochen, Germany). The cortical area stained was defi ned as the amount 
of staining within the color spectrum specifi c for the enhanced DAB staining, and above a 
fi xed intensity threshold, as described previously.18 Recording and analysis of the images 
were performed with fi xed settings.
Statistical analysis 
Statistical analysis was performed using SPSS 10.0.7 for Windows software. We used log 
transformed (10log) mRNA levels for analysis. A one-way analysis of variance (ANOVA) 
with a Bonferroni post hoc correction was used for comparison of differences between 
groups. Using a receiver-operating characteristic (ROC) curve, we determined the cut-
off point of mRNA levels with the best combination of sensitivity and specifi city that 
predicted the presence of CsA toxicity. Correlations between the mRNA data and the 
clinical characteristics of the patient groups were calculated using Pearson’s correlation 
test. P < 0.05 was considered statistically signifi cant.
Results 
Patient data 
The clinical characteristics of the patients and the controls are listed in Table 2. Renal 
function at time of biopsy, donor age, patient age, number of acute rejection episodes, 
delayed graft function, the time interval between transplantation and biopsy, MAP, number 
of antihypertensive drugs used, and use of ACE inhibitors did not differ signifi cantly 
between patient groups. There was signifi cantly greater loss of renal function in the chronic 
rejection group than in the chronic CsA toxicity group (38 ± 16 mL/min and 21 ± 13 mL/
min, respectively) (P < 0.01). There were signifi cantly more patients with a living-donor 
kidney transplant in the CsA toxicity group, compared with the chronic rejection group 
(35% and 5%, respectively) (P = 0.02).
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Number 19 17 6
Gender female 10 (53%) 4 (24%) 2 (33%)
Number of patients treated with cyclosporine A 13 (68%) 17 (100%) 6 (100%)
Patient age years ± SD 44 ± 14 49 ± 13 45 ± 6
Donor age years ± SD 35 ± 16 44 ± 10 47 ± 17
Living-donor kidney transplants % 5 35c
Number of acute rejection episodes 0.8 ± 1.0 0.5 ± 0.6
Delayed graft function % 21 18
Time between transplantation and biopsy years ± SD 4.8 ± 3.8 7.1 ± 3.4
Time between switch and biopsy years ± SD 2.5 ± 1.2
Mean arterial pressure 108 ± 10 106 ± 8
Number of antihypertensive drugs used (0/1/2/≥3) 2/2/8/7 2/5/5/5
Use of ACE-inhibitors % 21 29
Best serum creatinine level μmol/L ± SD 113 ± 27 124 ± 25
Serum creatinine at time of biopsy μmol/L ± SD 238 ± 83 201 ± 45 118 ± 25
Best creatinine clearance mL/min ± SDa 74 ± 22c 61 ± 11
Creatinine clearance at time of biopsy mL/min ± SDa 36 ± 14 40 ± 15 68 ± 14
Loss of renal function μmol/L ± SD b 38 ± 16d 21 ± 13
Proteinuria at time of biopsy g/24hours ± SD 2.9 ± 2.6 1.3 ± 1.5
Cyclosporine A trough levels at time of biopsy μg/L ± SD 110 ± 31 114 ± 30
a Creatinine clearance was estimated by the Cockcroft-Gault equation.
b  Loss of renal function was defi ned as the difference between the best creatinine clearance and the creatinine 
 clearance at the time of biopsy.
c  P < 0.05; d P < 0.01.
Abbreviations are: ACE angiotensin-converting enzyme.
Cortical mRNA levels 
GAPDH mRNA levels did not differ between groups (data not shown). Within the chronic 
rejection group, mean GAPDH expression did not signifi cantly differ between CsA-using 
and non-CsA-using patients. There was a signifi cant correlation between GAPDH mRNA 
and mRNA of the two other housekeeping molecules measured (r = 0.74 and r = 0.92 
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for β2m and HPRT1, respectively) (P < 0.001). Additionally, we tested comparisons 
between the chronic rejection and the CsA toxicity group for all transcripts using β2m 
as the housekeeping molecule. This yielded the same results as when GAPDH was used. 
These fi ndings support the suitability of GAPDH as a housekeeping molecule in the 
experiments.









Collagen Iα1 0.3 ± 0.2 0.2 ± 0.3 0.2 ± 0.3 0.8 ± 0.2
Collagen IIIα1 0.3 ± 0.2 0.2 ± 0.2 0.3 ± 0.2 0.3 ± 0.1
Collagen IVα3 0.1 ± 0.2c 0.1 ± 0.2c 0.5 ± 0.1c -1.9 ± 0.3
Decorin 0.0 ± 0.2 -0.2 ± 0.2 -0.1 ± 0.2 -0.4 ± 0.2
Fibronectin -0.1 ± 0.2c -0.3 ± 0.2c -0.1 ± 0.2c -1.6 ± 0.2
Laminin β2 0.6 ± 0.1e 0.5 ± 0.2e 1.1 ± 0.1c -0.1 ± 0.3
TGF-β 0.8 ± 0.1d 0.8 ± 0.2d 1.3 ± 0.1c 0.5 ± 0.2
Ratio TGF-β / decorin 0.8 ± 0.2d 0.8 ± 0.2d 1.4 ± 0.1 0.9 ± 0.2
a All values are mean ± SEM; b Mean log transformed mRNA levels of the chronic rejection group after omission 
of patients using azathioprine as immunosuppression; c P < 0.01, vs. III.; d P < 0.05, vs. II, e P < 0.01, vs. 
II; Abbreviations are: mRNA, messenger ribonucleine acid; CsA, cyclosporine A; TGF-β, transforming growth 
factor-β.
The mean log transformed mRNA levels of collagen Iα1, collagen IIIα1, collagen IVα3, 
decorin, fi bronectin, laminin β2, and TGF-β are shown in Table 3 and depicted in Figure 
2. The mRNA levels of collagen IVα3 and fi bronectin were higher in both patient groups 
compared to controls. The mRNA levels of laminin β2 and TGF-β were higher in the 
CsA toxicity groups compared to controls (Table 3) (Fig. 2F and H). The renal mRNA 
levels of collagen Iα1, IIIα1, and IVα3, decorin, and fi bronectin were not signifi cantly 
different between patients with chronic rejection and patients with CsA toxicity (Table 3) 
(Fig. 2A to E). The renal mRNA levels of laminin β2, TGF-β, and the ratio of TGF-β to 
decorin were signifi cantly higher in patients with CsA toxicity than in patients with chronic 
rejection (Table 3) (Fig. 2F and G). After omitting patients who did not use CsA from the 
chronic rejection group, comparative analyses between groups yielded comparable results 
(Table 3). In addition, there were no differences in mRNA expression of all molecules 
analyzed between chronic rejection patients who used CsA and those who did not use 
CsA as immunosuppression (collagen Iα1, P = 0.44; collagen IIIα1, P = 0.51; collagen 
IVα3, P = 0.57; decorin, P = 0.07; fi bronectin, P = 0.10; laminin β2, P = 0.52; TGF-β, P = 
0.53). There were no signifi cant differences between mRNA expression levels in cadaveric 
transplants and living-donor transplants within each patient group.
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Figure 2: Box and whisker plots of the log transformed mRNA levels. The boxes contain 50% of 
the values. The upper and lower border indicate the 25th and the 75th percentile, respectively. The 
upper and lower whisker indicate the highest and lowest value, respectively. The black line in the 
box indicates the median and the (◦) indicates an outlier. (A) Collagen Iα1. (B) Collagen IIIα1. (C) 
Collagen IVα3. [P < 0.001 chronic rejection (CR) and cyclosporine A (CsA) toxicity (CsAT) vs. 
controls]. (D) Decorin. (E) Fibronectin (P < 0.001 chronic rejection and CsA toxicity vs. controls. 
(F) Laminin β2 (P < 0.001 CsA toxicity vs. controls (P = 0.002 chronic rejection vs. CsA toxicity). 
(G) Transforming growth factor-β (TGF-β) (P = 0.004 CsA toxicity vs. controls) (P = 0.020 chronic 
rejection vs. CsA toxicity). (H) TGF-β/decorin ratio (P = 0.014 chronic rejection vs. CsA toxicity).




We performed immunohistochemical stainings to evaluate the tissue expression of laminin 
β2 and TGF-β at the protein level (Figure 3). In biopsies of controls, laminin β2 staining 
was observed in the GBM and in cortical vessels (Figure 3A). In chronic rejection as well 
as in CsA toxicity, sporadic expression of laminin β2 was seen in the tubular basement 
membrane (Figure 3B and C). TGF-β staining was sporadically observed in glomeruli and 
tubuli of controls (Figure 3D). In sections of biopsies from patients suffering from chronic 
rejection or CsA toxicity, some tubuli showed very intense staining for TGF-β (Figure 
3E and 3F). There was no relation between this sporadic intensive staining and mRNA 
expression levels or clinical parameters.
Figure 3: Immunohistochemical stainings for laminin β2 (A to C) and transforming growth factor-
β (TGF-β) (D to F). In control tissue laminin β2 staining was observed in the glomerular basement 
membrane and cortical vessels (A) In chronic rejection (B) and cyclosporine A (CsA) toxicity (C) 
expression of laminin β2 was observed in the tubular basement membrane. TGF-β staining was 
sporadically observed in glomeruli and tubuli of controls (D) In chronic rejection (E) and CsA 
toxicity (F), some tubuli showed a very intense staining for TGF-β.
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In both patient groups, the amount of laminin β2 staining was increased compared to 
controls. The mean cortical area percentage was slightly higher in the CsA toxicity group 
than in the chronic rejection group (5.7 ± 1.5 and 5.3 ± 1.0, mean ± SEM) (Figure 4A). The 
differences between groups were not signifi cant. The amount of TGF-β staining was higher 
in patient groups than in controls. The mean cortical area percentage was higher in the CsA 
toxicity group than in the chronic rejection group (15.8 ± 3.6 and 13.4 ± 2.2, mean ± SEM) 
(Figure 4B), though this difference did not reach statistical signifi cance.
Figure 4: Immunohistochemical staining for laminin β2 and transforming growth factor-β 
(TGF-β). Bars represent mean cortical area percentage ± SEM. (A) The amount of laminin β2 staining 
is slightly higher in the cyclosporine A toxicity (CsAT) group compared to the chronic rejection (CR) 
group, but the difference between groups does not reach statistical signifi cance. (B) TGF-β staining is 
increased in the CsA toxicity group compared to the chronic rejection group. There are no signifi cant 
differences between groups. 
ROC curve analysis 
ROC curve analysis (Figure 5) showed that a 15.6-fold increase of laminin β2 mRNA 
levels compared to controls indicates the presence of CsA toxicity with an 87% sensitivity 
and an 88% specifi city. The area under the curve was 0.90 (P < 0.001). Similarly, a ninefold 
increase of TGF-β mRNA levels predicts the presence of chronic CsA toxicity with a 60% 
sensitivity and an 88% specifi city (area under the curve 0.76) (P < 0.05).
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Figure 5: Receiver-operating characteristic (ROC) curve of laminin β2 and transforming growth 
factor-β (TGF-β). The fraction of true positive results (sensitivity) and false-positive results 
(1-specifi city) for laminin β2 (solid line) and TGF-β (dashed line) mRNA levels. The area under 
the curve indicates the accuracy of the test: 0.5 is the value expected by chance (diagonal line), 
1.0 represents the ideal predictor. The area under the curves for laminin β2 and TGF-β are 0.896 
and 0.758, respectively. Using a 15.6-fold increase in laminin β2 mRNA levels to those of normal 
controls as cut-off point, the sensitivity is 87% and the specifi city 88% for the prediction of the 
presence of chronic cyclosporine A toxicity.
Correlations 
No correlations were found between mRNA levels and age, donor age, number of acute 
rejection episodes, delayed graft function, time between transplantation and biopsy, the 
time between switch and biopsy, loss of renal function, MAP, and use of ACE inhibitors. 
Only in the chronic rejection group, TGF-β mRNA levels and the ratio of TGF-β to decorin 
mRNA levels correlated signifi cantly with laminin β2 mRNA levels (r = 0.56 and r = 0.68, 
respectively) (P < 0.05).
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Discussion 
This study was designed to enhance the discrimination between chronic rejection and 
chronic CsA toxicity as a cause of CAN. With current clinical and histologic parameters 
this distinction is diffi cult to make because of the similarities in clinical presentation 
and aspecifi city of the lesions in needle biopsies of patients with CAN. We show that 
quantifi cation of mRNA levels of laminin β2 and TGF-β can be used to distinguish 
chronic rejection from CsA toxicity, which will help in fi ne-tuning the immunosuppressive 
regimen. In this way, the benefi cial effects of CsA are not abrogated by its nephrotoxic side 
effects.3
In our center, we had the opportunity to defi ne on functional criteria a patient group that 
suffered from chronic CsA toxicity, comprising patients who developed a progressive 
decline in renal function after a change in immunosuppressive medication was made leading 
to a higher CsA exposure.10 The appropriateness of these selection criteria was supported 
by histopathologic fi ndings: peripheral nodular arteriolar hyalinosis, regarded as a fi nding 
suggestive of CsA toxicity, was present in 94% of these patients, and C4d deposition in 
PTCs, a feature frequently seen in chronic rejection,19 was absent in all patients of the CsA 
toxicity group. An additional selection criterion for the CsA toxicity group and a further 
proof of CsA toxicity might have been the recovery of renal function after stopping or 
reducing CsA administration. Unfortunately, these data were not available. In the chronic 
rejection group, 13 out of 19 patients also received CsA. However, since the CsA formulation 
in the majority of these patients had a relatively low bioavailability and administration was 
applied only once-daily, this group is less likely to have suffered from CsA toxicity. In 
addition, patients in this group had transplant vasculopathy or glomerulopathy, histologic 
features suggestive of chronic rejection, but they did not show histologic features consistent 
with CsA toxicity. Finally, although there was some heterogeneity in immunosuppressive 
medication in the chronic rejection group, no differences were found in mRNA data 
between patients using CsA and those who did not use CsA as immunosuppression, and 
analysis with only the group of chronic rejection patients using CsA as immunosuppression 
yielded the same results as the chronic rejection group as a whole. A striking difference 
in patient characteristics was that 35% of the CsA toxicity group, but only 5% of the 
transplants in the chronic rejection group were living donor transplants. This might support 
the opinion that injuries infl icted to cadaveric allografts before or during transplantation 
elicit a predisposition for the development of chronic rejection, as has been suggested 
before.2,20
The ECM is a meshwork of proteins, in which remodeling continuously takes place by 
means of protein synthesis and degradation. Accumulation of ECM proteins refl ects an 
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imbalance of this dynamic process, resulting from an increase in protein synthesis, a decrease 
in protein degradation, or a combination of both. The synthesis of ECM components is 
enhanced by several profi brotic cytokines, including TGF-β. During chronic renal allograft 
dysfunction, this cytokine has been shown to be up-regulated at the mRNA and protein 
level in the grafts, sera, and peripheral blood mononuclear cells of patients taking CsA-
based immunosuppression.21-22 TGF-β mRNA levels are up-regulated in cultured murine 
proximal tubular epithelial cells and fi broblasts after exposure to CsA.23 Moreover, in rats 
receiving CsA, administration of anti-TGFβ-1 antibodies reduces the extent of histologic 
damage reminiscent of CsA toxicity.24 Decorin, a low-molecular-weight proteoglycan, 
can bind and inactivate TGF-β, thereby preventing its prosclerotic action.25 The TGF-
β/decorin mRNA ratio may therefore be a better indicator of TGF-β activity than TGF-β 
mRNA levels alone. We found a signifi cant increase of TGF-β mRNA levels and of the 
TGF-β/decorin ratio in CsA toxicity, supporting the notion that CsA has a stimulatory 
effect on TGF-β expression.
Laminin β2 is a normal component of the renal vasculature and the GBM.26 We observed 
an increase in laminin β2 mRNA expression in the CsA toxicity group compared to 
controls, the expression in the CsA toxicity group being also signifi cantly higher than in the 
chronic rejection group. Laminin β2 mRNA expression was also higher in the CsA toxicity 
group when comparing it to the chronic rejection group with only those patients using 
CsA included. Only sparse information about factors stimulating laminin β2 expression is 
available. The results of our study suggest a direct or indirect stimulatory effect of CsA on 
laminin β2 expression, yet the underlying mechanism is unclear.
We performed immunohistochemistry combined with digital image analysis for laminin β2 
and TGF-β to evaluate the expression of these molecules at the protein level. The pattern 
seen at the protein level resembled that at the mRNA level (i.e., there was a tendency 
toward a higher expression of laminin β2 and TGF-β in the CsA toxicity group than in the 
chronic rejection group). However, differences in protein staining between groups did not 
reach statistical signifi cance. Furthermore, a correlation between mRNA expression levels 
and protein deposition was absent. The observation that the extent of protein accumulation 
does not strictly coincide with mRNA levels has been described before.27 Additionally, in 
vivo accumulation of protein is not only determined by synthesis, but also by degradation 
of ECM products. Although we did not evaluate the mechanism of laminin β2 degradation, 
the notion that laminin β2 mRNA levels were increased in the CsA toxicity group compared 
to the chronic rejection group, while protein levels were not signifi cantly different, might 
suggest that there is an increased degradation of laminin β2 in CsA toxicity. This might be 
due to the microvascular damage exerted by CsA.8
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Collagen Iα1 and collagen IIIα1 are components of the renal interstitium that are normally 
present in relatively small amounts.28 Accumulation of these molecules has been reported 
in a variety of chronic human kidney diseases29 and CAN.30-31 There was no difference 
between the chronic rejection group and the CsA toxicity group in collagens I and III 
mRNA levels. We observed no differences in the mRNA levels between the patient groups 
and the control group. This might be explained by the possibility that the accumulation of 
collagens I and III in CAN is a result of an early increase in collagen synthesis that might 
have taken place before the overt damage seen in the tissues. Furthermore, it might be 
that the accumulation of collagens I and III in patients with CAN is due to an impaired 
degradation of these proteins, as has been suggested before.32
Collagen IVα3 is a component of both the GBM and the distal tubular basement membrane 
(TBM).26 In a study by Abrass et al.,9 de novo expression of collagen IVα3 protein was 
reported in the proximal TBM in chronic rejection, but not in CsA toxicity. In our study, we 
did not observe signifi cant differences in collagen IVα3 mRNA expression levels between 
the two groups. Since we used total cortical tissue for mRNA analysis, it is possible that 
subtle differences of collagen IVα3 mRNA expression in the proximal tubulus epithelium 
between patient groups remained undetected. When we focused only on the chronic rejection 
group, the collagen IVα3 mRNA expression was higher in the C4d+ chronic rejection 
group than in the C4d- chronic rejection group (data not shown). C4d recently has gained 
much interest as a marker of humoral rejection, but there is only sparse information about 
the relation between C4d and accumulation of ECM.33 Future studies would be needed to 
decipher whether the relation found in our study is of pathogenic signifi cance.
In both the chronic rejection and the chronic CsA toxicity group, we observed a signifi cant 
increase in renal cortical fi bronectin mRNA levels in comparison to controls. There were 
no differences in the mRNA levels of fi bronectin between the chronic rejection and the 
CsA toxicity group. This is in line with previous studies showing an increase in fi bronectin 
mRNA levels in a rat model of CsA toxicity,34 and in allograft rejection, both at the mRNA 
and the protein level.35-36
One of the advantages of analyzing mRNA profi les may be that alterations in mRNA levels 
precede the development or aggravation of tissue damage.37 This holds promise for an 
earlier recognition of an unfavorable course after kidney transplantation.38-39 Furthermore, 
quantitative mRNA analysis can be performed rapidly, and requires only small amounts of 
renal tissue. In the future, diagnostic approaches using molecular analysis simultaneously 
with conventional strategies are likely to be implemented in clinical practice.40 We had 
the opportunity to compose merely on the basis of functional variables two patient groups 
that represent the extremes of a spectrum of causes leading to the development of CAN. 
Therefore, we studied the presence of markers that could discriminate between these two 
proefschrift bakker.indd   118 1-12-2004   9:02:01
Chapter 6
119
highly selected patient groups. An obvious prerequisite for implementation in clinical 
practice is to test the use of these markers in larger nonselected patient groups.
 
Conclusion 
We measured human renal cortical mRNA expression levels of ECM components in two 
well-defi ned groups of patients suffering from either chronic rejection or chronic CsA 
toxicity. In both patient groups, the mean mRNA levels for collagen IVα3 and fi bronectin 
were signifi cantly elevated compared to those in controls, whereas in CsA toxicity the 
laminin β2 and TGF-β mRNA levels were also signifi cantly increased. Most important, 
we showed that laminin β2 and TGF-β mRNA levels are signifi cantly higher in patients 
with CsA toxicity than in patients with chronic rejection, and that measurement of these 
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Late transplant dysfunction or loss remains an important problem after kidney allograft 
transplantation. A gradual but variable rate of decline in allograft function is observed 
in about 40 to 50% of the patients who receive a kidney allograft transplant at two or 
more years after transplantation.1 Various factors, alloantigen-dependent and alloantigen- 
independent, may play a role in the loss of function. A biopsy of the allografted kidney is 
often taken after prerenal and postrenal causes of functional decline are excluded to help 
to design a strategy that prevents further loss of function. In a small minority of cases 
histologic changes are found that suggest a specifi c cause of graft dysfunction such as a 
recurrence of the original kidney disease, de novo glomerulopathy or diabetic nephropathy. 
More frequently less specifi c chronic and sclerosing signs of tissue damage are observed. 
Since 1991 efforts have been made to standardize the interpretation of pathologic fi ndings 
of renal allograft biopsies in the Banff Working Classifi cation of Renal Allograft Pathology. 
In this system the descriptive term chronic allograft nephropathy (CAN) was adopted for 
chronic and sclerosing tissue changes, which include arteriosclerosis, glomerulosclerosis, 
tubular atrophy, interstitial fi brosis, and tubular atrophy.2 The severity of these changes 
is staged by the degree of the interstitial fi brosis and tubular atrophy. The pathogenesis 
of CAN is multifactorial and comprises factors that are alloantigen-independent and 
alloantigen-dependent.3,4 The tissue changes of CAN may represent cumulative and 
incremental damage to nephrons from time-dependent insults.5 The immune-mediated 
alloantigen-dependent injury may result from acute rejection, subclinical acute rejection or 
chronic rejection. Alloantigen-independent injury may result from ischemia/reperfusion, 
drug nephrotoxicity, viral infection and primary vascular changes due to hypertension, 
smoking or dyslipidemia. Also the age of the allografted kidney plays a role and may 
determine whether tissue damage occurs and how this is repaired. The kidneys from older 
donors are more susceptible to acute rejection and the ageing kidney seems to have an 
impaired ability to restore tissue.6 
Although CAN may represent the fi nal histologic appearance of many different insults 
to the allografted kidney, it remains important to identify factors that are still initiating 
tissue damage. Some specifi c histologic features may indicate ongoing immune-mediated 
alloantigen-dependent damage. Chronic allograft glomerulopathy (CAG), also known as 
chronic transplant glomerulopathy (TGP), represents an alloantigen-dependent, probably 
antibody-mediated, injury at the level of the glomeruli. CAG is found in a small minority 
(5-15%) of late biopsies with features of CAN.7 De novo arterial intimal fi brosis also 
supports the diagnosis of chronic alloantigen-dependent damage. However, most of the 
time it is not clear whether the arteriosclerotic lesions occurred de novo, or alternatively, 
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were already present at transplantation or induced by cardiovascular risk factors operating 
in the acceptor. 
Newer methods of studying immune-mediated damage in late allograft biopsies include the 
immunostaining for C4d in the peritubular capillaries (PTCs), and the electron microscopic 
examination of the peritubular capillary basement membranes. C4d is a split product of the 
complement factor C4 that covalently binds to tissue and its presence in PTCs has been 
studied as a possible marker for acute and chronic antibody- mediated rejection. At present 
defi nite evidence is still lacking that positive C4d staining of PTCs in a biopsy with CAN 
indicates ongoing antibody-mediated rejection.8 It has been recognized that extensive 
multilayering of peritubular capillary basement membranes at electron microscopy is 
strongly associated with CAG.9-11 Its signifi cance as an isolated fi nding in biopsies with 
CAN has not been established. More studies are needed to evaluate the importance of these 
new techniques in the diagnosis of CR. 
Drug toxicity may affect the graft, especially of the calcineurin inhibitors (CNI) 
cyclosporine A (CsA) and tacrolimus, which are used to prevent rejection. An important 
marker of chronic CNI toxicity is peripheral nodular hyaline degeneration (PNHD) of 
small arterioles. However, the changes of PNHD may be diffi cult to separate from the 
less specifi c, more commonly observed lesions of arteriolar hyalinosis.12 Furthermore, as 
a marker of chronic CNI nephrotoxicity, they seem to be not very sensitive.12 Although 
extensively studied, the pathophysiologic characteristics of chronic CNI nephrotoxicity 
are still far from being completely understood. Calcineurine inhibitors are the most widely 
prescribed immunosuppressive drugs in organ transplantation and the use of these drugs has 
allowed signifi cant improvement in the short-term success rate of kidney transplantation. 
With respect to their nephrotoxic potential, uncertantity still exists how severely they 
affect long-term graft survival and whether they should be stopped at some point after 
transplantation. 
This thesis describes studies that focus on chronic CsA nephrotoxicity, and on tissue changes 
that occur in the tubulointerstitial compartment of kidneys with CAN. Several issues were 
addressed: the contribution of chronic CsA nephrotoxicity to late allograft dysfunction and 
CAN; the direct tubulotoxicity of CsA; the composition of the renal cortical interstitial 
matrix; and the measurement of renal cortical mRNA of various proteins involved in 
extracellular matrix (ECM) deposition. 
In chapter 2 the present knowledge on chronic CsA nephrotoxicity is reviewed. Although 
extensively studied, the pathophysiology of chronic CsA nephrotoxicity is still far from 
being completely understood. The recognition of chronic CsA nephrotoxicity in allografted 
kidneys is hampered by the lack of easily assessable sensitive and specifi c markers. It 
has been recognized that more than half of the patients that suffer from late allograft 
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deterioration and who have CAN in their biopsy benefi t from withdrawal of CsA or a 
reduction of its dose.13 This strongly suggests that chronic CsA nephrotoxicity has an 
important contribution to late allograft deterioration and CAN. Several hypotheses attempt 
to explain the renal structural damage induced by CsA, including ischemia of the graft as 
a result of functional or structural vascular changes, direct cellular toxicity towards renal 
cells, and the stimulation of interstitial matrix production through induction of growth 
factors and cytokines. Possible ways to avoid chronic CNI nephrotoxicity are discussed 
and it is concluded that in the near future more strategies are likely to be used to prevent 
loss of allograft function as a result of CNI nephrotoxicity. 
Chapter three examines whether CsA is directly toxic for human proximal tubular 
epithelial cells. The exact pathogenesis of chronic CsA nephrotoxicity is, after 25 years 
of use of the drug, still largely unknown. Morphological studies reported proximal tubular 
epithelial cell vacuolization and inclusion bodies early after transplantation during CsA 
treatment, and animal and human studies have found an increase in the urinary excretion of 
the proximal brush border enzyme N-acetyl-β-D-glucosaminidase.14 Moreover the urinary 
excretion of β2-microglobulin is enhanced during CsA therapy suggesting proximal tubular 
cell damage.15 In both human and animal studies a higher rate of tubular cell apoptosis has 
been described during CsA exposure.16 Still it was not clear whether this increased apoptotic 
activity is the result of a direct toxic effect of CsA or the result of an indirect mechanism 
such as ischemia. It was hypothesized that a very high supratherapeutic concentration of the 
drug induces tubular cell necrosis and that lower, more therapeutic concentrations promote 
apoptosis. The aim of the studies, as described in this chapter, was to examine whether CsA 
directly induces cell death of cultured proximal tubular epithelial cells (PTEC) by either 
necrosis or apoptosis. Therefore primary isolates of human PTEC and LLC-PK1-cells, a 
pig immortalized cell line of proximal descent, were examined at various points after CsA 
exposure at concentrations of 0.01-100 µg/ml. Apoptosis was studied by the assessment of 
annexin binding and propidium iodide uptake, the measurement of cellular DNA content 
and cell cycle analysis and by the evaluation of nuclear morphology. Cell death was studied 
by the trypan blue exclusion method. Experiments were also performed under simulated 
hypoxic conditions by chemical ATP depletion, because of the possibility that in vivo PTEC 
could be ATP depleted when exposed to CsA. 
In human PTEC, cell death was observed at CsA concentrations higher than 10 µg/
ml; at these concentrations, PTEC died as a result of necrosis and the toxicity of its 
vehicle Cremophore EL, and not as a result of CsA inducing apoptosis. The addition of 
cycloheximide to relieve a possible block in the apoptotic process had no effect on human 
PTEC but resulted in apoptosis of LLC-PK1. In human PTEC, CsA did not augment cell 
death induced by chemical ATP depletion. 
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Earlier studies on CsA cytoxicity in cultured renal tubular cells had reported contradictory 
results. Only two studies reported loss of viability of cultured human PTEC .17,18 However, 
in the fi rst study the cells were deprived of essential nutrients before incubation with CsA 
and in the second study the cells were of foetal origin. We concluded that the results of 
our in vitro study argued against a direct cytotoxic effect of CsA on adult human proximal 
tubular epithelial cells in vivo. 
Chapter 4 describes the results of a long-term open-label prospective randomized study 
that was initiated in 1983 and compared cyclosporine continuation with conversion to 
azathioprine three months after transplantation. 
It has long been recognized that CsA has many toxic side effects: it raises the blood 
pressure and serum cholesterol level and may cause nephrotoxicity, all of which contribute 
to mortality and graft loss in the late post-transplantation period. It was hypothesized 
that reduction in exposure to the drug after the period with the highest risk of acute 
rejection would be advantageous. It was hoped that the withdrawal of cyclosporine and 
the replacement by azathioprine after a certain time post-transplantation would preserve 
the better short-term results of cyclosporine therapy while avoiding the consequences of 
long-term exposure to the drug. In 1995 data on 8 years follow-up were published.19 No 
signifi cant difference was found in patient and transplant survival. There was an apparent 
trend over time of an increasing difference in transplant survival in favor of the patients 
that converted to azathioprine. Benefi ts were noted on side effects and cardiovascular risk 
factors.
Chapter 4 reports the 15-year analysis of outcome and provides data on histological 
abnormalities in the allograft biopsies. One hundred-twenty-eight patients were enrolled. 
Three months after transplantation they were randomly assigned to continue cyclosporine 
treatment (N = 68) or to convert to azathioprine treatment (N = 60). The steroid dose was 
temporarily increased in the patients who were converted. Patient survival was not different 
in the two groups. Graft survival tended to be lower (64.7% versus 76.5% at 15 years) in 
the cyclosporine continuation group (P = 0.14), when data were analyzed on an intention-
to-treat basis. More allograft biopsies were taken from patients remaining on cyclosporine 
and prompted a high rate of late conversions to azathioprine or mycophenolate mofetil for 
suspicion of chronic CsA nephrotoxicity (19%). This could have infl uenced the results in 
favor of the CsA continuation arm. The graft survival of the patients that stayed on their 
assigned treatment was signifi cantly higher in the azathioprine arm, starting at two years’ 
post-transplantation. The glomerular fi ltration rate was signifi cantly higher in the patients 
who were converted to azathioprine at all points in time. The relative risk of CAN was 
signifi cantly higher in the group that continued cyclosporine (relative risk 4.3, [95% CI: 
1.4 to 12.9], P = 0.009). Conversion to azathioprine reduced the need for blood pressure 
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and lipid lowering drugs. It was concluded that conversion to a calcineurin inhibitor-free 
immunosuppressive regimen three months after renal transplantation improved allograft 
function, reduced the need for cardiovascular risk factor controlling medication and 
reduced the incidence of CAN.
The results of this long-term study emphasize that withdrawal of CsA after a critical time 
frame can be advantageous in terms of graft survival. The results are in line with the 
3-year data of a study that used sirolimus as the agent to continue along with steroids 
after withdrawal of CsA at three months. The 3-year results showed a 6% higher graft 
survival (P = 0.052) and a signifi cantly higher GFR of 12 ml/min;20 biopsy samples 
showed signifi cantly lower scores for chronic sclerosing lesions in the patients that were 
withdrawn from CsA.21 In this latter study, as well as in our study, cyclosporine treatment 
was monitored on trough level (C0) measurements. It has been shown that newer ways 
of therapeutic drug monitoring (TDM) of CsA, such as limited sampling methods or C2 
monitoring, leads to a decrease in the incidence of acute rejection. However, the effect 
of these newer ways of TDM on the incidence of chronic CsA nephrotoxicity is not yet 
known. It should also be mentioned that the results of our trial and that of the sirolimus 
continuation trial may not apply to patients with a high risk profi le for rejection. 
The more prominent changes in biopsies with CAN occur in the tubulointerstitial 
compartment with increased deposition of ECM. Chapter 5 examines the composition of 
the cortical interstitial matrix of patients whose allograft function declined as a result of CR 
or chronic CsA nephrotoxicity. Extracellular matrix accumulates in the cortical interstitium 
of dysfunctioning allografts regardless of the etiology, as is seen in chronic diseases of 
native kidneys.22 Surprisingly, the ECM composition of deteriorating allografted kidneys 
has hardly been studied. Defi ning the ECM molecules that accumulate could enhance our 
understanding of the pathogenesis of graft dysfunction and could potentially help defi ne 
the etiology if disease-specifi c changes are found. In this study we investigated whether 
the ECM composition differs in allografts with CR or chronic CsA nephrotoxicity. For 
this purpose, we studied the cortical interstitial ECM composition of kidney allografts 
with chronic CsA nephrotoxicity, with CR, and with suspected CR, here designated as 
CAN. The patients with CR used a CNI free immunosuppressive regimen. The patients 
with suspected CR were on an immunosuppressive regimen that contained CsA but their 
biopsy fi ndings strongly suggested CR as the main cause of graft decline. The patients with 
chronic CsA nephrotoxicity developed deteriorating graft function only after a switch to a 
CsA formulation with a higher bioavailability several years after transplantation. 
The expression of the proteins collagen I, III, and IV, collagen IV α3, laminin β2 and α-smooth 
muscle actin (SMA) was studied in allograft biopsies with chronic CsA nephrotoxicity 
(N = 17), chronic rejection (N = 12), or CAN (N = 19). Tissue from normal native kidneys 
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was used as control (N = 11). Biopsy samples were studied by routine light microscopy and 
after immunostaining. The area taken up by the stain was measured digitally. Glomeruli 
and blood vessels were excluded from the analysis. The mean interstitial fi brosis scores 
were signifi cantly higher in the CR and CAN group than in the chronic CsA nephrotoxicity 
group. The cortical tubulointerstitial areas of the CR and CAN group, but not of the chronic 
CsA nephrotoxicity group, contained more collagen I than normal controls. A difference 
was already noted in biopsies with mild interstitial fi brosis. The collagens III, IV and IV 
α3 were increased in all groups. Collagen III accumulated to a greater extent in the CR and 
CAN group than in the chronic CsA nephrotoxicity group. Receiver-operating characteristic 
(ROC) curve analysis demonstrated that collagen I staining had the best discriminatory 
value in differentiating CR from chronic CsA nephrotoxicity, with a sensitivity of 63% and 
specifi city 94% at a cut-off value of 19% cortical interstitial staining. Laminin β2 staining 
did not differentiate CR from CsA nephrotoxicity and no signifi cant difference was noted 
with the control group. Increases in SMA staining were observed for all patient groups, 
compared with the control group, but no differences were observed among the patient 
groups. We concluded that, during chronic CsA nephrotoxicity, collagen III and IV were 
preferentially accumulated in the tubulointerstitium. Early increases in the deposition of 
collagen I, along with collagens III and IV, were more specifi c for CR. CR seems to elicit 
a more pronounced fi brotic response than does chronic CsA nephrotoxicity. Our results do 
not support the conclusion of a report by Abrass et al.,23 which suggested that a pattern 
of new expression of laminin β2 and collagen IV α3 at the proximal tubular basement 
membrane is specifi c for CR. Our fi ndings suggest that the specifi c composition of the 
accumulated tubulointerstitial ECM in biopsies with CAN is infl uenced by the etiologic 
factors that induced the ECM deposition. 
In chapter 6 we studied the renal cortical mRNA levels of several extracellular matrix 
(ECM) components and the ECM-regulating growth factor transforming growth factor β 
(TGF-β). Patients with CR (N = 19) and chronic CsA nephrotoxicity (N = 17) were selected 
by clinical and histological criteria. Protocol biopsies without histologic abnormalities, 
taken at 6 months after transplantation from patients receiving CsA, were used as controls 
(N = 6). Total RNA was extracted from the renal biopsy tissue, and mRNA levels of 
TGF-β and the extracellular matrix (ECM) molecules collagen Iα1, IIIα1, IVα3, decorin, 
fi bronectin, and laminin β2 were measured by real-time polymerase chain reaction (PCR). 
In both patient groups, the mean collagen IVα3 and fi bronectin mRNA levels were 
signifi cantly elevated compared to those in controls, whereas only in CsA toxicity were 
the laminin β2 and TGF-β mRNA levels signifi cantly increased. The increase of laminin 
β2 and TGF-β mRNA levels was signifi cantly higher in the CsA toxicity group than in the 
CR group (P < 0.001 and P = 0.004, respectively). ROC curve analysis showed that with 
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a 15.6-fold increase in laminin β2 mRNA expression as cut-off point, the presence of CsA 
toxicity could be predicted with an 87% sensitivity and an 88% specifi city. We concluded 
that renal laminin β2 and TGF-β mRNA levels are possible new molecular markers to 
differentiate chronic CsA toxicity from CR in renal transplants. 
In chapters 5 and 6 a search was done for new specifi c markers of either CR or chronic 
CsA nephrotoxicity. In chapter 5 we wondered whether differences occur in the ECM 
accumulation of the renal cortex. Quantitative data of the ECM matrix composition of 
the cortical interstitium of human allografts suffering from chronic CsA nephrotoxicity 
or CR were lacking. We chose to study the molecules collagen I, III, and IV, because they 
are known to accumulate in the renal cortical interstitium during native kidney diseases.22 
The molecules laminin β2 and collagen IV α3 were investigated because an earlier report 
suggested that de novo expression of these molecules at the proximal tubular basement 
membrane could differentiate CR from chronic CsA nephrotoxicity.23 We found quantitative 
and qualitative differences in the ECM composition of kidney allografts suffering from 
chronic rejecting or chronic CsA nephrotoxicity. The collagens I, III, and IV accumulate 
in the renal cortical interstitium during CR. The most prominent increases are found for 
collagen I and III. A similar pattern of matrix deposition was seen in the kidneys of patients 
who likely had CR but were taking CsA. In the kidneys of patients that suffered from 
chronic CsA nephrotoxicity, however, only collagens III or IV accumulated signifi cantly. 
The regulation of renal interstitial matrix composition in vivo is complex and encompasses 
changes in ECM biosynthesis and degradation. In the normal kidney, the collagens I and III 
are found in the blood vessels and in the interstitium albeit in small amounts. Collagen IV 
is a natural component of the glomerular and tubular basement membrane and its α3 chain 
is normally found in the basement membrane of glomeruli and distal tubules. Laminin is 
found in vessel walls and in all basement membranes. The β2 chain, however, is only found 
in glomerular basement membranes and in vessel walls. A few studies reported an increase 
in collagen III in grafts with chronic dysfunction but did not compare changes induced 
by CR or chronic CsA nephrotoxicity.24 A number of in vitro studies have addressed the 
infl uence of CsA on matrix molecule synthesis by renal cells. One study reported that 
CsA stimulates the production of pro-collagen I and IV in cultures of murine proximal 
tubular epithelial cells.25 In cultured murine renal fi broblasts pro-collagen I synthesis was 
also stimulated.26 An increase in the cortical expression of collagens I and IV was found 
in vivo in a rat model of cyclosporine nephrotoxicity.25 The deposition of collagen III 
was, however, not assessed in this model. Other data on collagen production were derived 
from a study on cultured human cells that showed an increase in collagen III production 
by renal fi broblasts when they were exposed to CsA .27 Studies done on a monkey renal 
fi broblast cell line (CV1) showed that CsA stimulates the synthesis of type III collagen by 
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a pathway that leads to activation of the COL3A1 promoter and up-regulation of COL3A1 
mRNA.28 We report an increased deposition of collagen III and IV in the interstitium of 
the cortex of human renal allografts as a result of chronic CsA nephrotoxicity. In contrast 
to the results of the study done in rats,26 we observed no signifi cant increase in collagen I 
deposition. Although we did not fi nd a correlation between the exposure time to toxic CsA 
concentrations and the degree of collagen I deposition, we cannot fully exclude that, with 
time, collagen I may still accumulate during long-term chronic CsA nephrotoxicity. The 
difference in collagen I staining between the CsA nephrotoxicity and CAN/CR subgroups 
with mild fi brosis suggests that CR may at least stimulate collagen I accumulation earlier 
than CsA nephrotoxicity. We also found more expansion of the interstitial space in the CR 
group compared with the chronic CsA nephrotoxicity group, and also more deposition 
of collagen type III. The difference in interstitial fi brosis could not be explained by the 
amount of myofi broblasts present as measured by SMA staining, which marks activated 
myofi broblasts. We did not fi nd a difference in SMA staining between the CR, CAN, and 
chronic CsA nephrotoxicity groups. All contained more SMA+ cells than normal. To explain 
the higher degree of interstitial ECM deposition during CR as compared to chronic CsA 
nephrotoxicity, one could hypothesize a higher rate of myofi broblasts activity to produce 
collagen or, alternatively, a lower rate of matrix degradation by tissue metalloproteinases. 
Data derived from a primate model of chronic cardiac rejection suggest that the inhibition 
of ECM degradation plays important role in CR, as it was shown that the progression of 
myocardial fi brosis was associated with increased expression of TIMP-1 and 2, proteins 
that inhibit matrix degradation.29 
CsA may also induce tissue remodeling by growth factor and cytokine release. Effects 
on matrix synthesis and degradation have been found and are reviewed in chapter 2. The 
results of chapter 6 showed no difference between the chronic rejection group, the CsA 
toxicity group, and the control group in collagens I and III mRNA levels. The accumulation 
of collagen in CAN might be explained by an early increase in collagen synthesis that might 
have taken place before the overt damage seen in the tissues. Alternatively, it might also be 
that the collagen accumulation is the result of impaired degradation of collagen. Chapter 5 
demonstrates that differences in interstitial matrix protein composition might occur during 
the process of deterioration of allograft function caused by either CR or chronic CsA 
nephrotoxicity. However, the clinical signifi cance of immunostaining for collagen I, III or 
IV remains to be established. We did not study follow-up biopsies and do not know exactly 
know how matrix composition may change over time. 
Chapter 6 shows that real-time PCR analysis of the mRNA level of laminin β2 could be a 
potential new tool to detect chronic CsA nephrotoxicity. However, because the study was 
small and done on a highly selected population it is too early to recommend this test in 
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daily clinical practice. The protein laminin β2 is normally found in glomeruli and vessel 
walls within the kidney and the major increase in cortical laminin β2 mRNA content during 
chronic CsA nephrotoxicity may be caused by arteriolar vascular damage and subsequent 
repair. This may explain why the expression of this protein did not increase signifi cantly in 
the renal cortex of patients with chronic CsA nephrotoxicity. It should also be noted that in 
chapter 6 the whole renal cortex was studied, whereas in chapter 5 glomeruli and vessels 
were excluded from the analysis. 
In conclusion, long-term CsA therapy has an important effect on the evolution of CAN. 
Cyclosporine A withdrawal may decrease the number of patients that suffer from late 
allograft dysfunction. Cyclosporine A appears to be not directly toxic for human proximal 
tubular epithelial cells. Qualitative and quantitative differences in interstitial matrix 
composition may occur during the decline of function of a kidney allograft that suffers 
from either CR or CsA nephrotoxicity. The assessment of cortical laminin β2 mRNA 
content could be a helpful new diagnostic tool of chronic CsA nephrotoxicity and deserves 
further study.
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Verlies van nierfunctie na een niertransplantatie is een belangrijk medisch probleem. Bij 
ongeveer 40-50% van de patiënten die een donornier ontvangt ontstaat na enkele jaren 
een langzaam progressief verlies van nierfunctie. Deze achteruitgang in functie kan 
verschillende oorzaken hebben die al of niet specifi ek samenhangen met een reactie van 
het immuunsysteem (afweersysteem) van de ontvanger op de lichaamsvreemde donornier. 
Wanneer vastgesteld wordt dat de functie van de getransplanteerde nier achteruit gaat, zal 
meestal een biopt worden genomen (het verkrijgen van een kleine hoeveelheid weefsel 
met een naald). In dit biopt wordt vaak chronische schade vastgesteld, zich uitend in 
verbindweefseling en verlies van functionerende cellen van de glomeruli (zeefl ichaampjes) 
en de tubuli (in de nier gelegen kleine afvoerbuisjes van urine). Sinds 1991 worden 
deze afwijkingen ingedeeld volgens een internationaal aanvaard classifi catie systeem 
het zogenaamde “BANNF-systeem”. De toename van bindweefsel naast de tubuli en 
in de glomeruli, en atrofi e (verlies van cellen), wordt binnen dit systeem aangeduid als 
chronische allograft nefropathie (CAN). De ernst van de interstitiële fi brose (toename van 
bindweefsel rondom tubuli) en de ernst van atrofi e van tubuli bepalen de mate van CAN. 
Naast aspecifi eke verlittekening en verlies van functionerende cellen worden soms meer 
specifi eke afwijkingen in het biopt gezien die kunnen duiden op een bepaalde oorzaak van 
de achteruitgang van de transplantaatnier. Chronische allograft glomerulopathie (CAG) 
(een specifi eke vorm van ontsteking van de zeefl ichaampjes) duidt op een immunologische 
oorzaak, namelijk chronische afstoting op het niveau van de glomeruli. Deze afwijking 
wordt echter slechts in een klein percentage van de biopten gevonden. Arteriële intimafi brose 
(toename van bindweefsel in de slagaders) kan goed passen bij chronische afstoting, maar 
kan ook een gevolg zijn van een hoge bloeddruk of reeds aanwezig zijn in de nier bij 
transplantatie. Perifere nodulaire hyaliene degeneratie (PNHD) (bolvormige afzetting van 
glazig materiaal aan de buitenkant) van de kleinste slagaders is een specifi ek kenmerk van 
chronische schade veroorzaakt door cyclosporine A (CsA) en tacrolimus. Deze medicijnen 
worden gegeven om afstoting te voorkomen en ontlenen hun specifi eke werking aan de 
remming van het enzym calcineurine. De remming van dit enzym in lymfocyten (bepaald 
type wit bloedlichaampje) verzwakt de werking van het immuunsysteem. Hoewel PNHD 
vrij specifi ek is voor nierschade als gevolg van deze medicijnen, wordt deze afwijking 
zeker niet altijd gevonden in biopten van nieren die door deze medicijnen beschadigd zijn 
geraakt. 
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Kort geleden is er veel belangstelling ontstaan voor een methode om chronische afstoting 
vast te stellen door middel van het aantonen van het C4d eiwit, een brokstuk van 
complementfactor C4 (een eiwit dat onderdeel is van het afweersysteem). De aanwezigheid 
van dit molecuul in de peritubulaire capillairen (naast de nierbuisjes gelegen haarvaatjes) 
duidt op lokale complement activatie (actief worden van deze afweereiwitten), en zou 
kunnen duiden op door antistoffen veroorzaakte weefselchade. Deze antistoffen worden 
door het immuunsysteem gemaakt en zijn gericht tegen lichaamsvreemde moleculen. 
Recent is echter ook aangetoond dat activering van het complement systeem zeker niet altijd 
hoeft te leiden tot weefselschade, omdat cellen zich kunnen aanpassen aan de schadelijke 
invloeden van complementeiwitten. Op dit moment bestaat er nog geen algemene 
overeenstemming over de betekenis van de aanwezigheid van het C4d fragment in biopten 
met CAN. Recent werd ook een sterke associatie vastgesteld tussen CAG en een bij hoge 
vergroting door middel van elektronen microscopie (EM) waar te nemen sterk toegenomen 
gelaagdheid van de basaalmembraan (onderlaag) van de peritubulaire capillairen (naast 
de tubuli gelegen haarvaatjes). De meerwaarde van dit onderzoek voor het stellen van de 
diagnose chronische afstoting is echter nog niet voldoende bewezen. Overigens is het zo 
dat de aanwezigheid van markers die duiden op chronische afstoting niet uitsluit dat ook 
andere processen actief zijn in het beschadigen van de transplantaatnier, zoals toxiciteit 
van chronische calcineurine remmers. 
De onderzoeken in dit proefschrift concentreren zich op de volgende vragen. Wat is de 
invloed van langdurige blootstelling aan CsA, de oudste en nog steeds veel gebruikte 
calcineurine remmer, op het verlies van nierfunctie na transplantatie en het ontstaan van 
CAN? Brengt CsA direct schade toe aan de proximale tubuli (eerste gedeelte van de 
afvoerbuisjes) van de nier? Is er een verschil in de eiwitsamenstelling van het bindweefsel 
en in de concentraties van mRNA moleculen die coderen voor bindweefseleiwitten, in 
nieren met chronische afstoting of chronische cyclosporine toxiciteit?
In Hoofdstuk 2 wordt een overzicht gegeven van wat er in de literatuur bekend is over 
door CsA veroorzaakte chronische nierschade. Hoewel er in de afgelopen 25 jaar veel 
onderzoek is verricht, is nog steeds niet duidelijk hoe deze schade precies ontstaat. Ook is 
het moeilijk de aandoening in het biopt te onderscheiden van chronische afstoting. Eerder 
onderzoek heeft aangetoond dat meer dan de helft van de patiënten met een langzaam 
achteruitgaande transplantaatfunctie en CAN baat heeft bij het stoppen of verminderen 
van de cyclosporine dosering. Dit laat zien dat CsA waarschijnlijk een belangrijke rol 
speelt bij het late verlies van nierfunctie. Er zijn verschillende hypothesen hoe CsA de nier 
beschadigt. De belangrijkste zijn: “vernauwing en beschadiging van de kleinste slagaders 
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van de nier”, “directe beschadiging van cellen van de nier”, en “directe stimulatie van de 
vorming van bindweefsel als gevolg van het vrijkomen van groeifactoren in de nier”. 
In hoofdstuk 3 is het schadelijk effect van CsA op proximale tubulusepitheel cellen 
onderzocht. Dit werd gedaan door het effect van CsA te meten aan de hand van het 
optreden van celdood, via apoptose (geprogrammeerde celdood) of necrose, van proximale 
tubulusepitheel cellen. CsA werd toegevoegd aan gekweekte menselijke proximale 
tubulusepitheel cellen (PTEC) en aan dezelfde soort cellen van een varkens cellijn, die de 
eigenschap heeft eindeloos te kunnen delen (LLC-PK1-cellen). Een toegenomen celdood 
kon niet worden aangetoond, ook niet onder condities van zuurstofgebrek of condities die 
apoptose zouden kunnen bevorderen. Geconcludeerd werd dat dit onderzoek geen steun 
gaf aan de hypothese dat het toedienen van CsA in de mens op een directe manier schade 
toebrengt aan proximale tubulusepitheel cellen van de nier.
In hoofdstuk 4 worden de lange termijnresultaten beschreven van een in 1983 gestart 
onderzoek naar het effect van vervanging van CsA door azathioprine, een afweer 
onderdrukkend middel dat anders werkt dan CsA en niet toxisch is voor de nier, 3 maanden 
na niertransplantatie. Kort na introductie van CsA als geneesmiddel in 1978 bleek dat 
het gebruik van dit middel in plaats van azathioprine een spectaculaire daling gaf van 
het aantal acute afstotingsreacties, hetgeen resulteerde in een toename van het aantal 
niertransplantaten dat na 1 jaar nog functioneerde. Een keerzijde van het gebruik van 
CsA vormde echter de bijwerkingen die bestonden uit hoge bloeddruk, nadelige effecten 
op diverse vetten in het bloed, nierbeschadiging, jicht, zwelling van het tandvlees en 
overmatige beharing. Aangezien de kans op een ernstige acute afstoting sterk afneemt na 
ongeveer 3 maanden na transplantatie werd gepostuleerd, dat vervanging van CsA door 
het oude middel azathioprine na 3 maanden, van voordeel zou kunnen zijn ter voorkoming 
van verlies van transplantaatfunctie en ter vermindering van de nare bijwerkingen van 
CsA. In 1995 werden de resultaten van 8 jaar follow-up gepubliceerd. Er werd toen 
geen signifi cant verschil gevonden in patiëntsterfte en verlies van transplantaat functie. 
Wel was er een trend waarneembaar die aangaf dat er na een langere tijd van follow-up 
mogelijk toch een verschil in transplantaat overleving zou kunnen ontstaan in het voordeel 
van de azathioprine gebruikers. De overgang naar azathioprine bleek een gunstig effect 
te hebben op de bloeddruk, het bloed cholesterolgehalte en het voorkomen van jicht. In 
hoofdstuk 4 worden de resultaten beschreven na een periode van 15 jaar. De sterfte in 
beide groepen bleek na 15 jaar niet te verschillen maar wel waren er meer patiënten met 
een nog functionerend niertransplantaat in de azathioprine groep. Er was geen verschil in 
de transplantaatoverleving wanneer de patiënten werden meegerekend die gedurende het 
onderzoek van medicatie waren veranderd. Het bleek echter dat veel patiënten in de CsA 
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groep later toch op azathioprine waren overgegaan omdat, op grond van de uitslag van 
het biopt, vermoed werd dat zij leden aan door CsA veroorzaakte nierschade. Er werd ook 
vaker een biopt genomen bij patiënten die CsA gebruikten en ook werd vaker in deze groep 
de diagnose CAN gesteld. Uit dit onderzoek kon worden geconcludeerd dat langdurige 
blootstelling aan CsA een belangrijke oorzaak is van verlies van transplantaat functie, en 
dat het van belang zou kunnen zijn dit middel na verloop van tijd te staken of te vervangen 
door een ander middel.
In hoofdstuk 5 vergeleken wij de samenstelling van het bindweefsel in de nierschors 
van patiënten die ofwel leden aan chronische afstoting, danwel nierbeschadiging hadden 
opgelopen door langdurige toediening van CsA. Hiervoor werden patiënten geselecteerd 
met een langzaam achteruitgaande transplantaat functie en door middel van biopsie 
vastgestelde CAN. Een deel van deze patiënten werd niet behandeld met CsA en kreeg 
naast prednison azathioprine. Er werd vanuitgegaan dat deze patiënten lijden aan 
chronische afstoting. Een tweede groep met vermoedelijke chronische afstoting gebruikte 
wel CsA, maar de afwijkingen in het biopt waren zeer suggestief voor chronische afstoting. 
Een derde groep had een stabiele transplantaat functie tijdens CsA-gebruik, maar leed 
aan verlies van transplantaat functie na het gebruik van een nieuw CsA-preparaat, dat 
beter in het lichaam werd opgenomen. Deze groep werd aangeduid als de groep met 
chronische schade door CsA. Ter vergelijking werd een controle groep van normale nieren 
onderzocht. De aanwezigheid van de bindweefseleiwitten collageen I, III en IV, collageen 
IVα3 en laminine β2 werd onderzocht. Verder werd ook gekeken naar de expressie van 
het α-smooth muscle actin (SMA), een kenmerkend eiwit van cellen die gespecialiseerd 
zijn in de vorming van littekenweefsel (myofi broblasten). De eiwitten werden bestudeerd 
met behulp van een kleuringsmethode die gebruik maakt van een specifi eke antistof. De 
oppervlakte van het gebied dat in het biopt aankleurde werd genomen als maat voor de 
hoeveelheid eiwit en werd gemeten met behulp van een computerprogramma. Tijdens de 
computerbewerking werd de aankleuring van bloedvaten en glomeruli (zeefl ichaampjes) 
bewust niet meegerekend. Tevens werd direct microscopisch onderzoek verricht, waarbij 
de toename van het bindweefsel op een schaal van een tot drie werd gescoord. De toename 
van bindweefsel was groter in de groep patiënten met chronische afstoting en vermoedelijke 
chronische afstoting. Hoewel er geen verschil in SMA-kleuring tussen de drie groepen 
onderling werd gemeten, was de aankleuring voor SMA in alle drie de patiëntengroepen 
groter dan in de normale controle groep. De chronische afstoting en vermoedelijke 
chronische afstoting groep hadden wel meer collageen I in het bindweefsel dan de normale 
controles. Nadere bestudering van een subgroep van patiënten, met slechts een geringe 
toename van bindweefsel, liet al een verschil in de hoeveelheid collageen I kleuring zien 
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tussen de chronische afstoting en vermoedelijk chronische afstoting groepen en de groep 
met schade door CsA. De collagenen III, IV en IVα3 waren toegenomen bij elke groep 
van patiënten. In de biopten van patiënten met chronische afstoting en vermoedelijke 
chronische afstoting was het collageen III meer toegenomen dan in de biopten van patiënten 
met schade door CsA. Aankleuring voor laminine β2 verschilde niet tussen de patiënten 
groepen en de normale controle groep. Geconcludeerd werd dat structurele schade door 
CsA vooral leidt tot een toename van de collagenen III en IV en minder door een toename 
van collageen I. Een toename van collageen I, naast III en IV, wordt vooral gezien bij 
chronische afstoting . 
In hoofdstuk 6 werden mRNA (messenger ribonucleïnezuur) moleculen gemeten in de 
nierschors van patiënten die leden aan chronische afstoting of schade door CsA. In de 
kern van de cel worden de genen, die gecodeerd liggen in het DNA, normaliter afgelezen 
door polymerases (afl eeseiwitten). Hierbij worden mRNA moleculen gevormd, die op hun 
beurt weer buiten de kern worden afgelezen, en zorgen dat er specifi eke eiwitten worden 
aangemaakt. De patiënten in hoofdstuk 6 werden op klinische en histologische gronden 
ingedeeld in een groep met chronische, en een groep met chronische CsA niertoxiciteit. 
Nierbiopten van 19 patiënten met chronische afstoting, 17 patiënten met schade door CsA, en 
6 normale transplantatie nieren werden bestudeerd. Gemeten werd het mRNA dat codeerde 
voor de volgende eiwitten: transforming growth factor β (TGF-β) (een eiwit dat o.a. de 
vorming van bindweefsel stimuleert), collageen Iα1, IIIα1, IVα3, decorine, fi bronectine 
en laminine β2 (eiwitten van het steun- en bindweefsel). In beide patiënten groepen waren 
de gemeten mRNA’s van collageen IVα3 en fi bronectine signifi cant verhoogd ten opzichte 
van controles. Alleen in de groep met chronische CsA toxiciteit waren de mRNA’s van 
TGF-β en laminine β2 verhoogd. De mRNA’s van collageen Iα1, IIIα1, IVα3 en decorine 
verschilden niet in de drie groepen. Geconcludeerd werd dat het mRNA van TGF-β en 
laminine β2 sterker is toegenomen in de nierschors van patiënten met schade door CsA dan 
in de nierschors van patiënten met chronische afstoting. Nader onderzoek naar de waarde 
van het bepalen van deze mRNA’s voor het vaststellen van de diagnose “nierschade door 
CsA in een transplantaatnier” lijkt gerechtvaardigd. 
Kort samengevat zijn de belangrijkste bevindingen van dit proefschrift dat langdurige 
toediening van CsA de transplantaatfunctie kan aantasten, en dat het van voordeel zou 
kunnen zijn dit middel na verloop van tijd te staken of te vervangen door een ander middel. 
De chronische aantasting van de nierfunctie door CsA wordt waarschijnlijk niet veroorzaakt 
door directe celbeschadiging van de nierbuisjes, zoals eerder wel is gepostuleerd. Het 
bindweefsel dat gevormd wordt in de nier als gevolg van chronische afstoting lijkt anders 
van samenstelling te zijn dan het bindweefsel dat gevormd wordt door nierschade als gevolg 
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van langdurig CsA gebruik. Hierbij wordt er ook een kwantitatief verschil gevonden in 
mRNA moleculen die coderen voor de eiwitten TGF-β en laminine β2. Meting van met 
name de hoeveelheid laminine β2 mRNA in de transplantaatnier zou informatie kunnen 
verschaffen over de aanwezigheid van CsA toxiciteit. 
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Ik wil iedereen graag bedanken die op de een of andere wijze heeft bijgedragen aan het tot 
stand komen van dit proefschrift. 
De afronding van dit proefschrift zie ik als een onderdeel van een proces dat in 1987 als 
arts-assistent inwendige geneeskunde in het Slotervaartziekenhuis begon. Prof. Dr. L.W. 
Statius van Eps toonde mij dat wetenschappelijk onderzoek een aangename verdieping kan 
betekenen. Van Drs. Hoc Oei leerde ik de klinische praktijk van de inwendige geneeskunde. 
Dr. Dees Brandjes en Dr. Pleun Snel gaven mij steun en advies op belangrijke momenten. 
Hiervoor wil ik hen bedanken.
Ik zou alle medewerkers van het Laboratorium Nierziekten en Nierpathologie van het 
LUMC willen bedanken voor de uitstekende sfeer die door hen werd gecreëerd en de altijd 
aanwezige bereidheid een handje te helpen. Met name wil ik hierbij Marion Paape noemen 
voor haar hulp bij de eindeloze reeks experimenten met nier tubulus cellen. 
Dank gaat uit naar Drs. Klaas Koop en Dr. Michael Eikmans van de afdeling Pathologie, 
voor de uitstekende samenwerking bij het werk van de hoofdstukken 5 en 6, en naar Drs. 
Marco Mallat, voor zijn hulp bij het verzamelen van de gegevens en de statistiek van 
hoofdstuk 4. 
Verder wil ik mijn oud kamergenoten in het LUMC Paul van der Boog en Prataap Chandie 
Shaw bedanken, die met mij chronisch moe waren en mij hulp boden en opbeurden wanneer 
dit soms nodig was. Mijn dank gaat ook uit naar mijn laatste kamergenoot en paranimf Dr. 
Yvo Sijpkens, voor zijn adviezen bij het opzetten van het werk van hoofdstuk 5 en de 
leerzame discussies over klinische casuistiek.
Speciale dank gaat uit naar mijn ouders voor al de liefde en steun die ik, vanaf mijn wieg 
tot op heden, van hen heb mogen ontvangen.
Dorinda, Morgan en Grant. Jullie schenken mij elke dag weer het levensgeluk! Dorinda, 
jouw creatief vermogen binnen ons drukke gezinnetje was en is van essentieel belang. 
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Mijn speciale dank gaat ook uit naar wijlen Prof. Dr. L.C. Paul, wiens stimulerende rol, 
opbouwende kritiek, snelle en uitstekende manuscript correcties, strategische adviezen, 
positieve en nuchtere blik onmisbaar zijn geweest voor het tot stand komen van dit 
proefschrift. Leen, je was naast een groot wetenschapper ook nog eens een verdomd 
aardige vent!




De auteur van dit proefschrift werd geboren op 27-12-1960 te Hillegom. In 1979 behaalde 
hij het diploma Gymnasium β aan het Triniteitslyceum te Haarlem. In hetzelfde jaar 
werd aangevangen met de studie Geneeskunde aan de Universiteit van Amsterdam. Het 
doctoraal examen werd in 1984 cum laude afgelegd en in 1987 werd het artsexamen 
behaald. Van 1987 tot 1989 was hij werkzaam als arts-assistent Inwendige Geneeskunde 
in het Slotervaart Ziekenhuis te Amsterdam. In 1989 werd in dit ziekenhuis gestart met 
de opleiding Inwendige Geneeskunde (opleider Prof. Dr. L.W. Statius van Eps). In 1993 
werd de opleiding voortgezet in het Academisch Medisch Centrum te Amsterdam (opleider 
Prof. Dr. L. Arisz). In 1995 werd hij als internist ingeschreven in het Specialisten Register. 
Van 1995 tot 1996 was hij werkzaam als chef de clinique op de afdeling afdeling Maag-, 
Darm- en Lever ziek ten van het Sloter vaart zie ken huis te Amsterdam en van 1996 tot 1998 
als internist in het Onze Lieve Vrouwe Gasthuis te Amster dam. Van 1998 tot 2002 was 
hij verbonden aan de Vakgroep Nierziekten van het Leids Universitair Medisch Centrum 
(Afdelingshoofd achtereenvolgens Prof. Dr. L.A. van Es en Prof. Dr. L.C. Paul), waar 
de opleiding tot nefroloog werd afgerond in 2002. In deze periode werd het onderzoek 
verricht, waarvan de resultaten in dit proefschrift zijn beschreven. Vanaf 1 oktober 2002 is 
de auteur werkzaam in het Amphia Ziekenhuis te Breda als internist-nefroloog binnen de 
maatschap inwendige geneeskunde en gastro-enterologie. 
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